var title_f35_61_36816="Pharmacokinetics insulin detemir";
var content_f35_61_36816=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Variation in pharmacokinetics of insulin detemir",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 499px; background-image: url(data:image/gif;base64,R0lGODlhCgLzAfcAAKCz/3YrdOaZgKCPcJCm/6+Hp/8AAJMpVZC8psDZzdKZkw5Xm/+goL4yDVMtoABmM6DGs/+QkGBgYDVUKnBwcLDA/2YZAP9AQINxVNDj2dJNIH5AQDoyro5KKODm/1CWc9DZ/yB5Tf8gIDCDWf////9wcP4xMNwcAv9QUJyP3Nm0qLqljv8QEOKNcN+AYFBz/0CMZgshe1laLrOci3CpjfLNwHRSMWpLGHCN/0p4T89AENgmAGaRzL1VU9ZZMP/Q0DBZ/xVeLps+C8+ql3YrI5Q1O3s1Gqp3Vv+AgNNxlP/AwHJMndevwNlmQOYWATB2jIdDENnF2P/g4LzMvDJF3FhS160zKK9wr3qLaJVNj1VkOQA91IpwubeZvezW4JdEXbhIPlNGweszILZzf9k5L/9gYPMKAlBOIOmmkNdwY3tq04aGwwBYa9szEI8zje/D0O+FiT9Pg+1hUM8lS8jGuycu06O272FzTrAgEe3Y0wVbWJNml3tPS4Cl02lZt+cnELJGF9AtANHVyEBs5vKMgAszPcl4VcpmVel2YFZZeIFhO+lWQCtnOVYTE+7l7z8AADUkDI6Y746uluRKMICAgD5Y7wAAAMDAwEBAQPDw8NDQ0CAgIBAQEDAwMODg4KCgoFBQUJCQkLCwsICzmYCZ//Dz/xBA/xBwQOyzoCBN/8wzAPD280Bm/8DN/wAz//zz8P/w8ODs5mCA/7DQwPbZ0GCggPnm4O/AsNxzUP+wsAAzGQwz719AIRAw7dQIKrwNQkBYRAtHxHCmmcZdM3+jidqNfZpoSX1jYIF0bu3o483N797Y73aCXkCJc0+HYu9DUBBicvEYEoCP5+4jMChQ5+9mY6OokeHNycSOeaZmgKDAzO+1un6VeVB/zGBw79DJ7yYcQ/JJQT8qw99cVp64o6deM/E3ONDf7DBJ7nims++ToO8TIPR4cbxAKMVNMAAMP38CAmBGVoCGn+bQw1Ri6tqHpLHBr++jsMZAE5qn7DhxuWBmgHNmv7+FcH2F549WryH5BAAAAAAALAAAAAAKAvMBAAj/AEkIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOPKnUu3rt27ePPq3cu3r9+/gAMLHky4sOHDiBMrXsy4sePHkCNLnkx5pyhKlEQlxEShoCZMn1Zm+oTZ08DLoUwPzHTpUuXTmDUj5OwZtGjSlFSTQK3aU+vWul+zzNTJEqbilBAaL+iJkmuGlywl10jJknVOpilY6sQJ+0AJ1l8T/zeOXDkm5s4bRp+esfr17Nu7m3Zvnb3wldU7k9Akqrlr/yQYRwkmyTWXXiYDgiKbJxRgoiB4BBJ0SWYSYCKbKKBgEopAAEpoGijSZWIJJySEYol+olhnyWv5CcQfgAAKGKGBriHo4IINPiighBRaKBCGGnKYnockgEiJiCSa2Fl1EgB3X0ufWEegJiSsV6V0AXJCAYihaFIed5QUp0km3VFSYXGbnDdQdZxgYp0nKYKiXWdWHgTeJ9GdlycJZLr3WpQCUmmllSNuaUmXX3ISpiVjlnmmJWkSxKablsBpiZwnXmkfQXfuuWd1aR75ZEuUcKIinlgSep6IekqniYDgUf9iYmgk+IalpJa4pt0lIGZCAne1DunZdle2eh4onQS4IoumWodqcqryudx6rxIY66wc1rlmriTs2uuvJHY4bLKeLvcJBZRskumoKvm6n3aYDIrlcgG26pyAmE3IrUDaClSda/+6KZDACX3CSSe+vppsnMqquOxk7moCr7zJ0TutdHli5ty/A/VLAscBL0swQgYjvB+xDHdML7soDYhnrK8q6mbFnVwC3oZWdodnKJ8ofMknoESnIK4A52piZpdqWpCJWlISmroYWhLab9Y9N5nLNrs64oDz1nyz0jpfwrPPQAstm7/c/ns0wx4zje7TlkQdGigSpHsryyddQukm02n/t0msWVqnn5WagAipZqIUh6WbJG5btK6mguKrx5RKuV9xWhYUXmV6W8e3QH4DPqLg/GJZuOeIK54c40R/zC0FkU9+98AOn+dlof6amjnePV2i3Ya8K+X7ocHrJaW7xR91fPLMN+/889BHL/301Fdv/fVmafLbJVRi35P2v3XvfViVrzx+TuWref5X4Lspwfo6tW/J+/CD5cmb9et0f6X5fwUe/f27yf8C2JX9qWZCGrMaAVdiwCppTFgLjIr7OqaxCEVwJRN0IGYseMGnRMc7BsFMB1PyweD4a1MjrIoIUwiTFbLQKi58IUtiKEOp0LCGLUMhDp1ywx2WpIc+NEnh/zBBRP1QRBP5KggQg5gRJEJwiUwUibpUpD6JgCdUStRhFC9yRQ5+TItbDEnSLhIlUCAEimGMSBkPgsY0ckROGAER4xT4RTdmRI4jUmAb7ZgRCbSpiBRxUyhMtIks8vEigiSkpMB4SI2kjyIgcs3m1sTIRi4kkspapCV3UkYTVbGOm5RIJ823x1BC5BKZAF9rxCcR2BlnchWspCkP4kpMsCaWs9xIrh6pEQQOSJa5TIgvvRjMiuQGN5ihVUdKWcyEMLOZL3kmNA05TYuEolnm24g0q3lCblZkRESkzUR88xsTbjOU5HQSJb1Jkc9dhD6zAyU7caUi+5yTnZfgWzIpwv8kda5znrhq0iWCc09vKs5yEwEVgZDXTYBuK1QMLSg3LxU+ipzLbkZsqENJcFF1ZVSi1aQAADGyJ01uVEKkBOZJScBLidDNbpsCKR9fqi57qvSkDQpnRiFSKtxRc6M93d0/V9rCm85TpkRtj1HZidRgduITDOXIMJcKzakmNSGYkwAre4nLq/Krq141iCb8CKlQRDUirKGjPE+a1p+G1SCjoZQETPgQ8DxsqCe1q1vfehAGcUKtDUnRJPHqUMHeda18TchZGdKnwWrUoY09bFOLiUzMbNUhyMrkXueZWcdONpjlq5pEHOZZqoaStHf9bC411BrObMKMEaHavgg7T9n/6tG07Iybvwj0SYg4FrEbLW1iC7IJRcEOFANaJm6nqdpZiqJZnJAY8LS5XGg2d5ZtXSxGrttI7m6SAu4C2ke8y0fyNhITm+BVNh+SictQ4rLmrWF7LbtZoZSiFa0AAClIUYFWeCB5mpgiJujqEHi6xqonNTCCf1IBHLyAFaxwhYQh/IL9QtgUrjAFhPdLAPy2ohTCyUSGLDJQEgBuwQ4tcaxQvJNSvMAUpAAAfkGsEA+0ogL7lQWEIyxhDUMYBziowGJQu16edmIT5qyuJcOEZJPyhACmkAWNNWJj/O7XFDhQTDi3vNOIoHcTW40vDr/MSjFfxAOsSEUrSOIBIADh/7/QKyltU5zSnZACy1MmCQ5MIWTDnC2OdSvOSIHLzpcK2sk2AYGbQaCSCmDZMJDKzXabJYGompmFPZ1fRJUMklKQwhWkaEmb30yYqF1KmR65dBRV7ZBWpIIVcHbJnvs8mOaoS0sEfieng8nqhZRizwSYSQVeHevBZG221Nl1LnudEACY4gXFjomnQZ1nwWSiS8odLqFV0oo009omaE7Ft4XjXrUy+4Llri9KPCALGFf7JsOGtV9CKzmJREdFf942N+9tnT+fmwSejnK0dTJtUrzbLsch4sHi2RDflCib/yagwz2JaJQA4NVrFkq4x22X9IJOAhWqSJQGHfEIjrziJf/pdioAoJJYQAABsSCBFJSAhAj8YCLxHvhc5senDCV3IpkormlYDFmhE10k7HY3ShJAgxEE4QxnCEIQeIGHaqCABSxAgc0hUvCDw8Wu9ZEAbCMS4Oh+dYPKdmPZBQXWkQRcFjr/iMudcYoJGAEMKEACA5SQgVHA4AEjoMEMInD1rG+9IRu3i42CpIlcK+QSpqpbTNMeRsjPL4bx9cDFWZHxkTDd6TKwxjWkQBBb1OD0txCAMWQwggfAYBQqIDzWL5CLhjhayo6Bp2Qpv0Xdo3wjICAAEFzBCpaPZBYwOMUIbNAAM2igCdDXgSqmrwPoQ18AAvCBDopBjlqE4BQwmMX/DyIggguQ3tdp7jxceKXT8fJ+k81tBQ5SEeUKeJ0jq/jAKciBDTEYoAQCcAunVwO2sBA1gAuq4AK0EAsIAH6xAAslwAJI0BBQFmpxgU1Ftl3vt2TKVgoV0G6pgAPqd3yn4AzFoANOwAJKQBG20ALVdwurQAOnMAok8AMXIAIruBCKBgSM9hZCBRIl90IgVQoA8AKuAAQE0IMmkX9B0AGqMAlmcAGwcBGvgAYaoAFoMAUjMAIJQAIRwAJlMIULcWfB5hafEC+r5H7adk9EaIQvAABxJxKzUHcN4ALsYAARwBG30AQ60ALccAo0sAqwUAYskIcL4WqscH9kAXYZ6BC+/3FWQRhAj6huCdGGrvCGihgSTNgBAiAFKCACN+cRtOACqjAME3AKs0ACSlB+oViJ7cZxZrEdGoNqENFexWFuGxhEtohs+lYQloiJFHELLYB9xFiMxniMxGgNp5ADQ/AKSpB1YggSryAAOgAFQQADGUACSMACJRCNCOFoWaYW4kRiKoKLK8VvdIRGvwgAmbgQaKADyBiPyFgMp2gPArGNDHASqIAPNxAEgSgFN5iPCqFoiZgWftR+FeEm5khUCkmJFWCExdeODOECOkALFTGHH7AKMncBJtCKJvEKTQAIOXAKCEACDGAAAumKpqCEZdFSE9GQlOhNMElbrdBuSBiHEP8Bkj7wChSRf6goEAzAjd6IEmigCkewhQlwkimZEATgCmUYGDM5Z/MUlfIEAvMXgix5EbTgAy7AkxMBAaeQkapoAiJQey6xlU0gCWFZDCjJECAQZRIpF6xRHNj2e940l4dSZpTgAcIXZSOIEbTQhxSRADAQAqmoBBfAAkvpEq/ggioggzZgBot5EKXACjzoF/w2LW0HUJkZLxUUA5cIixiBCqqAChMRC7UwgzJ3dUgwlDBxC30oCDAQBHgwmQcxa4RxdCc1TPsQlxLhghYZEaswCg9QC6sgBWVgAK2JEzpJC3NoBLZpEOB4GJGYQtf1Ci7gA8EJEWAJAw+IBAZQBuf/pxNFiQaxMAIToAINQZC+SRU2A1gauIbv9wo+0ARe+RAJEAIhkACwsI0oMJ48gZavQANBYI8MUQrtlpVd8SrGcVm6Jp8dEZguEBGxkHwQYJIscAE5CBSNqQO3YA/+6BBN+ZRgMSG06BBOBF+5GEQpGpMR8QqooANoABGrUAsPQAzbQH4msKFDAZstoAKMMAIx55ZwaT9d5hApsglQ46LQlKRLKpURMYo64AO38BA/MAqnwAtOYAAXgALRGRS2UJ9KYAM/eaCWqaBTkQluYkvP1VsOISYKw6TNBKfEAqUNAaPap4ANwQAocAF4EAQ5MAO54JFKgZ0y2g4h2hB7ZnxW/wEoo7Muo7UswqUU95VfMaaIr1ADqYcG2wkYmzNY9ySlPoAK96kQiBkNHRAEIXChUxGjAkAGEyCkDQEArsCoVBEmD8cJ+eZbkrp7GtcK+/VgPEZ8rFBhrOCXAgGjLdAEPjB9GrADYrADgVB9AlADJBALCZAAEDAKo5CtdvGpqbUBX4oQqJCnnaoQnugERgB+XWgVtPB8JrCuqcgQtGqrNlQzs8I9FGEqmYAkcvoSNkYKOjZhshBjM3YQHkAK6LAEh6AKTSAGYmAGZIAHFGsERsALE3AGNyAEqiAENzABOTAKNAADrQd+HzAKEJAAQ8oW/Oqva7IBIiACDOCaBoEKV/9Iqg4BgSfAC8WZjVnxCrigAebwpzQwq7WqQqjlpg0RK0zyryoBAANLfAXrXw4BowgIBWegBxMQBA/QtWwwAs0gDAuwANqQAIIQAWVgDk6wA6qgAS4gAKhQAyowBdv6AckHeDBAAwjgs2bBtDy3TrmQmMt5EDarAab5EEjQAKdIAyu7Fe/4B04Qq42LEPVKFWe4ZeOIVoZTb3YpansGBKRAtTmJCld7BrxgBB2ADdrQB/2VZ11HEEoQAWrrBPXZBNPnsE2ACwJwBAPADFpwCq43CrOgkWIhYtbBuRqFmBIIoIV7uAIBATTArdI7vdxqA6o6CsT7FTWgAyfAAmQ6rwr/Ubl5UZ0kUAHHKgtoehADWAPYd7UyYAN4YAYoYJYLEW77db/7pQYBEABqgAMsl6k1gArtC323KwRCAAXlMAB7mxY09APJKZ7NSxCEGQLUO73cYAQ2gLJlAZInYABHEJbZS7lHGxXnQhAl7BH90AM8uhIJmwqpQAClQAsDWIzWZ7u3W5/D4LE3oAhYAAYxGwE0qxANhr9ETApuUAdA8JcEAcACXI1c+3rDSxY9JAX+5wQtQBAVSpII0Z/KGcRh0QI7YADVoH/gK8L2yhTp8kBEtBG+tAF4YAIGIAJ5pwRevBEwKgDLWgRFYAW3+3zQN4zYJ4BoIAclUAwzMAOj8AEP/zABHXAIiVkGhMoRucAFvcB5d+qCAjALfvcAIVALEDC5V0F0zbuNGoqaMxjCBJEL5QegaHELGmAGZYCRqFwQ4stDScvGXaUEDFACFxDHF4AEucDKVEi6qnAAAZAFXXB6tKAED7yhqzAFkoABE7C1DwB+r2cNxYAE2jyzJeEI/mAKVcAEwmwQNfB8wZkBCKB/gdeuodx2ESwQsMAORhAEWgDKAgGQZfkWjRmFyUDG4TvCTZHGFaS0D2oQP8AASJCYGap3kVy1xGwFDrALrACLUpAGeKAIHxACgFcLwquyM4GgruAA5lACK2wQAqAKAlAQnxeWn5wVK/TOA9GAMKACMf+LBEownlw8uHBBCzdYA7LcbE7pFCcsEEPNEW0kBbmQ0CLApSWwdwxhtapgBQFQB1gWbRkAvckHfjRADnybE+zWCwEwDYZX0gJBC02gAdZaEC6nzjTAzlOBGTD9vCEAA+zMp73MpWWwynZRBmaACP08gwnQ1QMBAEBQ1XIhTbBAc59oACZQBtr82NosAAh4ABGdCm9IEBDwAa0XAic7C/bME91mCinAAGUAx40dASv8ji1QqhLcdGEJcyNxC1XKEshgAYar0oXJqgcxcyVAv3ZRAgbQBmgwC7VQmJyct93qsyAgC6GZFFHSGqeihhYRu49dAtFazA5QCbIAhwUBAfr/iQAJMMtE0QpAsHICEbulzdhlgNokYAu4oAM4ixBrfQqdHMUc0aGzjR/HoNbJV5KIcZIn0ATbmQEJILLGPdc0IAz6sAXUAMNGIXZXYh2DlmwZ4QjEfAB7IA32dxDevapQcXHmDbtoa9plIAcaoAN6qhAF3noj0K0ZIaAu4UKmjL2LwQAiYAY7sNoIQeDcCgN363rIDd5uvRMREh0fQ9AWIVEAwAVfoAo+oABRoBAdrttRAeJnfN6EF8cnEAijytoGsQrE/X0nW8FkXubYoAqK4OKkkhzDeQq18NmG0Z8s4AS37RAewAPBMLZ223p4O+bZKt4uscaswVJIbkym5QEF//AFDeADaFCAUq6fVE4VVp4QsMCnBrC2KH6u8o0AZd7p0ksMQuAD1sANGKDCay7TcJ4YnmgAJ1DnDkHYqWBwApGtnD6yf1fNPq7mLWEiQZM102XUSxUFadAAGtACjo4Qq5AACADpXDHplM6nZrDljH7sG1ED73gCS52hJN0SFKALdP0aSmACOO7qDdEKLwZ3CUHgmjzk7XJQ26FdBc0QtNACV9gCmi4QsaDJGQ14HxDpW+Hsz44CaxsIbnsLXu4QUsAA7LAIbTCtTUAITh0TZjIqX2gGBO+8iNduL6DENXFtRGRWQFhJLagBDZAGUV4QVz2yp6DVECDYYQHwAW8Ga//r5NXqED9ACJMgrTqAC5x6E+SLFhDIAmKgA+R+oKSQCkj4YV4BRLaABj7QAF9QAHCGraNQC5vd2ak+FjAf8AYQ7Tqw8/IoAIigAdPK8/dOEz+fFjYoAmJwAmRACIG8vgRIuQP7avyVvlFBQ03frAHABTxQtyWbt+AN6Gyx9VxvApDrBIq/+Io/CQLQ8z6R9mqRCyXQp4lpAF1vBjKv+DvQ+dRXw9A3BlkQAGGQClLL8QHNHkyAgEWQtcA7Aiebsn0B4qJ5EJUO2ZDNAOPME5IfF0rw+9rMyxyJ+ZkfDeFACKmHfdZ6Xx0WFcOECWtghBzQCIkADLoADJL3QNq//dz/3/3e//3gH/7iP/7kX/6UEANxYP7qL/7wGRLPv/7wH//yP//0X//0fwwbsAFEAA8bABCUBA4ceInEQYQJFS5k2NDhQ4gREV4aiAnTGmnyCG7k2HGjRY8hRRIEOdIkx5InVVJKufJkS5ciMVGSWLMmRYEwY3rUubNjT58kZwYNCZRozqFHUdK02dTp06cCoUKUOvVhVasMsWZVuJVrQq9fSYQVW5Ms17NomZY9mNaq27dr2cJlWxcq3ahy5+oVi9ep3798vwK2O1aw2sKGCxM2exixXcaJJXd1HDdx5IiYqVa2DJnzZMWeL3/Ou5h0adGgVdvUfPV0YNOxZddtPfg1/+vbuGfvHb179e+GtYPnbuy7L3GJwrUiL6t8ofPnzF0bP04d+HUSlwza1Z64O/ftdb+DLzwe+0HzZdOrD892/df38NuzP1/f/n38+fXv59/f/38AAxRwQAILNPBABAvM5BNKPsnELk0u8YStBSkJ5UGuLtEEIU9CsRDDrDRMqELpOvzwoAodhMrECxOKcMIEH3rRrgpbjPFGHJ/qxBJMLOmkLk04sUQ6hTLZsUdOQHxKE0p4RKhHS3zMikknDwqSx02sglJKEo7k0qktf7RSSCKfSlFJrq4ss0gvk1Rvw4NYRLMpEREi0So5UWRQxafyRGjGHCESxRJQSADFElHY2v9xSPWk7HG+pqDEBCFRMslkE0sgtUlShDCF06pKL8100EIPTdSpUDHdbtE1m/JSTLFYFc/RTL+ictKDwoTq1j+FxCTLqXTtkscvI43ySzUDpYrRJlsdixMKGBXLSB83kSDDKhPCFMapLqlSE0s2wbRQrrZtdixpodr22WidlYhUQxHtC9p0p92xE2vF4vSgVGsFM0pcSfCUq34vgdfUpwo+SFZlHTr3XFsRhfirTCTgBNNO5qQz24NCsYQCbHH1tpNLdvwkK49BfrjeplImAVxRJl5t5TVhlpliizHW+ClvA+7UEm43xhVccQn9ylxmWW5qXUroddc/l6MNpa9jo2z/1WOaDiWy54SivTZkK528uSmvO/6YBKmhKhvdqp++Kuk1m2ybLazjbZXrhFyGCu+RS7bkZKtcpnkql21WumEOw71k3a880U4CSyQI2qpPfPQb8F09JvnBQzcRSNOaNNH8kgcxFWVH0CPq/HNPFGe8qdUpkfDxyCefLGpLpubK8Usgl5ytykk2WSy8D1p772/FPrymtXHX3am15T7Wbf4+wXQTzJtbXm0hPc9qy1qr3j4i8A3SZEdOsndKfJqsD1f9mthHaOzJWt9kcaDnGp/7cFsV3XLO9U92Sxpd6RCFuqnETkKuy59TFMg739kOcROkYAWBdz34WfAh5SOB/P51/yzzoS+D8Zub+7AHFQ+ii3oaZGELXfhCGMZQhjOkYQ1teEMc5lCHO+RhD334QyAGUYhDJGIRjXhEJCZRiUtkYhOd+EQoRlGKU6RiFa2In5hR4lQMwQTIXISJEaqGREGLkIsE8qkrFiaLW1xIFxWiCTDaZ4wuCg/vtCPBNCKOWpjY0WE4RgJPDDAi3nKX9DgxIU98QkiUCpfp8liXPfaxIX8MZOoSQkj9RemQgFSkJeY3t0dasEle1IQoKgnIAfKIJTQJ5AAzwRJQnMoTFMBELCE3k0tqUQKYOJUoQIEJ3Z3ykhPSGts8uTBLaAJcsAolWs72MlMO8JSqxGUrDfLKWv/Kkpa2VGUuRbHLXv4ymIKcCDGTFqVPSuCOzaxg5VS5IUxi0hLQOlQozseoTnCCEjvSRCY4oc9d7mgTPmsSJ6DkCVJFC2SYZAjkMIfOg0AUouzMijtnAk9GyZOeubsnTfK5z2T6E6B8DBdB53nQhJ6NoQtxKEIm2qSBUmJnFL1R0471iXgyykmZcBIhwTUTyFnob3FaaVtqFa1LHOpB+USlppaZkIlK9Jg0fYuQooTTjOp0UjydlE9VGVSPAc5xLGuSQZCq1C5xoqkMeapLp/oJClACU16kaqAwpIloYSKnNKlST4fUs4KUdSJkrVVZe5SrqTJEkRmD6lSFZKl51nX/KnfN6147iCu/yk6VnxMseghrEMMe87AOWaySJjpYn0k2RizBaVDBpc8e8ZVkkJsaJv+J01B8YpmX+AQovBVLsBQ2U1iDV1FJ4DFoNQiQ3srUhILapK+ptims7d2QXssSnc42d9lh1G0vkdvd9va3bBRsWYlrNOMiN64nG2tzDSUBue5PugG6BJS8h7ZwBbWDVvUiJjVxqHAl6nRWIwGSggvaowoJFA8yLvgmJT1GZQLAC54vnezLlGhZS6f89SxN/hulTQhYVgb+JILNqmAGs8zBxmSWkKBV4RpeIm0wDqKMt0tjHDMEYDPNsQ133GMgB1nIQyZykY2cwwhpp05H/75hkrWDRiY/csVRtuGUqfzIJPcouleWYZYjx+Vmtq6BYJ6hmPFIZin6Ds00VPOar2hm9BDEkm6OEZxx8jk6P1HLE6nICvOMnT1np89/ZqK3NhkdQivL0LaDTqJ32GhH8wfSkb7hpCmNH0tfeoaZ1vR5ON3pF34a1L8R9ahzxCRytsXPpgYSnue3alb/5r8WceNUIBdTysSaQLfG5at1rSxMHSu1NqkcuRD9awAVeznIzpHRuHIoJM2n1Mx2ILE40Z5pU7suoKCrlnLnMWD5Wtv86VEowA0WWI+7LhajdbdhF77Ehkbd+TmUQU6b7XlzxcpOKbbHUovvfDek3xwDeP/A80MBXzF40Aa/D8J5lIk795rh/yGdk5cMn4VPPD8RT7fG11ffqg27Oh6XdMdJbpZEEiSMWSn4yYfj8kqbHOYOk/nMHxIKq/7RJnaUUK5tXj8l91zcP7/PSS3ibtaAcuhEh4zS5c3089yX5ZFbJ7qhvhiqC13VV6/P4gay8rfFFE0t1zhMZ6Iksl99UQCbClzj6+60M9ztc7U617FDKCVDmWd/jLvGi/d0u6+GAltOIHwxpZe+BxwUhq9X4n++7+m6GOmOn7dNX1z3wP+Glu3uTeZBQ3nPN6fmVwd96LuVcdMTD/Wpr0sn+FSe1bPeKhyXfWHQJwG9QwXikCq9unf/7/PaA8li4bKRrU+79eA/BXLx7r3LFwSl3yXsWMdOvk0Gdfzmz3yW1zaTPo8P+Oo/xJ9yA374E8PjhoDiR9/PPrLV30Hmj97uDCJI7iMivvibXyL4x7z+v4f/OWMIJYsSaZM/v9MOAuw//wuWUNCOLtoEY3sK9jNAksM+CoQ6eRmLmRA5lrtAm2s/jdsEfUI4UGCJ1FhA1EDBqRAFq+IEvHoe0VPBFJRBM+kO9JsKEAy4HGQ4CsCQ3pqsLNK7HWS1TAjC8qPBTbkfaMPBqjEI2kPC4AKhJ4RCm9CEYMOEM4OIntOvKaTCLfyr2KNCiJAwDpwufJmcIYy1fdqEoElD/3XDP52LFHGBMjc0tV/ZBDSqQ22jNT5EOqf4O/DzQoLzQBpcPJAiPD3UNEPckS1LRGZjI7SwKgkYO0LMN5uKHLSrRJjrnywcOTGcjk8UlAkDuw4MRVA0xYcIJEyBlk68C008OUdUt+ryF95AxWWzxZrIBHuCiizivVdUt148Qlwsj6qBxFiMNOaKEvL6RZcDH0K5wYVwnOPiO2akNmn0NwUcxifpBIvgBElquy/LRiqsnEasRpK7H+ORgF2aLBGckC4Uw0s5pHfUxoi6FjI0wSURQTiZRyS0QhcUtJwwR6ioAFIAAU1bPquRgAi8CSGBL8QTyF+7hIbcimNMCA9gBf9TeAFTyEgCMMhEwyZgeplWfA7xEUYAWQUIGAUESACWXIVEg7DEqsiDIAVTwIFSOAgQIACN5EiPnLkdnIUPeAAYGIVagAGjfACkPAWjhAEaGAWnZEmWpLOKbAUgAIJWaIic3ElWqIA1SyrOs478mIVaOIURQIBYcIhYgEqnHAUaWMoRQEqkXMqhVMmzLLJYLAUcMAVSqImcTAVW6Mkry7k4tA3/yAAaCIEQoIG6FItVgMpZcMoPOIUQqIVZcMkgc0QAMAVW8ACnKAWatEkuu7zJoLxYGIUQOAUayIDrSIBReMsRGIUE6LFEzEwAsAoP0EgCuLJP0KsnywrHmZO+iwX/BBiBU6BM/FgFsTzND4AAy2Sn3zTJ+siFElACKXCIzATMqaBKq4wyhBzMiChCBIJO1YAAGHiA5ZwKgmyFGhAAVHgFsRDOoFzO5rwi8KRF5MMPWCgDFiiDCzAAA7gAFGCAhCAAU8DOrCDQF+BMI/ORr+sWEKI+4EgAGAgB5nyKGkAFBaCHXXCAOnCFOnCAJSiAGigLlIzPCrWiZCzA/FACEbgAWEAIKVACJGhRJSABWShQu8BLvbxJIqu1r3gUCFWNWICBU0AAm3gFVGiBJtABVfCBL9iFF7gGhGgFApAFIHAFdJAFArjKryhR8zxRKgJScQQOJGCBCHCIMg0DIFDQ/8IAAVZIhdocMnY7uv/zxd+IhbEchfl8iFtwAVVoAgGoAVsoBY3kSoeogDUIgw4FAlkAAB61Ci+VzykS06W7jh8wARP4AYiQBXQwgxJ4UcmogFSA00fNMcj7FzsFjVUYheJczIeghRbQAQ1AA1vwgFYgyIwsVYdAUlwoggDgAFd4AUflCi+FgVmIIkq9z+uIABZAAogoBVYAglKQAhRoVtBoBYwkBV39M4jbkV0cU664hRYQgBXQAi1QAVuACFtAA3cIgACgAox0Bc1kBRww1Kbg1Qb41WAd1qxAyVP4gD1Fom7lKHBNDFi4ABGo0YcoBSBghUdVAoQV0MloBY3EAf82/bNk7KkwzIpXwIUGUIQbGIYmGFkmVQVV0IGRHVkBEIAmOABgZQVSqIBWuFiuwFd9FdZtbYpViMxjXaKM1auNZYsfUAIliIAyLQNQdQiGlQWGYAAREAEkSNrC8ABZcAVZoFlH40eruAUdgIIgGAEIaAhbqAGyvYVscIBdqAM3SAIkaFu3dVsGkNqpsFlgxVmrmIV/DVgl0tqngAUGQAIUuIALYAH/ZAHBRYESyIWI8ABGfQiIZYESqE7J8IC8fAEu7TTo8ASP1QKzjAgQwIFUqIMlqIe3LV23RQEDCFC5hQqbDQNX2Mqp2NlT6NkoEg6/RV0UQIIIIFpNfQoQMAX/po2IHygDAyiD3k0Mz9TMy1UIEGiFLogEUgAArD0y4RBOLWgAXGhFDyAAIOgFB/iFqK2J203duP0KJNWBQ8gHvzTQmsBbgK1d5CDaFPgHX1Ddr/jd3LQJKSgBw1VY5AWAUSWFF2CFeHWFXqgEVqiCAHAAVwCCgqSi3glAV7zbtzwDHbgFhQAAHCAFDu5gVgjWK2hRyXWK8bVfjsUFHVABUnAF0HwK2Q3bJ4KLoTXawPXPXxCHVHiBBn7grPjdOCXhGYXa3SXa1bUJWCBaJDZaNwiAA/iFHkiC3U0IJSDeAwiDUZUFe3UicOER+4MIVBNC5HhhQ9AAWkgIAE6FDk5j/wDwAoRVXK4o4fLdWh3AhWXQyB92Cgg4BdUsoi8GviP+W/4UAQNo0TJAAgZQgmXAyPwlgQqQhSvO4pooBQK9Y6dISxswAkzOZEzuAAzoZGJYS2IwhnAQ3MH1T1MmZcEtZN3134aQgjI1gSQghSuF3SeiCFJciEEpGmMkDvdNBh/wAfc8iDOm5IOABSQwgPBlC78dXOO1io7VAQHIhl4Agi5YWWte2RbAYIfI4z0Wolx2pPkhggswAf8E0FU+3oOg2h1lCBAgBSpwgD1gAokAgRsFAmJ+iARIyQ94S6VsyrX8Z4D+5xEIAi0YAuq0CwYwgWaNAgD+yyaapangp7aqVP+IkN1ZoAUNcAGEGGa/Nd0ZvYARLoz9fdoIKGKJENeVlQZTcIBiuOaVRdl0bQhW1VsekuhioYQNINpnpcmrFVs08AFVwAUXaIcmdQE0GNGEkORRxYFzSMmADui2PIUHGIEPGAUIiE2ryICxBFuazoopLt5t+Myc9aFM6BFMKEKDmgqpEs+FcN9VQAUdQANhHlUAGF4WMAHTTVzgyAXcdWOrKIUb3cuEeIVYFQCHqIUR6OocWmuKXggC3UyGgFUN0AEXaE+cBIIwUAAXAGofcAEF4IJgtQMIiM+nfuoEcFUShQDirIVuZgtXvut6wE0icqd5ihI/3L9jskCJkF17EAD/DdAADD7jfEjo/URn/IyAp43crKDKVFheEqiBX0bqhUBsxb4hxlbWhRBVVnBuEujT33YBbVYIQgUCg/QAP3CALxgGKMiBB5iAAcgD0KCF9XRp+l7ZfsgBsgRTtnBaEbiCquRuHtqnaeQESGyKx+IptSrYg8DbHHABlK2BvkyFFNBPE4jj/7DrCzBkIm4Kor2CXniBeojigxAAHWiBYE6IVRiBWgiiA4+sxj6ISR5sVHBwDWiBMoYImsTIF0gHEx0CF2gCk20CFwjUmIYK+RYAJdUAVdCAJhjX+nZpFG4AKJgA86Td/X7aLMjI6c2hffquv7m4pniucHzxg9jZCegA/1XoAWnYSXHIAoVu5gLp6MDtz3I257ZFZVM2ABMQ3GdQA1cIgGnQ8zKIAAZYUstGcRUHIjEvx4Zw5J5EBSD3AVptCjvQh2b40oAdWwH48SAf8id36SRf8iYP1Bt3ClpAA1wAhBsIguLE6itfBwdY5x6CSe8cwwmjxG3Wgg341V0whTBwgzlgARYw4UA5YiX427bNBSQ2aTeF06ItA3I2gx2g7FIngVU4hVH4IQmLEgqjaIaV1oNAhd9GhSKXiARAABOt7oTQ9E+n7xqo9rI49SOQgSBIzNb+Cqf1BQ7IbAGY9BzaTT70UdoQDEnmgF7/9WAf9ggwbh2qACCoSQUtWv9zOIFA8IFDz4BTgGEj8goQSIXgFXcNQIWaOHfEnupa0G9loQVRiExGwAIFOGqyrQmyRYWVHVklV4VA2IEdYOIGyOhbOPFH4vgb3YIASHgUWPgiomfNtFclQAEnmHYXKGOM13gi2ooKMIXcBHmRhwgIKHkVX8kYAsr2voEbgAIhOPtyGFlPt3mTZXJAZc+YPwgGGFxfcNcAsIImDdQZgquE4Hv1GDQpeIMUAIJdCAY9MIZBZ/giUmo0VlApKINooHiLz2Oq96EpJNAK0HqIKE2yBPsbQkmnlMsQgMsHCIIJOP2qfsp7VwgZJedfsHsrQNmtdyG5Egr3EIgNeAQi8AX/B+gFKliDUHiAym+iVqhaWeBSYxYBJ1AFNKCDIq2xhXPkAhh3iEiAWniAWnD1IoLKfHbKthz9EGBK2Fx9WMiFMhABMzgAd7WCkKd9/CtDq1CCDYiBXQiDLngFCBD+KvIAUgCIVKkIlCJBggEiVU5OBPmARIkUgxInUqxo8SLGjBo3crRIiVIpIA7aaUClEcKIU6NidWzp8iXMmDAzJBhFA0aIByFg0IDAUqKUCGVE+DoRqKTMpEo5Utr08SMmTEsvUoqnwiCEBxCmcu3qNWYFVqZkgTCISpWAayN4XTBg4EIZBl/n0q1IKdESK0gxxhp1asTWuoIH06U56sODEaMy/1CElQvJoqNy5BKuLPEThYmY637EqtUy6NAcPeAwBaQCibOoVo2AsUqKEiQiRFAWbTsjMgt7Lyao9aBWgtvCh1+cVStEiFqzLKLSEEhMbeLSYXbOGng69sEATL3woHoVjBGrJOa6IAIJrOy2KR3LOCvlSvXybWcYNeLBB58Umz+PPr/jJ5ZccoklBX7CGSXW/bcgV6WURsBZaJBQywg/GaTEBSygx6BgnVmUAU7XcThiXbFAgJhijEnEHxmkENAKjDAWRKJBEoBCAoEFSsDZBJ/R+GNLraTCSgE+aCDAB6eoKJESKGgYEZBLeTjRKjSoNF6UWXZlHHLKraiBFQ6Iw/8Kmay4cuaZppRJJg6kkNLKdJhQgqMlJFAiFV0U6CKiln1SRIorpNSAiw5QMLIkUGUYUAaUc7XyYnZTGoTAKR9Y6CemSdV3X34s8SfGhhR5ECOMbr4Zp1SZXEJCVHRBoEtmmcpqEAispNKKLS7o0MEQWE4khaKMTgUCALIA4QoQssCJ3ZQJjDBCcLNKK5OJSYZAwyz8/cFOoySGYgkoA0pgSSiuTjDntLISYAoOpbwigAaADICoQVIgwQIKSrxELA5mpvLCmzOq11ksSSKQLsJJJUDDfTBgAIgOgeCCBi0kZtJJgQV2kgmCCWfqwQumvFgKKj40oAg5vhoEy70X6Iv/kQcVkCKWmgGPSAkFftGgssc9t7QKBLWcEkIOHQQSiA4TV7xgJqFEFQrHHfvsZwUvmKkmPwEUAQUWy03EsggX5CJRKa3MbErNFXgQpZ4w0Ds13B1lgAAMD0xgRAM7IK103FSh23efMZPywrF1BLMAD2tPpM4vbryQiius4ABAWX7iDDjmLq0yCw0hBHEGHk7onXQNmdv5t+l+tpLCEhzsErksxiIrSxa+oMBAeplKmjrvF8WCQHA/KEGIAKXHfclTUT21PPPNO/889NFLPz311Vt/PfbNE8FLIYXEEEMcyyNDBDzw8JH9U6vahjxUcqL/Pvzxyz8//fVPrz7c7N/p/779+/efPP/sp7z/DZCAAayfnG6jvwIK8IAIdOD8GPjA/7WPggnM3O64kkENoq4rG5RSBz0Ywql8EDQlTMoJUThCENIlhTJxIXVW6DMYvoSGNZShCluIwxzOxYY6/CEQv+LDjgyRiDuMSRF1d8QYSk2IS7xhE72SRBEG0YlVpOIVOWi6KWaEi118oku86LcoYnE4YvQIGMOYRiNmUYs9XKOszmgXODKFjhqRI0XwmEc7flE6epTIHwHJR4wE8nRkdCPmBkQXRS4Sf15h5FcgGUlHdkWSCqQkVyxZSUxORZOd5OQnG9m7UZKylKY8JSpTqcpVsrKVttHEJTwxl0x8gv8SUOukJiTiiVDYMmpJuUQuJULLKe6ylwYZ5id8GZNi3lIisJQlaJCpzBENs5lKAaYueWlNmWBTmLUcpCuVIk2vaIITlgAnRS5mCUxYghPTdIkmKLFOibBTY0mJ5zwNUs51bkIm9bREJwyCMXYGNCn/LCgJ9onOjgwUoHN5plfUyU533lOeeGJVxhAKE3xedJ+Y6GdSmBm1cS5Tm8qEqM8aqtGlYOyckXQoO0HJkXpeVBSZyMQmBOTPAl00p8GUiU1xKiBRgIsEoLCEKJIS1Jyqr6UL3QhRb3TUpHZFoY+EqU53mk8SLDWrMKGpRHw6lYMKdJ0OjQlZ9WnOp84nqkb/RaoGOUEBl0YUY53YxI6uudWwWgKaMSEQnjRhiU3k9EZKyakn5DknxU4FsXaSK10rw1jGdsWpdQUoXpcC2Io4lpv5FCxhi6rUmzLVrVONSVebWiC2ymeykb0nUinblUxIgBM53ZheL2qQb8XKs3giUCcugbEDyYS3dnKpbItricwIVhTJHYxrn0oJyLKVtrYF6DtdstmJGPeX+QSucC1B3MP2NbrkleV058ragSH3tS/M2Gq98q05HXWQ2zXIXPPq3cDO87ktye9ul0uCuZYrKQA+LnzXaxHjEpgrzfVvUub7Vvvu9cD71Wd/3QsT45pXucyNrYanxWByTcUT4rKE/wT8OpUABXe49/xWcDl2VKdQQqYa0QSML8GxnIoCYzbGyIw/EsvBXqKzMQlyjU18iXGl2DKeILKRlSLPBHeFxeEd70ZzLOPBClkmOAaojknAYx8r5cAjLjBMDjzljCl4Ok/eRJH7KsUQl9mcTlHKP3UKXzpvJM+r0gTGOIFll+x5Tp/I6SYG/ZJCA5LPczn0YBUtEyUzWcVLoYCdB+lnEjAarfD9c6Al3RIkDxnOUR41l5N84ib3DNKJDiesdefoWGOE0a4W9UY6fdw207rXvv41sIMt7GETu9jGPjayk63sZTO72c5+NrSjLe1pU7va1r42trOt7W1zu9ve/ja4w/8t7nGTu9zmPje6063udbO7186lBFUtgone6hMTuCbMMCkBzXz7NZ6U+Gm63x3visybIpqw93D4fcxv7vvdAG/3bSSKsRXulQSJ/bFBCMTWNXMCvRnrOFcHy+N0S5zOFb84RzQ+5wKBnOMezxjGIc4ZASdUFChH+TrvNKfE1pgEmbgTKKjqCQpgIujjumDG4S0BTFBVFKDARIFRPpFYThhHsqwvCTCmCcGulNzyjJUmbN5znMspgTxf1c+LLnSiGz3nU1c60w3idKgbROoSoTrW8e5Sqo+L1zLPSIBynkuVq7ydFDhqKADt0k5wghJazwQnGr90jG1Ct/LkRD09EdX/uWZG5RYZF5ZBz+k6jT7dgZfT4PfuUsMjXvFzYrzjLaEJyEseE5S3fDszv3kBe74iopfI7+10V0v/3YTmNBDhV5+qeWpcsHLq+7eIa2L3ynNVc73EUTnGeIv3vCJcn8j3Sy9+dE83Y59I/pzmmQnmn9P5lIC+eOvee4NUf8ACyn7WOcF9ToYfwxr96CY8XPFVRtRowlxhAvpxGp6wX43lnJDVX8ZRn05VHzsZRAVixCdwAm4ZRAZuoDndVDuRnD4dYALmEwMCVvpAIJ10UP1RIOld4EV0oC/JIEXc1wBaxp2cX98JVuOxU/oF17iUi8pF3vmFwidw3SV8QriAy8C1/6CAzJdbzR8JfItcUcKBUCEFWCEJ9J086Ze55eCStV873cnqASGJDaGgXYIRIqESEkjQTYQTquE5RaF7YaEW2uGBgIIExJ4X3iBhXEI93Zn94dXqHV+sqJwmHNVgJVWPxddEweEE6hSmgQvHSGGeScUl+pwigkJ2iRsgFoggzhUhpp8hRuCcJCIoMqJlPWKjrUr9TSInriBFZGImlh+KdaIfysclNFguTssuklgvKgUsDUg39Q5P4WK2DeOACCDcHGMw4hl86dYzykomTiOwDSM79aE1+gk2otg2BtuTydk3zko4Et84hhOTJV36nGOUpKP+dB87qlI5qqPOxSONzP/jAvmdPWpJNqLRPo5IP+7RP54SgYDcHA3kghQk8RUSQqYLQzZkG0HkKT2kREqRPlYkOT1dVNCbRWIkiVCkR3ZFTmWMNJZRSP4HSJ7kUojWVPgbJaWkSmaES8LhRcakTIACR8rEuFQeC9akTfreYCGdIf3kf9RWVBRcTASIYR0kUYaGUvpjU8pHNcLEUU3US/pkVFZlOzkSTEalbbBTKHwLSAmSV1oGWIolTZbldOiYMhbjSxzVqhSIQKrlYMDl+A0lXQqHgEzlSyjlt0hjV0alX+5VYOZlHnnCN33EvWnEJGJCJSYPVkZlY6oKZBqmz+SjZVoGZmbmbYTC8VWcSXL/JmEUpmhyGuZt5CGVZkSqJl0IInRFZmaSpmgW2VMsJkYo2YBYmmzaJG5SHVmypmW0FE+9F5vNJXCiEJX95nEOBrgQIzMyBYrlpnEuJ3VEp2/SH2yKJgVoY3Xy5DTtZkzKk3emJXUKBl+6BGY0Bc0pZ3miZxbmFL2Bp2US3VHm5EvYIF62J0zYoHzq50booXr2pH+6BIDmFOr054ASkjnJFVMm6EaUH4OSp4MqRSckEw5mp2EiaFkGmgQ8Z2hOKBSBqDDW1mBtk2ZVpoi2xGamaFLQUj2x2olCBYZ65YqyqFIMHSfEnEWoCiZpaEjy6HTa6FIgY0aMC+lJqJBShJEG/2mSckRifoSHagRRySWTJumUHil2NulL5FmB6OhEQN6UNaiWgimVsqeW9lkoDMi8bcJSjlpAlamZJikovCmW5ueZagRc2UnZwcSe1amPVmSfIumdZsQmNB6mgcKd7OeAdGmV2igxMmqcDqpFiMLxcYIBohmf1qmdnimcbqqk7qgiEekLzShd/qlXUkDUKGFqfqqnsio9wVlVruqnmmpUasJIYoI5khCpqiWtRmUmPJ04OZyYNmkmCKuguqpB9CloEtGn4QiKnumaCUiNIqsFHmV9cpMs9Z2zyuig8t05TSu1ttDwNaqQOt4mqFiv2uTAcQUAPly6NmS7Hiuyclmu/v9Vxb1rQ/Lnrqql0xUIKNhmRgAoxvQhvu6jwHpjpFJrYuWUXNVrFx2fBHznvnqkLUasvIZrxhmpl7IRxrZqx/pc4r3RxxZsuU5sVJLsSXJpLFpRx6JsSNpeVGjgrF3Eu/WoyWJkzZKrq8IZfknA0u0nfK2ry55jjhRIE96sV3rjr+7pS5jYFN4r0kKk0/7lxSKrka6WjSRFgBBs1Fbk1latq6Yd3WmCw2YEToEcuBJroZrYs34sORVqMKWtkNqqpW5rPbotjmgkUu6nOe2hgN7pJfStpAwtRn7mskInfOmsiEYrlhJuRUboa45s1xLlJyDgMsqqpDquRF7t4bJQy07/7k8CVG1i7qBqLkTu7VKY2DuZ7jaqruJ+qlGiZkwUK5m97oTSrldlKd6ep4rC3LAmadFeJd7ORUz9bpMWL9gO71flru4OKvImrPJ6ms1+6vM2b/S2aHiFbPKCqKpgjPZa7/XaK0narVA2adGuk9xi7JJtrEakr5a6L7UK1jpFKRKB7kmyLkYiD8CqkeSG79CRrqzAghJEABIUsAEfMBKUgH98G/7uYyawk2NSakm2hL8JYANbxA88hnm8RRkgsAfLBm0kI5Ta7pkGXjsViH1yBFGFltDab0cMcBm0RdggQS78gEswwGwsMLSt8MhB76wGFBWuq0toXf+B749IAQOU/4AMl0EEKEHuJAUOh/C0EfFZGTGyOp4cnh/91hrpdSrJJkBNQAASZAgLXMBDPLFXRLEOLxuVwukFxyPjdi6edrGfmmwp2EEfpMNhwMApPIAesMEC6EEQKEIegIYaQ1sbN64Lh2TlWivqusQHrp/+be9ScM4oXDImX/JN3McpwMAHcMMGHEAAqIGpvEAwsMEp1MI5GHLYvAyzRXII+nD4bgQXIqwsK0XBqEQmX7IwLMACBAMPgMAPlIAIsEBcoDGt5EOSQEM3EEDlSMQqJIAgoIIArMAQCAIYy0QElHG3IFste6GG2gIaoEENvIJNbsZlpPBG/Kq/SqxgUMrOUAQIyP+CaQDAPQyFCJTB2EyELVAzOddAOa/CKISAHiwANMBA3XwOFKgCLghAEzSBDqhCAwiBENyAMRwBMwzACuhHRrCMMXdzsbEzJVLyV5QCAERCF7iABjSAKBeBKuhAEwiAAnSBqdS0Td+0iyyLHzbF8rTKal7EAH/wASsADATBCkyESQOBKXhDEpQBC4hACdjwRNCCAPgAQwuACzx0E6gCV+sARQvBBsSDSx/AEihDRdhCDdyCAGD1Q1s1V/vAQ7uAAJgERQCLhiBzsxVmBXBBAFiBKviAANB0TccBMChCBwhBA1iBKPuBP+D0TctOskDK38XxBOuqRggwEqCACBiACXT/sFAjQQc8AAZkiFvMAT2YQh24wTNwdgR08y2otAa4wC1kBFoD9FqjgjIQQMhwhzNzRALMwB1MwBkYgwYciTn/SoZEQLTBZCsUABg0QGzfwnFPRALgxB7XzQPYzQRMwA1ggFzfQjljxKNAtiw4tnkDgOJkG08D0CO1bb1oMAu8hQK7Mm/shIok9Vh8AwEzQLe8Airgwl8LwNIoBQjoNtq8AAAIDF9AwE6oAES3gC1QBIaIwD4nG/wSOA5QQRFoABpEuEXEAh8fTEXkwSH0QAcowgQEgQ3gw1arggY0gVyT84BLxKOYt2OHDBDggE5XGzpzoDrvZ2X+QBK3RRnTsFRv/0SVnIKIz3M9K/hEvLYqNAEqePhcFPgLuAKCO3lFCPQDjMI8uIAquMCMHwQLlICyXThMeAABAMEuBABaTDdFxILQjILKOMZQ4EsBX8AF9IAzPAAvnIABmIEZOMFC6A1XP3QLzLZMtAIOKDWCp3cwKsEGwIMBiAAKPARIb8QsVEos4DdZXAQttIAOcDiVE4ZJX3mWZwSIh8As2IKoN4Hx1IsJmECmF9sfAcCxvEABvHipU4lf1IKFxIYJcPZD+I6VwMAsKIGyKwEDFLAImIEcCEDSwHmaAwCO63i0BciiGghdSPox4HVLrPosMDkQJLhFiLMG6EALjHlonDqWm3tx7P9ELLxLca+1vf/BH9i7vu97DfR6OOERAAgEAHhBE2iAolsEpcAASyCxk+RzLoD7liMAciAAz0RxBBDKwSsFoys1KwCAs2Vt0XKnZcuEXzxBo4/FM0+Ef2+1bKuHu6f6lo9Cl48HNe+7ACzCHxD6H0S7vrcARP91Q6NCrK/SGQV8KgDAu7x5vMNAAihBCZgAvrS2TMwCH9PApRzEbMjBtHeFBxi9xy9bAhGIngLwRIwKKfBACLDBFrCCLMA7RdCCrvgAKlC7y1v7u2u5uGfED0SAk5TxAtcANeOCVcN0C9D1RA6S16cGr1/EKnxAEBiDk5hACdC3UmSAb3xAtEgEDrP/wA7owNx7ReInW6uoCqtUtsbHQRzYuKnIgpkgCyojAKRThH/7gA6IOZC8vNsbxCzI+0bsfQ7Tdg3AS0nQfeokkUkLPL0bPEZQCi9Ew+3U+lII9F8Az0TgsBl0vu13Regb27eESxhiale0Auqrvqm0ggdQSi3wzFTH/ef3Ce6nN5fTOUccskbcAkQLAPFjjg+5e8cDhK0WOtoQyoUEYUKE44CFwKaERESJEylWtHgxIoRaIx6MqIUgAQkGIsycCOQD1SuMKy0CSJUKAEuZM2nWtHnTZqZOlnha6pQJ50xKlGhmgBEiZMVXNdD40OGCVlCpU1mWAvDCFRACHiLGOjqL/+ZIEQxk1miiQ4AtqmvZBh1qEZYSuRGQwElBz5WDA2ZKqmoT7kJghQk7BKGxqm3QBAg2dqyFrIEBMRqeRm3rEmZizZs5S8wUChOmUEA7k3jLchWNU6Mm0roloIkGVU1cpCx9e6ZVWaZS4QBBYlYIGLHCihAR4QdLWi5UuVCLGzpOShtKBL7AwkB26wfEuXoB4I0SQpRbPL+YYcSIDNFtLm48gZeicjpQqmSLGUAp9vv57z99cRUIQhhBhddcaEIVDZoQ4BbL+ntwogpkeUkWO0Z5YBTEZmLgAhFYuAAJiC6yhTmoIDzRtA1ClEsKikgxJT8SmNJAAwHsA/BC1lCkyf+9IB6Y4IwO+nGQKgCAMEWW33ZcksmV/ptoFVQMEUIIVVTxoYkW0KjhxiZRBAGHVEwZhI0QECCOJikYKMEEA0woIZcWKbJFAB2aqMFL6J6cqJQXqCigBQQ1qE2mBIRDM0+WYIGjASOAOSWIEUZZQYBKLb0U00wtHSOAAJawQ79ERYXwyVXsOaIBHxjkclRRPSAAiGDYeCCEWmbRcKa4kLjAABHKiEAJWCR6pc4mbmlVsz2XEgCMBuwUgFWZUjsFAWRlgiUC49LowIYJHgjiDBuO0JRcTXFR5YsClrGW3c7eChALKJrDs91WPbgqmAX06GiUpGr6IYIyeBUBxFx+eAX/FRrLXZhhaJukJA5SSOnCBdmKCEAB8yZKgOOOFxsF5FM+QLRejBhAyLoeOuDF2wnuwKCHC1BASESWED63h4Yx7ULiVkpm95KhKAlNAl0gsYCIY4RemummnX4a6qilnprqqq2OI4YYCtGFawmsZpoPIuAZG54NjiHCgrTVXpvttt1Wm49LTgx6KEzeyRocSCAphG9gJuAa8MAFD3yCrw0/HHGqgQkckkbK/hoZtN9+G5ys40h8arl/noruoTHBHOrQQA/989GbFt10plFPfenVWR9K8/46d5112msv/XXPc68b99xtTz32zafasy3iiyeKM+PXUn555Ddjnj3opZJ+/3rnk7U+Merdwv544Zt3l/vukw//e/DN31H7m9JXn3yq1q/pffjbH35+72WKX6j6qz//ef235/9E+Luf/6RDQJsIkCUITKAB5Wc/+gHwehAU3/gk2B8FYuSCGGQgTTJokQ56cIP5c+D+KFjB8vWvNB+kiAr/V0IXRvCFMEThCHFyieAlxoalySFndriZHvrwhm35IYSGKMQgGrEzRWSLEpd4xLUwkYZRlOIUqVhFK14Ri1nU4ha52EUvfhGMYRTjGMlYRjOeEY1pVOMa2dhGN76RSZn4BCU+QRrNaOISntiMHCkxGiFqQiKeCEUf7SiVSwDSM3MMYUQESciI8LGOU/9ppB8lgkc97geShWyLJfc4R0o+EZEkmKQmaxhKEvBxkaIcJCUzKclVFpKTWtwJJnyyGU1wwhKptIhOLEFLTpDSJpqgRC8lQkuedGIqwiRmRG7Zy01IxZi1JMEspRmUaCKTmbjU5U2oic3ENHObFOGlL4FZE2Viopg98SZOzllJXGLimdZUZ0S6OZVrujOXWhSFJUBBAlBYQhSa2Uk+cVhLWjqRJsZEZ0REkYlMbMISCGWJQiUCUVPipKEPjeg++/nPgAYloxDV3EDDSROO+hOgAuVJSSVyCYNGlCoUZahDRQpNniyUBBalSkg3yk+UfhSjNIXpNFeqxWES5ajZ4wT/BQjaFl52YhMSWOIyJwLRSwbFpQvVhCU2AdF+UsWqSU0qWC2hR0ostal6yudY2XJWprL0kTuBqlSfSNWKlpVzy9xqV31KVk+INa1Bsapp0ApXUQGWpVsVBVvZkgkJcAKiP6krTiMSCktQgCpZjYhLO3GJnXxiKpbFLGKpIloSKJaxuCEtW1AbWKo4FrI+KWdNNDsR0+Z1oZz1rCVAKxXTrta3lz0tQFNbRdMyNRTF60lR22JZovwznLWNCFPpiltmErO4NKFuZYWL3Kls1zTLdW1njmuJ5LZVvHB1Lkqja1fwWne46MzuTMBb3vMGBbzDXK5h8+QJrl5isGzxhA0l/2AJCVx1LZ/wyW57KxVNWLazQPnnJmDnYAhfAigQFcVOJIqRCcPOv5sAMF6D8mFK5JHABkbwbUI84hVLZcCXKPCBE6Pgzn6WKg9esIS5WuGg6DjCOQUoh0vc4xO3OMA4MTGKZaxiLX4CoptocPbG+11cUngt0YRpem3aE7lpYiecmLJNuAxlro6ZzPuVyHw7Y2YpJ6/KUqHAlcOpZblxWZ5ePm2Y0UyTMke5z35Wc0TYDEdDHxrRiVb0ohndaEc/GtKRlvSkKV1pS18a05nW9KY53WlPfxrUoRb1qEldalOfGtWpVvWqWd1qV78a1rGW9axpXWtb3xrXudb1p23Ya/8SfAITF00MJjB7EQpQNqbF3vVFep1DYAu7LcTGyLGHrexlP0i84e2wVOxKgmXOMTHdvrZEsj3MbQel29+Gq7jHHR2e+Nrcvw4NKAL6V1Ec+6OiAAUmJCC3S+ybAqQZWoEpq2AKewLcppkjJj6hCVCAgjTAFg1GegkaCQAlE8eWACD/KreOK1yYp5UAJkARaFC/O4fxlji9RUmJe2Mi3/vuNwn+TWyB89uuBqcEwpFHx6E1/OERD819K1JxfmNc4xw/ccvlRseQa2LkJW83S1ZKR237kwKUsKpLKbwTTSgYFJQIO0eZ2s+yD5OyTOVEsGkZkWNeeSdSZSoF/kn0iRz/E6JS7QQnKLH3AefTpUSxBC7L6hNKSOCrpq46aOMNiqxvvcdeB7vYXc7PspPg7O4dPNst4XafwN3AmL9s3S+C99Dvve+c+DtRAu9twvu3E4dP/NQtslz5wvSv8Ixo6/fZR8ODFrpa7zxk3Y7sZbbd27e/MzohOxR2J/+UvdwqZvcZita3Xpp7pcAnS237q+depLzPJYStHnyIkoD40L/7QpGP3S0zn8JoLz06MyF94Vb/+vnMPle3P1va82QizM0TOKETPqHAbAjw1sqYji2XhEb90o39Og/64o2YjMzqam+hein/TiwBBQ+nRAETcGmdSA0A1yyiBrAAD3ADTWMB/2lpaR7Q+CKw+K6uAuPvAosuAzFhA1eQqkBQBGmP4hoQqXaPny7hoFyq37wuFCjgEsDOskDhEkRBqmhJFBTM+ETME9pP+aAPupqQKNaOIpaJmCDr3yxBE7aK71xQ/WRMFC6BEzgB1apuCBEQCo/QwHbrwZjQCYtQCkmACq0wDLFQC2kQnboQ3MBw/WaQDP/pDAdvaPQvtySgDd8QCEtvua6uwAiQCCFKzEhAFCCKn4BC+HxKEyCKlpBNvzRhECmQ/h7LEbdqzMQQncDszKaLqwrMAxlpoDoB2kKt3GAqEzmM6wYPtD6RJyDONECxn0qxl7otFVfx/U7JFfkOFsMwB273rBZFL6ogURePqRcrkbbiDEVCIZ7Asa74iy3I0RzrpfUOC6jW0ZDEMYDeER7r0R7vER/zUR/3kR/70R//ESADUiAHkiAL0iAPEiETUiEXkiEb0iEfEiIjUiInkiIr0iIvEiMzUiM3kiM7ctUCAgA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Variation in pharmacokinetics of insulin detemir among six individuals given the same dose on four separate  occasions (note significant peak effect at 8 to 12 hours and duration well short of 24 hours in some  patients).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Heist T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53:1614.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_61_36816=[""].join("\n");
var outline_f35_61_36816=null;
var title_f35_61_36817="Kim biceps load test two for SLAP lesion";
var content_f35_61_36817=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1124px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/82887/Biceps_load_test_two_video.mp4?title=Kim+biceps+load+test+two+for+SLAP+lesion\" style=\"width:480px;height:288px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Biceps load (Kim) test two for SLAP lesion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The positioning for the second biceps load test is identical to the first. However, in the second test, the shoulder is abducted 120 degrees before the shoulder is maximally externally rotated, again with the elbow flexed to 90 degrees and the arm supinated. The patient is then asked to flex the elbow while the examiner resists. The test is positive if pain develops when the patient flexes their elbow or increases when the examiner applies resistance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Simons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_61_36817=[""].join("\n");
var outline_f35_61_36817=null;
var title_f35_61_36818="Chromic phosphate P 32: Drug information";
var content_f35_61_36818=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chromic phosphate P 32: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7896046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Phosphocol&reg; P 32",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7900347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Radiopharmaceutical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7900412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Consult manufacturer potency tables when applicable. All doses should be individualized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     General dosing ranges (based on 70 kg patient):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Intraperitoneal instillation: 370-740 megabecquerels (10-20 millicuries)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Intrapleural instillation: 222-444 megabecquerels (6-12 millicuries)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Interstitial use: ~3.7-18.5 megabecquerels/g of tumor weight (0.1-0.5 millicuries/g)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7900413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7900416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Phosphocol&reg; P 32: 185 MBq (5mCi) per mL",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7900345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7900414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     This product is for intraperitoneal or intrapleural instillation;",
"     <b>",
"      not",
"     </b>",
"     for intravascular use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7900348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of peritoneal or pleural effusions caused by metastatic disease by intracavitary instillation; may be injected interstitially for the treatment of cancer",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F15245838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7900404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal cramps, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic: Bone marrow suppression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Pleuritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Peritonitis, radiation sickness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports: Radiation damage (interstitial or loculation injection), leukemia (children)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7900352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should not be used in patients with ulcerative tumors or in exposed cavities or where there is evidence of loculation, unless the extent of loculation has been determined",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7900353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse events:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Leukemia: May increase risk for developing acute lymphocytic leukemia; cases have been reported in children following intra-articular injection of this product for hemarthroses (",
"     <b>",
"      not",
"     </b>",
"     an approved use).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Intestinal fibrosis/necrosis and chronic fibrosis of the body wall: Have been reported as the result of misplacement of this product. Avoid placing into intrapleural or intraperitoneal loculations, bowel lumen, or body wall.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Effusions: May be less effective in bloody effusions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatric: Safety and efficacy in children have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Not for intravascular use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Experienced staff: Should only be used by nuclear medicine physicians and/or radiopharmacists qualified and experienced in use and handling of radionuclides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Patient information: Patients must be instructed in measures to minimize exposure of others.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8018282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7900349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Radiopharmaceuticals have the potential to cause fetal harm and should not be administered to patients who are pregnant unless therapeutic benefits outweigh potential risks.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F7900351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9033 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-6FA69E1D15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_61_36818=[""].join("\n");
var outline_f35_61_36818=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7896046\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7900347\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7900412\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7900413\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682642\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682643\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7900416\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7900345\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7900414\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7900348\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245838\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7900404\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7900352\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7900353\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299039\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018282\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7900349\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7900351\">",
"      Lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9033\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9033|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_61_36819="Intrauterine fetal transfusion of platelets";
var content_f35_61_36819=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intrauterine fetal transfusion of platelets",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/61/36819/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/61/36819/contributors\">",
"     Kenneth J Moise Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/61/36819/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/61/36819/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/61/36819/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/61/36819/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/61/36819/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrauterine platelet transfusion is performed much less frequently than red blood cell transfusion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/57/13210?source=see_link\">",
"     \"Intrauterine fetal transfusion of red blood cells\"",
"    </a>",
"    .) The most common indication is neonatal alloimmune thrombocytopenia (NAIT). This disorder is analogous to red cell alloimmunization, except maternal antibodies directed against platelet-specific antigens are actively transported across the placenta where they can cause profound fetal thrombocytopenia and impaired platelet function. The most common platelet antigen involved is HPA-1a (PLA(1)); the HPA-3a (Bak(a)) and HPA-5b (Br(a)) antigens comprise the majority of the remaining cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36819/abstract/1\">",
"     1",
"    </a>",
"    ]. Until recently, many European centers managed this disease with serial in utero fetal platelet transfusions, while North American centers preferred maternal therapy with intravenous immunoglobulins (IVIG), corticosteroids, or a combination of the two [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36819/abstract/1\">",
"     1",
"    </a>",
"    ]. When immunotherapy is used, a common approach is to use cordocentesis to determine the fetal response to therapy and transfuse platelets if fetal thromobocytopenia is detected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36819/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A less common indication for fetal platelet transfusion is in the treatment of fetal thrombocytopenia in cases of hydrops secondary to maternal parovirus infection. Severe thrombocytopenia",
"    <span class=\"nowrap\">",
"     (&lt;50,000/microL)",
"    </span>",
"    has been observed in approximately half of these cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36819/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The technique of transfusing platelets into the fetus will be described here. The general management of pregnancies and neonates with alloimmune thrombocytopenia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/9/14490?source=see_link&amp;anchor=H7#H7\">",
"     \"Neonatal thrombocytopenia\", section on 'Neonatal alloimmune thrombocytopenia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11768?source=see_link\">",
"     \"Fetal blood sampling\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most centers prefer to undertake these procedures in an operating room setting on the Labor and Delivery unit because a serious complication (eg, prolonged bradycardia) may necessitate an emergency cesarean delivery if the fetus has attained a viable gestational age. Patients are usually instructed to avoid oral intake for six to eight hours before the procedure and intravenous access is secured.",
"   </p>",
"   <p>",
"    The abdomen is prepared and draped as for a surgical procedure. Prophylactic antibiotics effective against skin flora are used by some centers. Maternal sedation may be necessary for anxiety and left lateral displacement of the uterus will help reduce the risk of maternal hypotension.",
"   </p>",
"   <p>",
"    One operator provides ultrasound guidance using a transducer covered with a sterile sleeve. The cord insertion site at the placenta is identified, the skin infiltrated with a local anesthetic, and then a 22-gauge six inch needle is directed into the umbilical vein under continuous real-time ultrasound visualization. As compared to intrauterine transfusion of red blood cells, a smaller caliber needle is used to minimize the risk of bleeding from the puncture site since the risk for fetal exsanguination is increased two-fold (2.3 percent: 95% CI 1.2 - 4.4 percent) over cordocentesis in other conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36819/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Choice of venous access site, monitoring the fetal heart rate, and other types of complications are similar to intrauterine transfusion of red blood cells. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/57/13210?source=see_link&amp;anchor=H11#H11\">",
"     \"Intrauterine fetal transfusion of red blood cells\", section on 'Choice of access site'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An initial sample of blood is withdrawn for hematologic evaluation. In addition to determining the platelet count, mean corpuscular red cell volume (MCV) can be assessed as a method of affirming that fetal, as opposed to maternal, blood has been obtained (mean corpuscular volume greater than 100 microliters suggests fetal red blood cells).",
"   </p>",
"   <p>",
"    After withdrawing a blood sample, a short acting paralytic agent is used to minimize fetal movement. Options include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15079?source=see_link\">",
"     vecuronium",
"    </a>",
"    (0.1 mg per kg of ultrasound estimated fetal weight) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36819/abstract/6\">",
"     6",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/14/6374?source=see_link\">",
"     atracurium",
"    </a>",
"    besylate (0.4 mg per kg of estimated fetal weight) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36819/abstract/7\">",
"     7",
"    </a>",
"    ], drugs which are associated with minimal fetal cardiovascular effects. Both agents cause fetal paralysis for up to two hours.",
"   </p>",
"   <p>",
"    An automated hemocytometer (eg, Coulter counter) proximate to the operating room suite is critical for providing results quickly. A fetal platelet count of less than",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    warrants immediate transfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36819/abstract/4\">",
"     4",
"    </a>",
"    ]. Antigen-negative platelets (from a blood group O donor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36819/abstract/8\">",
"     8",
"    </a>",
"    ]) should be processed and available in the operating suite to treat significant thrombocytopenia and reduce the risk of puncture site bleeding. Alternatively, maternal platelets can be obtained by apheresis 48 hours prior to the procedure and washed to remove the offending antibody. The decision to transfuse should not be undertaken on an empiric basis as the infusion of platelets when the fetal platelet count is normal can result in thrombocytosis, hypercoagulability, and fetal death.",
"   </p>",
"   <p>",
"    If platelet transfusion is to be performed, a second operator infuses the platelets using a 20 mL syringe attached to a three way stopcock connected, via extension tubing, to the blood bag and the procedure needle. In addition, a nonluer lock stopcock is used to connect the procedure needle and distal end of the extension tubing to facilitate manipulation of the tubing without disturbing the needle. During the infusion, the primary operator should be able to visualize the transfused platelets streaming away from the needle as they mix with fetal blood. The fetal heart rate should be monitored periodically to check for bradycardia.",
"   </p>",
"   <p>",
"    At the end of the platelet infusion, a second blood sample is obtained to determine the final platelet count and the needle is removed. The site of puncture should be visualized to determine if there is excessive bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     AMOUNT TO TRANSFUSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The volume of platelet transfusion is determined using the following equation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36819/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    Volume transfused (mL) =",
"    <br/>",
"    <br/>",
"    Volume of fetoplacental unit (mL) X (final &ndash; initial platelet count) X 2",
"   </p>",
"   <p>",
"    ---------------------------------------------------------------",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Platelet count of transfused concentrate",
"   </p>",
"   <p>",
"    The fetoplacental volume is calculated by multiplying the ultrasound estimate of fetal weight (grams) by 0.14. The factor of '2' is used in the numerator of the equation to allow for possible platelet sequestration in the fetal spleen or liver.",
"   </p>",
"   <p>",
"    Since the half-life of platelets is only about three days, the target final fetal platelet count is 300,000 to",
"    <span class=\"nowrap\">",
"     500,000/microL",
"    </span>",
"    to achieve a nadir platelet count of 30 to",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    at the time of the next transfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36819/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TIMING AND FREQUENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most authorities recommend initiating platelet transfusions at 26 to 30 weeks since this is the gestational age range when intracranial hemorrhage is most likely. Although no clear gestational age threshold for delivery can be gleaned from the literature, delivery after 32 weeks of gestation would appear prudent if serial transfusions are being performed. The procedure must be repeated weekly because of the short half-life of transfused platelets (ie, three days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36819/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SOURCE OF PLATELETS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many centers keep a registry of donors with known platelet antigens. Donors should undergo routine screening for infectious diseases and should be cytomegalovirus (CMV) negative as well. Single donor platelet apheresis can be undertaken using an automated cell sorter. A concentration of greater than 2000 X",
"    <span class=\"nowrap\">",
"     10(12)/liter",
"    </span>",
"    is desirable to reduce the risk of volume overload in the fetus. Platelets should be leukoreduced and irradiated to prevent graft-versus-host disease. In cases of Rhesus incompatibility with the pregnant patient, Rh(D) immune globulin should be given. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/39/11895?source=see_link&amp;anchor=H9#H9\">",
"     \"Preparation of blood components\", section on 'Platelet concentrates'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20586?source=see_link\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mother can also serve as a source of platelets for fetal transfusion since the putative platelet antigen will be lacking on her platelets in this situation. Donations should be planned 48 hours in advance of cordocentesis to allow adequate time for processing while still maintaining platelet viability. An additional step of washing is required to remove the offending maternal antibody. This is usually not undertaken until just before the cordocentesis since washing can result in activation of the platelets and reduce survival time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common indication for fetal platelet transfusion is neonatal alloimmune thrombocytopenia (NAIT). The most common setting is after diagnostic cordocentesis performed to assess the fetal response to maternal therapy with intravenous immune",
"      <span class=\"nowrap\">",
"       globulin/oral",
"      </span>",
"      glucocorticoids. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fetal platelet transfusion is performed under ultrasound guidance in an operating room setting on the Labor and Delivery unit because a serious complication (eg, prolonged bradycardia) may necessitate an emergency cesarean delivery. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transfusion is indicated for a fetal platelet count of less than",
"      <span class=\"nowrap\">",
"       50,000/microL.",
"      </span>",
"      The amount of platelets to transfuse is calculated using a formula. The target final fetal platelet count is 300,000 to",
"      <span class=\"nowrap\">",
"       500,000/microL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Amount to transfuse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When used in rare cases as a primary treatment modality, most authorities suggest initiating platelet transfusions at 26 to 30 weeks of gestation with weekly subsequent transfusions, and delivery after 32 weeks of gestation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Timing and frequency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Donor platelets may be obtained from donors identified by the blood bank as compatible or from the mother. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Source of platelets'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36819/abstract/1\">",
"      Bussel JB, Zabusky MR, Berkowitz RL, McFarland JG. Fetal alloimmune thrombocytopenia. N Engl J Med 1997; 337:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36819/abstract/2\">",
"      Berkowitz RL, Kolb EA, McFarland JG, et al. Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. Obstet Gynecol 2006; 107:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36819/abstract/3\">",
"      de Haan TR, van den Akker ES, Porcelijn L, et al. Thrombocytopenia in hydropic fetuses with parvovirus B19 infection: incidence, treatment and correlation with fetal B19 viral load. BJOG 2008; 115:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36819/abstract/4\">",
"      Radder CM, Brand A, Kanhai HH. Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it? Vox Sang 2003; 84:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36819/abstract/5\">",
"      Silver RM, Porter TF, Branch DW, et al. Neonatal alloimmune thrombocytopenia: antenatal management. Am J Obstet Gynecol 2000; 182:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36819/abstract/6\">",
"      Giannakoulopoulos X, Sepulveda W, Kourtis P, et al. Fetal plasma cortisol and beta-endorphin response to intrauterine needling. Lancet 1994; 344:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36819/abstract/7\">",
"      Daffos F, Forestier F, Mac Aleese J, et al. Fetal curarization for prenatal magnetic resonance imaging. Prenat Diagn 1988; 8:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36819/abstract/8\">",
"      Yeast JD, Plapp F. Fetal anemia as a response to prophylactic platelet transfusion in the management of alloimmune thrombocytopenia. Am J Obstet Gynecol 2003; 189:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36819/abstract/9\">",
"      Murphy MF, Waters AH, Doughty HA, et al. Antenatal management of fetomaternal alloimmune thrombocytopenia--report of 15 affected pregnancies. Transfus Med 1994; 4:281.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6787 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-8B92F8E3C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_61_36819=[""].join("\n");
var outline_f35_61_36819=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      AMOUNT TO TRANSFUSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TIMING AND FREQUENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SOURCE OF PLATELETS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11768?source=related_link\">",
"      Fetal blood sampling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/57/13210?source=related_link\">",
"      Intrauterine fetal transfusion of red blood cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/9/14490?source=related_link\">",
"      Neonatal thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/39/11895?source=related_link\">",
"      Preparation of blood components",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_61_36820="BTK expression";
var content_f35_61_36820=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F82104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F82104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Peripheral blood flow cytometric analysis in XLA",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 360px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Top panels: BTK expression in B cells of a normal individual, a patient with XLA, and an individual who carries a BTK mutation. Bottom panels: BTK expression in monocytes of the same individuals as above.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_61_36820=[""].join("\n");
var outline_f35_61_36820=null;
var title_f35_61_36821="Colchicine and probenecid: Drug information";
var content_f35_61_36821=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Colchicine and probenecid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/25/33172?source=see_link\">",
"    see \"Colchicine and probenecid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F154382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anti-inflammatory Agent;",
"     </li>",
"     <li>",
"      Antigout Agent;",
"     </li>",
"     <li>",
"      Uricosuric Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F154370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Gout:",
"     </b>",
"     Oral: One tablet/day for 1 week, then 1 tablet twice daily thereafter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Current prescribing information states a maximum dose of 4 tablets per day; however this exceeds the usual maximum dose of colchicine for gout prophylaxis (1.2 mg per day).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F154371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F154372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute:  Probenecid may not be effective in patients with chronic renal insufficiency.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15826358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F154362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Colchicine 0.5 mg and probenecid 0.5 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F154351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F154365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not initiate therapy until acute attack has subsided.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F154364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F154380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F154368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to colchicine, probenecid, or any component of the formulation; children &lt;2 years of age; small- or large-dose aspirin therapy; blood dyscrasias; uric acid kidney stones; initiation during an acute gout attack; concomitant use of a P-glycoprotein (P-gp) or strong CYP3A4 inhibitor in presence of renal or hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13112766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F154378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F154357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Probenecid may increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefotaxime: Probenecid may increase the serum concentration of Cefotaxime.  Management: Avoid cefotaxime doses greater than 6 g/day with concurrent probenecid.  Any patients receiving this combination should be monitored closely for evidence of cefotaxime toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins: Probenecid may increase the serum concentration of Cephalosporins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor like cobicistat.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyanocobalamin: Colchicine may decrease the serum concentration of Cyanocobalamin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Colchicine. Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Probenecid may increase the serum concentration of Dapsone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: UGT1A6 Inhibitors may increase the serum concentration of Deferiprone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: May increase the serum concentration of Colchicine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doripenem: Probenecid may increase the serum concentration of Doripenem. This effect is due to probenecid's ability to decrease the active tubular secretion of doripenem.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ertapenem: Probenecid may increase the serum concentration of Ertapenem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: May enhance the myopathic (rhabdomyolysis) effect of Colchicine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: May increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are receiving ritonavir-boosted fosamprenavir.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: Probenecid may increase the serum concentration of Ganciclovir-Valganciclovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemifloxacin: Probenecid may decrease the excretion of Gemifloxacin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Colchicine may enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imipenem: Probenecid may increase the serum concentration of Imipenem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoprofen: Probenecid may increase the serum concentration of Ketoprofen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): Probenecid may increase the serum concentration of Ketorolac (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): Probenecid may increase the serum concentration of Ketorolac (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Probenecid may enhance the adverse/toxic effect of Loop Diuretics. Probenecid may diminish the diuretic effect of Loop Diuretics. Probenecid may increase the serum concentration of Loop Diuretics.  Management: Monitor for decreased diuretic effects or increased adverse effects of loop diuretics with concomitant use of probenecid. Bumetanide prescribing information recommends against concomitant use of probenecid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LORazepam: Probenecid may increase the serum concentration of LORazepam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meropenem: Probenecid may increase the serum concentration of Meropenem.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Probenecid may increase the serum concentration of Methotrexate.  Management: Avoid concomitant use of probenecid and methotrexate if possible.  If used together, consider lower methotrexate doses and monitor for evidence of methotrexate toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Colchicine may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, colchicine may decrease the serum concentration of Cyanocobalamin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Probenecid may increase the serum concentration of Mycophenolate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitrofurantoin: Probenecid may increase the serum concentration of Nitrofurantoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Probenecid may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oseltamivir: Probenecid may increase serum concentrations of the active metabolite(s) of Oseltamivir.  Management: Consider a change in therapy when using oseltamivir together with probenecid; reduced oseltamivir dose may be necessary.  Increase monitoring for adverse events, such as thrombocytopenia.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegloticase: Probenecid may enhance the adverse/toxic effect of Pegloticase. Specifically, Probenecid may blunt increases in serum urate that would signal an elevated risk of anaphylaxis and infusion reactions.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: Probenecid may increase the serum concentration of Penicillins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Probenecid may increase the serum concentration of PRALAtrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Probenecid may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the therapeutic effect of Probenecid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Benzoate: Probenecid may increase the serum concentration of Sodium Benzoate. Specifically, probenecid may inhibit the renal transport of the hippuric acid metabolite of sodium benzoate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phenylacetate: Probenecid may increase the serum concentration of Sodium Phenylacetate. Specifically, probenecid may inhibit the renal transport of the phenylacetylglutamine metabolite of sodium phenylacetate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Probenecid may decrease the protein binding of Sulfonylureas. Probenecid may increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Colchicine. Management: Colchicine should not be used with telaprevir in patients with impaired renal or hepatic function.  In those with normal renal and hepatic function, reduced colchicine doses (as directed) are required if used with telaprevir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Probenecid may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aminophylline; Theophylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Probenecid may decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13112764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13112765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Colchicine-Probenecid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5-500 mg (100): $96.80",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F13112768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Uric acid, serum: An increase occurs during childhood",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Males: 3.4-7 mg/dL or slightly more",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Females: 2.4-6 mg/dL or slightly more",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Target: &lt;6 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Values &gt;7 mg/dL are sometimes arbitrarily regarded as hyperuricemia, but there is no sharp line between normals and the serum uric acid of those with clinical gout. Normal ranges cannot be adjusted for purine ingestion, but high purine diet increases uric acid. Uric acid may be increased with body size, exercise, and stress.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F154367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Jordan KM, Cameron JS, Snaith M, et al, &ldquo;British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout,&rdquo;",
"      <i>",
"       Rheumatology (Oxford)",
"      </i>",
"      2007, 46(8):1372-4. Available at file://rheumatology.oxfordjournals.org/content/suppl/2008/02/21/kem056a.DC1/kem056b.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/61/36821/abstract-text/17522099/pubmed\" id=\"17522099\" target=\"_blank\">",
"        17522099",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhang W, Doherty M, Bardin T, et al, \"EULAR Evidence Based Recommendations for Gout. Part II: Management. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including therapeutics (ESCISIT),\"",
"      <i>",
"       Ann Rheum Dis",
"      </i>",
"      , 2006 65(10):1312-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/61/36821/abstract-text/16707532/pubmed\" id=\"16707532\" target=\"_blank\">",
"        16707532",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8717 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-A7B94B43F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_61_36821=[""].join("\n");
var outline_f35_61_36821=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154382\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154370\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154371\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154372\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15826358\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154362\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154351\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154365\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154364\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154380\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154368\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13112766\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154378\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154357\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13112764\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13112765\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524429\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13112768\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154367\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8717\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8717|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/25/33172?source=related_link\">",
"      Colchicine and probenecid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_61_36822="Reticulocytosis";
var content_f35_61_36822=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Reticulocytes after supravital staining",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Supravital stain of a peripheral blood smear shows blue-stained residual reticulin (ribosomal RNA) in reticulocytes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stanley L Schrier, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal peripheral blood smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a normal peripheral blood smear. Several platelets (black arrows) and a normal lymphocyte (blue arrow) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (red arrow) should equal one-third of its diameter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_61_36822=[""].join("\n");
var outline_f35_61_36822=null;
var title_f35_61_36823="Epidemiology, clinical manifestations, and diagnosis of tuboovarian abscess";
var content_f35_61_36823=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, clinical manifestations, and diagnosis of tuboovarian abscess",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/61/36823/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/61/36823/contributors\">",
"     Richard H Beigi, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/61/36823/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/61/36823/contributors\">",
"     Howard T Sharp, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/61/36823/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/61/36823/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/61/36823/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/61/36823/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H25899106\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A tuboovarian abscess is an inflammatory mass involving the fallopian tube, ovary, and, occasionally, other adjacent pelvic organs (eg, bowel, bladder) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/1\">",
"     1",
"    </a>",
"    ]. This may manifest as a tuboovarian complex (an agglutination of those structures) or a collection of pus (tuboovarian abscess). These abscesses are found most commonly in reproductive age women and typically result from upper genital tract infection. Tuboovarian abscess is usually a complication of pelvic inflammatory disease.",
"   </p>",
"   <p>",
"    Tuboovarian abscess is a serious and potentially life-threatening condition. Aggressive medical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical therapy is required and rupture of an abscess may result in sepsis. The mortality rate associated with tuboovarian abscess was approximately 50 percent or higher prior to the advent of broad-spectrum antibiotics and modern surgical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In current practice, the mortality rate approaches zero for abscesses that have not ruptured. Current mortality rates for patients with ruptured abscesses are not reported in the literature; data from the 1960s suggested a mortality rate ranging from 1.7 to 3.7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment modalities include broad spectrum antibiotic therapy, minimally-invasive drainage procedures, invasive surgery, or combinations of these interventions. For the large majority of small to medium sized tuboovarian abscesses, antibiotic therapy alone can affect cure.",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, and diagnosis of tuboovarian abscesses are reviewed here. Other manifestations of pelvic inflammatory disease (PID) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11992?source=see_link\">",
"     \"Pathogenesis of and risk factors for pelvic inflammatory disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35832?source=see_link\">",
"     \"Treatment of pelvic inflammatory disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/58/934?source=see_link\">",
"     \"Long-term complications of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25899120\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data regarding the incidence of tuboovarian abscess (TOA). In the United States from 1983 to 2000, 200,000 women were hospitalized annually for pelvic inflammatory disease (PID) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/6\">",
"     6",
"    </a>",
"    ]. It is important to note that not all cases of TOA are associated with PID. Nevertheless, since approximately one-third of women who are hospitalized with a diagnosis of PID are found to have a TOA, it can be extrapolated that approximately 66,000 cases of tuboovarian abscesses occur annually in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. A study from Norway reported that the number of patients admitted with a diagnosis of PID decreased between the time periods of 1990 to 1992 and 2000 to 2002, but a higher proportion of those patients had TOAs (increased from 26 to 43 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/9\">",
"     9",
"    </a>",
"    ]. The cause of this increase is not clear, but it may be related to changing practice patterns in the treatment of PID. In current practice, most women with PID receive outpatient treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Women who are admitted to the hospital have severe disease, and this includes those with TOA.",
"   </p>",
"   <p>",
"    Women with a TOA are most likely to be between the ages of 15 and 40 years, but age should not exclude the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/34/43560?source=see_link&amp;anchor=H4862349#H4862349\">",
"     \"Management and complications of tuboovarian abscess\", section on 'Postmenopausal women'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk factors for TOA are the same as for PID, and include the following: multiple sexual partners, age between 15 to 25 years, and a prior history of PID. Several cases of TOA following oocyte retrieval for in vitro fertilization have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11992?source=see_link&amp;anchor=H9#H9\">",
"     \"Pathogenesis of and risk factors for pelvic inflammatory disease\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Modern intrauterine devices (IUD) cause little, if any, increased risk for PID. The use of an IUD may be a risk factor for the development of a TOA (specifically unilateral TOA), but this association has not been substantiated by well-designed studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. IUDs that have been available since the late 1990s appear to be responsible for little, if any, increase in the risk for developing PID. The slight elevated risk of developing PID among users of modern IUDs appears to be primarily limited to the first three weeks after IUD insertion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11992?source=see_link&amp;anchor=H17#H17\">",
"     \"Pathogenesis of and risk factors for pelvic inflammatory disease\", section on 'Intrauterine device and tubal ligation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some data suggest that women human immunodeficiency virus (HIV) infection are more likely to develop a TOA than other women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25899127\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2672684\">",
"    <span class=\"h2\">",
"     Progression of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of the formation of a tuboovarian abscess (TOA) has not been fully elucidated. TOAs most frequently result from upper genital tract infection, usually pelvic inflammatory disease (PID) (",
"    <a class=\"graphic graphic_figure graphicRef67365 \" href=\"mobipreview.htm?2/17/2324\">",
"     figure 1",
"    </a>",
"    ). A TOA may also arise from local spread of infection associated with uncontrolled inflammatory diseases of the bowel, appendicitis, adnexal surgery or, occasionally, from hematologic spread. Pelvic abscesses that do not involve the tuboovarian complex often differ in etiology and management from TOAs and are not discussed here. Rarely, women who have undergone previous hysterectomy may still be at risk for the formation of a TOA, likely from local",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hematogenous spread from non-gynecologic organ systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unclear why some women with upper genital tract infection develop a TOA, while the majority do not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/8,15,22\">",
"     8,15,22",
"    </a>",
"    ]. In the majority of cases, the infection appears to originate within the lower genital tract from a sexually transmitted pathogen or from a woman&rsquo;s endogenous flora. Infection then ascends to the fallopian tubes. Ascending inflammation can progress to cause not only damage to the endothelium of the fallopian tube (destroying both the secretory and ciliated cells), but also edema of the infundibulum of the tube. This results in tubal blockage due to clubbing, ischemia, and necrosis, which contributes to the development of pyosalpinx. Prior infection may also result in abnormal tubal architecture that predisposes to TOA.",
"   </p>",
"   <p>",
"    Delay in diagnosis because of a failure to recognize or report symptoms by the patient (and thus not seeking care) does not appear to offer a complete explanation for progression to the development of TOA. This is supported by the fact that a sizable percentage of women with TOAs do not report specific antecedent acute symptoms directly attributable to PID [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TOAs are either tuboovarian complexes (an agglutination of pelvic organs with or without bowel) or a collection of pus that can be approached for drainage. Different treatment approaches are required depending upon these two forms (eg, drainage is typically feasible only for collections). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/34/43560?source=see_link&amp;anchor=H18590491#H18590491\">",
"     \"Management and complications of tuboovarian abscess\", section on 'Candidates for antibiotic therapy alone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Uncontrolled tubal infection with associated tissue invasion and destruction typically produces a copious purulent exudate with gradually increasing tissue edema. This edema in turn may compromise local blood supply and result in tissue necrosis. Tubal structures may adhere to and coalesce with the adjacent ovarian tissue (and often adjacent nongenital tract tissues) to form a complex mass. Necrosis inside this complex mass may result in one or more abscess cavities with an anaerobic environment that allows or even promotes the growth of numerous anaerobic bacteria that were previously present in the endogenous pelvic flora [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/8,15\">",
"     8,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2672691\">",
"    <span class=\"h2\">",
"     Microbiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;TOAs are typically polymicrobial. The bacteria found in TOAs are often similar to those found in patients with uncomplicated PID. There is also some overlap between the organisms commonly isolated in women with bacterial vaginosis and those isolated from patients with TOA; however, no direct link between bacterial vaginosis and TOA has been confirmed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11992?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathogenesis of and risk factors for pelvic inflammatory disease\", section on 'Microbiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30602?source=see_link&amp;anchor=H2#H2\">",
"     \"Bacterial vaginosis\", section on 'Pathogenesis and microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mixtures of aerobic, facultative, and anaerobic organisms have been isolated from TOAs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Common organisms include Escherichia coli, aerobic streptococci, Bacteroides fragilis, Prevotella, and other anaerobes, such as Peptostreptococcus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/7\">",
"     7",
"    </a>",
"    ]. Scattered case reports highlight the potential for an occasional unusual pathogen to be isolated from a TOA, including Candida species,",
"    <em>",
"     Pasteurella multocida",
"    </em>",
"    , Salmonellae species, and",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Rarely, in an immunocompromised patient,",
"    <em>",
"     Mycobacterium tuberculosis",
"    </em>",
"    may also be causative of a TOA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/26\">",
"     26",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    TOAs that occur in women with an intrauterine device (IUD), typically long-term users, are often associated with a specific anaerobic pathogen, Actinomyces israelii [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The reason for the relationship between this potential pathogen and IUD users remains controversial. Management of women with an IUD who develop a TOA is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/34/43560?source=see_link&amp;anchor=H4862342#H4862342\">",
"     \"Management and complications of tuboovarian abscess\", section on 'Intrauterine devices'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/27/19898?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of problems related to intrauterine contraception\", section on 'Actinomyces on cervical cytology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    N. gonorrhoeae and C. trachomatis are rarely isolated from the abscess cavity of a TOA. The role of these organisms appears to be limited to antecedent infections, such as cervicitis or PID. As an example, in a series of 232 women with a TOA, N. gonorrhoeae was found in the endocervix in approximately 33 percent of cases, but was present in less than 4 percent of the associated TOAs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/7\">",
"     7",
"    </a>",
"    ]. Some data suggest that N. gonorrhoeae facilitates invasion of the upper genital tract by lower genital tract flora, thus indirectly increasing the risk of progressive infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2672637\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2457194\">",
"    <span class=\"h2\">",
"     Typical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuboovarian abscess (TOA) is a complication of pelvic inflammatory disease (PID), and the classic presentation is the same as for PID alone, including acute lower abdominal pain, fever, chills, and vaginal discharge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/7,8,22\">",
"     7,8,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the presentation of many women with TOA differs from the classic scenario. Fever is not present in all patients and some patients report only low grade nocturnal fevers or chills. Also, not all women present in an acute fashion. These variations in clinical presentation were illustrated in one of the largest series of women with TOA (n = 175) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/7\">",
"     7",
"    </a>",
"    ]. As many as 40 percent of patients were afebrile upon presentation; 25 percent complained of chronic rather than acute abdominal pain; and 23 percent had normal white blood cell counts.",
"   </p>",
"   <p>",
"    In addition, some women with TOAs may present with seemingly unrelated symptoms, such as diffuse persistent upper abdominal pain or a change in bowel habits. Most women will not be overtly septic-appearing if their TOA is intact.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26295331\">",
"    <span class=\"h2\">",
"     Ruptured abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a ruptured TOA classically present with an acute abdomen and signs of sepsis, although this is not invariably noted. Most women will not be overtly septic appearing with intact abscesses. Rupture is probably a misnomer, as the process is more like a leak, slow or fast; it is not typical for the abscess to burst open. A ruptured TOA may sometimes produce a life-threatening illness, requiring immediate surgical exploration. (See",
"    <a class=\"local\" href=\"#H6513544\">",
"     'Excluding sepsis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2457328\">",
"    <span class=\"h1\">",
"     EVALUATION OF WOMEN WITH SUSPECTED TOA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of women with suspected tuboovarian abscess (TOA) includes making the diagnosis of pelvic inflammatory disease (PID) and then pursuing further testing to evaluate for TOA. In addition, other etiologies of the clinical presentation should be excluded. (See",
"    <a class=\"local\" href=\"#H2457409\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6513158\">",
"    <span class=\"h2\">",
"     Establishing a diagnosis of PID",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a presentation consistent with PID or TOA should be evaluated for PID with a complete history and pelvic examination. Laboratory testing includes a complete blood count and cervical testing for gonococcus and chlamydia. A pregnancy test should be performed, since this may affect choice of antimicrobial therapy and clinical course.",
"   </p>",
"   <p>",
"    The diagnosis and evaluation of PID are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6513071\">",
"    <span class=\"h2\">",
"     Further evaluation for TOA",
"    </span>",
"    &nbsp;&mdash;&nbsp;TOA is a potentially life-threatening condition. Once a woman has been diagnosed with PID, it is a clinical priority to decide whether she requires further evaluation for TOA.",
"   </p>",
"   <p>",
"    Further evaluation for TOA involves pelvic imaging. A very low threshold is warranted for performing imaging among all women admitted with PID, given the serious nature of a TOA and the frequent inability to adequately assess for masses on pelvic exam. We routinely order imaging studies for women with a diagnosis of PID who have one or more of the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acutely ill",
"     </li>",
"     <li>",
"      Significant abdominopelvic tenderness precluding a complete pelvic examination",
"     </li>",
"     <li>",
"      Adnexal mass noted on examination, particularly a tender mass [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/7,8,22\">",
"       7,8,22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lack of, or poor response to, antibiotic therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6972009\">",
"    <span class=\"h3\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukocytosis is found in most, but not all, women with TOA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/7,8,22\">",
"     7,8,22",
"    </a>",
"    ]. Of women admitted for a diagnosis of PID, one study suggested that women older than age 41 and those with higher laboratory markers of inflammation (white blood cell count and erythrocyte sedimentation rate) are most likely to have a TOA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6972017\">",
"    <span class=\"h3\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most useful and commonly performed studies in the evaluation for a TOA are pelvic ultrasonography or pelvic computed tomography (CT).",
"   </p>",
"   <p>",
"    Ultrasound is typically the first line imaging study since it produces high quality images of the upper genital tract, is less expensive than CT and does not expose the patient to radiation. Ultrasound is also preferred when other genital tract pathology must be excluded (eg, ovarian cyst, ectopic pregnancy, degenerating uterine fibroid).",
"   </p>",
"   <p>",
"    Ultrasonographic images of TOAs typically demonstrate complex multilocular masses that often obliterate the normal adnexal architecture",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cul-de-sac anatomy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77543 \" href=\"mobipreview.htm?3/21/3411\">",
"     image 1",
"    </a>",
"    ). These masses also often appear to contain speckled fluid and internal echoes consistent with inflammatory debris [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/7,8,29\">",
"     7,8,29",
"    </a>",
"    ]. This would be compared to a typical non-inflammatory mass with clear fluid and a thin rim. Choice of imaging modality is often institution-specific, with radiological potential for imaging-guided drainage procedures and local expertise being relevant considerations.",
"   </p>",
"   <p>",
"    CT is preferred in women in whom pathology associated with the gastrointestinal tract must be excluded (eg, appendicitis, phlegmon or abscess associated with inflammatory bowel disease). A few studies suggest use of CT may pose a slight advantage in terms of increased sensitivity to detect a TOA when compared to ultrasound (78 to 100 percent versus 75 to 82 percent, respectively). However, CT imaging is more costly than ultrasonography. In addition, the higher sensitivity of CT scan also assumes the patient had both intravenous and oral contrast, which may not be possible in ill patients for various reasons (eg, inability to tolerate oral intake of contrast) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/22,29,30\">",
"     22,29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific findings noted on CT that are consistent with a TOA include thick-walled, rim-enhancing adnexal masses. Again, this is in contrast to non-inflammatory masses with thin walls that are not rim-enhancing. Inflammatory masses are also often multilocular and may have an increased fluid density suggestive of purulent exudate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/31\">",
"     31",
"    </a>",
"    ]. CT imaging in some patients with TOA may show evidence of thickened fluid-filled tubes consistent with pyosalpinx, adjacent regional bowel thickening, and mesenteric stranding.",
"   </p>",
"   <p>",
"    In addition, CT (and occasionally ultrasound) may show changes suggestive of abscess rupture, with free abdominopelvic thickened fluid (often pus) and the presence of an abscess wall in the pelvis.",
"   </p>",
"   <p>",
"    There are few data about the use of other imaging modalities (eg, magnetic resonance imaging, radionuclide scanning) for the diagnosis of TOA. Such imaging modalities have limited use in routine clinical practice and are not routinely used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6972490\">",
"    <span class=\"h3\">",
"     Surgical evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical evaluation is indicated for TOA (",
"    <a class=\"graphic graphic_picture graphicRef60914 \" href=\"mobipreview.htm?9/18/9509\">",
"     picture 1",
"    </a>",
"    ) in several clinical contexts, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abscess rupture is suspected due to a finding of an acute abdomen or of signs of sepsis.",
"     </li>",
"     <li>",
"      A finding of a TOA in a postmenopausal woman, since this may be associated with gynecologic malignancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36823/abstract/32-34\">",
"       32-34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/34/43560?source=see_link&amp;anchor=H4862349#H4862349\">",
"       \"Management and complications of tuboovarian abscess\", section on 'Postmenopausal women'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2457481\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical diagnosis of tuboovarian abscess (TOA) is made based upon the finding of an inflammatory adnexal mass on pelvic imaging in a woman who meets diagnostic criteria for pelvic inflammatory disease (PID). Treatment may be initiated based upon a clinical diagnosis.",
"   </p>",
"   <p>",
"    The minimum criteria for diagnosis of PID are cervical motion tenderness or uterine or adnexal tenderness on examination in a woman with lower abdominal or pelvic pain. Additional diagnostic criteria for PID are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\", section on 'Diagnostic criteria and guidelines'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Purulent material obtained from a pelvic mass using imaging-guided drainage add further support for the diagnosis of TOA by confirming the presence of an abscess, but the anatomic source is not always correctly identified (ie, TOA versus diverticular abscess).",
"   </p>",
"   <p>",
"    A definitive diagnosis of TOA can be made only with direct visualization of the abscess during an invasive surgical procedure, such as laparoscopy or laparotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2457409\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for tuboovarian abscess (TOA) includes a wide array of other conditions that may also cause lower abdominal or pelvic pain, similar to the differential diagnosis for PID (",
"    <a class=\"graphic graphic_table graphicRef59205 \" href=\"mobipreview.htm?4/33/4636\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The differential diagnosis of the cause of lower abdominal pain in a woman includes diseases of the following organ systems:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reproductive tract &ndash; PID, ovarian mass, ruptured ovarian cyst, ovarian torsion, degenerating uterine fibroid, dysmenorrhea, ectopic pregnancy (including infected ectopic pregnancy), septic abortion, miscarriage",
"     </li>",
"     <li>",
"      Gastrointestinal &ndash; appendicitis, gastroenteritis, inflammatory bowel disease, irritable bowel syndrome, diverticulitis, constipation, cholecystitis",
"     </li>",
"     <li>",
"      Urinary tract &ndash; cystitis, pyelonephritis, nephrolithiasis, urethritis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The absence of fever does not entirely exclude TOA since, as noted above, some women with TOA are afebrile. (See",
"    <a class=\"local\" href=\"#H2672637\">",
"     'Clinical presentation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6513534\">",
"    <span class=\"h1\">",
"     FURTHER EVALUATION TO DETERMINE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the severity of illness and determination of the etiologic organism help to guide management of tuboovarian abscess (TOA). Management is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/34/43560?source=see_link\">",
"     \"Management and complications of tuboovarian abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6513544\">",
"    <span class=\"h2\">",
"     Excluding sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with TOA may present with or develop sepsis. A complete evaluation should include vital signs, physical examination and laboratory testing to exclude sepsis, particularly in ill-appearing patients. The diagnosis and evaluation of sepsis ares discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6120?source=see_link\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6513584\">",
"    <span class=\"h2\">",
"     Determining choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing that may aid choice of antimicrobial agent includes blood cultures and fluid obtained from the TOA cavity (whether it be from surgery or percutaneous drainage procedures). These should be obtained prior to administration of antibiotics, if possible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/34/43560?source=see_link&amp;anchor=H26297661#H26297661\">",
"     \"Management and complications of tuboovarian abscess\", section on 'Antibiotic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25899171\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A tuboovarian abscess (TOA) is an inflammatory mass involving the fallopian tube, ovary and, occasionally, other adjacent pelvic organs (eg, bowel, bladder). This may manifest as a tuboovarian complex (an agglutination of those structures) or a collection of pus (tuboovarian abscess). (See",
"      <a class=\"local\" href=\"#H25899106\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TOAs are found most commonly in reproductive age women and typically result from upper genital tract infection. (See",
"      <a class=\"local\" href=\"#H25899127\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TOAs are typically polymicrobial. Mixtures of aerobic, facultative, and anaerobic organisms have been isolated from TOAs using modern culture techniques with attention to specific anaerobic methodology. Common organisms include Escherichia coli, aerobic streptococci, Bacteroides fragilis, Prevotella, and other anaerobes, such as Peptostreptococcus. (See",
"      <a class=\"local\" href=\"#H2672691\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The classic presentation of TOA includes acute lower abdominal pain, fever, chills, and vaginal discharge. However, the presentation of many women with TOA differs from this classic scenario. (See",
"      <a class=\"local\" href=\"#H2672637\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Detecting TOA in women with pelvic inflammatory disease (PID) is a clinical priority. TOAs are most commonly detected based on findings from pelvic imaging. We order imaging studies for women with a diagnosis of PID who have the following characteristics: acutely ill; lack of, or poor response to, antibiotic therapy; adnexal mass noted on examination; or significant abdominopelvic tenderness precluding a complete pelvic examination. (See",
"      <a class=\"local\" href=\"#H6513071\">",
"       'Further evaluation for TOA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Imaging studies are a crucial component of the diagnosis of TOA. Ultrasound is typically the first line imaging study. It is also useful for excluding other genital tract pathology (eg, ovarian cyst, ectopic pregnancy, degenerating uterine fibroid). Computed tomography may also be used, particularly when pathology associated with the gastrointestinal tract must be excluded (eg, appendicitis, phlegmon or abscess associated with inflammatory bowel disease). (See",
"      <a class=\"local\" href=\"#H6972017\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with a ruptured TOA classically present with an acute abdomen and signs of sepsis, although this is not invariably noted. A ruptured abscess may be life-threatening, and requires immediate surgical exploration. (See",
"      <a class=\"local\" href=\"#H26295331\">",
"       'Ruptured abscess'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/1\">",
"      Granberg S, Gjelland K, Ekerhovd E. The management of pelvic abscess. Best Pract Res Clin Obstet Gynaecol 2009; 23:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/2\">",
"      PEDOWITZ P, BLOOMFIELD RD. RUPTURED ADNEXAL ABSCESS (TUBOOVARIAN) WITH GENERALIZED PERITONITIS. Am J Obstet Gynecol 1964; 88:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/3\">",
"      VERMEEREN J, TE LINDE RW. Intraabdominal rupture of pelvic abscesses. Am J Obstet Gynecol 1954; 68:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/4\">",
"      Rosen M, Breitkopf D, Waud K. Tubo-ovarian abscess management options for women who desire fertility. Obstet Gynecol Surv 2009; 64:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/5\">",
"      Paik CK, Waetjen LE, Xing G, et al. Hospitalizations for pelvic inflammatory disease and tuboovarian abscess. Obstet Gynecol 2006; 107:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/6\">",
"      Washington AE, Katz P. Cost of and payment source for pelvic inflammatory disease. Trends and projections, 1983 through 2000. JAMA 1991; 266:2565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/7\">",
"      Landers DV, Sweet RL. Tubo-ovarian abscess: contemporary approach to management. Rev Infect Dis 1983; 5:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/8\">",
"      Wiesenfeld HC, Sweet RL. Progress in the management of tuboovarian abscesses. Clin Obstet Gynecol 1993; 36:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/9\">",
"      S&oslash;rbye IK, Jerve F, Staff AC. Reduction in hospitalized women with pelvic inflammatory disease in Oslo over the past decade. Acta Obstet Gynecol Scand 2005; 84:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/10\">",
"      Ness RB, Soper DE, Holley RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002; 186:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/11\">",
"      Rein DB, Kassler WJ, Irwin KL, Rabiee L. Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing, but still substantial. Obstet Gynecol 2000; 95:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/12\">",
"      Varras M, Polyzos D, Tsikini A, et al. Ruptured tubo-ovarian abscess as a complication of IVF treatment: clinical, ultrasonographic and histopathologic findings. A case report. Clin Exp Obstet Gynecol 2003; 30:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/13\">",
"      Geissd&ouml;rfer W, B&ouml;hmer C, Pelz K, et al. Tuboovarian abscess caused by Atopobium vaginae following transvaginal oocyte recovery. J Clin Microbiol 2003; 41:2788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/14\">",
"      Marlowe SD, Lupetin AR. Tuboovarian abscess following transvaginal oocyte retrieval for in vitro fertilization: imaging appearance. Clin Imaging 1995; 19:180.",
"     </a>",
"    </li>",
"    <li>",
"     Sweet RL. Soft tissue infection and pelvic abscess. In: Infectious diseases of the female genital tract, 5th ed, Sweet RL, Gibbs RS (Eds), Lippincott Williams and Wilkins, Philadelphia 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/16\">",
"      Scott WC. Pelvic abscess in association with intrauterine contraceptive device. Am J Obstet Gynecol 1978; 131:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/17\">",
"      Burkman R, Schlesselman S, McCaffrey L, et al. The relationship of genital tract actinomycetes and the development of pelvic inflammatory disease. Am J Obstet Gynecol 1982; 143:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/18\">",
"      Burkman RT. Intrauterine devices and pelvic inflammatory disease: evolving perspectives on the data. Obstet Gynecol Surv 1996; 51:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/19\">",
"      Cohen CR, Sinei S, Reilly M, et al. Effect of human immunodeficiency virus type 1 infection upon acute salpingitis: a laparoscopic study. J Infect Dis 1998; 178:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/20\">",
"      Kamenga MC, De Cock KM, St Louis ME, et al. The impact of human immunodeficiency virus infection on pelvic inflammatory disease: a case-control study in Abidjan, Ivory Coast. Am J Obstet Gynecol 1995; 172:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/21\">",
"      Canas AM, Holloran-Schwartz B, Myles T. Tuboovarian abscess 12 years after total abdominal hysterectomy. Obstet Gynecol 2004; 104:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/22\">",
"      Lareau SM, Beigi RH. Pelvic inflammatory disease and tubo-ovarian abscess. Infect Dis Clin North Am 2008; 22:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/23\">",
"      Hsu WC, Lee YH, Chang DY. Tuboovarian abscess caused by Candida in a woman with an intrauterine device. Gynecol Obstet Invest 2007; 64:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/24\">",
"      Thaneemalai J, Asma H, Savithri DP. Salmonella tuboovarian abscess. Med J Malaysia 2007; 62:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/25\">",
"      Myckan KA, Booth CM, Mocarski E. Pasteurella multocida bacteremia and tuboovarian abscess. Obstet Gynecol 2005; 106:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/26\">",
"      Ilmer M, Bergauer F, Friese K, Mylonas I. Genital tuberculosis as the cause of tuboovarian abscess in an immunosuppressed patient. Infect Dis Obstet Gynecol 2009; 2009:745060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/27\">",
"      Onderdonk AB, Kasper DL, Cisneros RL, Bartlett JG. The capsular polysaccharide of Bacteroides fragilis as a virulence factor: comparison of the pathogenic potential of encapsulated and unencapsulated strains. J Infect Dis 1977; 136:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/28\">",
"      Halperin R, Svirsky R, Vaknin Z, et al. Predictors of tuboovarian abscess in acute pelvic inflammatory disease. J Reprod Med 2008; 53:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/29\">",
"      Gagliardi PD, Hoffer PB, Rosenfield AT. Correlative imaging in abdominal infection: an algorithmic approach using nuclear medicine, ultrasound, and computed tomography. Semin Nucl Med 1988; 18:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/30\">",
"      McClean KL, Sheehan GJ, Harding GK. Intraabdominal infection: a review. Clin Infect Dis 1994; 19:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/31\">",
"      Hiller N, Sella T, Lev-Sagi A, et al. Computed tomographic features of tuboovarian abscess. J Reprod Med 2005; 50:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/32\">",
"      Jackson SL, Soper DE. Pelvic inflammatory disease in the postmenopausal woman. Infect Dis Obstet Gynecol 1999; 7:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/33\">",
"      Protopapas AG, Diakomanolis ES, Milingos SD, et al. Tubo-ovarian abscesses in postmenopausal women: gynecological malignancy until proven otherwise? Eur J Obstet Gynecol Reprod Biol 2004; 114:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36823/abstract/34\">",
"      Lipscomb GH, Ling FW. Tubo-ovarian abscess in postmenopausal patients. South Med J 1992; 85:696.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7589 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-62FEFCC119-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_61_36823=[""].join("\n");
var outline_f35_61_36823=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25899171\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25899106\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25899120\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25899127\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2672684\">",
"      Progression of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2672691\">",
"      Microbiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2672637\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2457194\">",
"      Typical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26295331\">",
"      Ruptured abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2457328\">",
"      EVALUATION OF WOMEN WITH SUSPECTED TOA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6513158\">",
"      Establishing a diagnosis of PID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6513071\">",
"      Further evaluation for TOA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6972009\">",
"      - Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6972017\">",
"      - Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6972490\">",
"      - Surgical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2457481\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2457409\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6513534\">",
"      FURTHER EVALUATION TO DETERMINE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6513544\">",
"      Excluding sepsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6513584\">",
"      Determining choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25899171\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/7589\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7589|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?3/21/3411\" title=\"diagnostic image 1\">",
"      Tuboovarian abscess ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7589|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/17/2324\" title=\"figure 1\">",
"      Female genital tract infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7589|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/18/9509\" title=\"picture 1\">",
"      Tuboovarian abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7589|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/33/4636\" title=\"table 1\">",
"      Differential diagnosis of PID",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30602?source=related_link\">",
"      Bacterial vaginosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=related_link\">",
"      Clinical features and diagnosis of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/58/934?source=related_link\">",
"      Long-term complications of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/34/43560?source=related_link\">",
"      Management and complications of tuboovarian abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/27/19898?source=related_link\">",
"      Management of problems related to intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11992?source=related_link\">",
"      Pathogenesis of and risk factors for pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35832?source=related_link\">",
"      Treatment of pelvic inflammatory disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_61_36824="Ultrasound examination in obstetrics and gynecology";
var content_f35_61_36824=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ultrasound examination in obstetrics and gynecology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/61/36824/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/61/36824/contributors\">",
"     Thomas D Shipp, MD, RDMS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/61/36824/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/61/36824/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/61/36824/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/61/36824/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/61/36824/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/61/36824/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"ultrasound\" refers to sound waves of a frequency greater than that which the human ear can appreciate, namely frequencies greater than 20,000 cycles per second or Hertz (Hz). To obtain images of the pregnant or nonpregnant pelvis, frequencies of 2 to 10 million Hertz (2 to 10 megahertz [MHz]) are typically required.",
"   </p>",
"   <p>",
"    Real-time imaging is the most common sonographic technique used in obstetrics and gynecology. Multiple individual B-mode gray-scale images are obtained and rapidly displayed in succession, thereby creating a video of the area of interest over time that can be used to evaluate its structure and some aspects of its function. Real-time ultrasound is especially useful for imaging mobile subjects, such as the fetus or heart, and for quickly viewing an organ from different orientations.",
"   </p>",
"   <p>",
"    The physical principles of ultrasound imaging are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/60/27592?source=see_link\">",
"     \"Basic principles and safety of diagnostic ultrasound in obstetrics and gynecology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BASIC PROCEDURE AND EQUIPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sonography, like surgery, is an operator-dependent technology. A high level of competence can only be achieved by supervised experience with a large variety of normal and abnormal examinations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Preprocedure issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sonographer should know the reason for the ultrasound examination and results of other evaluations related to the patient's problem. All of this information is critical for targeting specific structures, choosing whether to use a transvaginal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transabdominal technique, and deciding whether additional studies may be helpful (eg, saline infusion sonohysterography, Doppler velocimetry).",
"   </p>",
"   <p>",
"    In the past, patients were routinely asked to fill their bladders prior to the ultrasound examination. With improvements in ultrasound technology and use of the vaginal probe, this has become unnecessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/1\">",
"     1",
"    </a>",
"    ]. There is little benefit to having a full bladder for obstetrical exams and it is often very uncomfortable for the patient. Furthermore, a full bladder can distort anatomy (eg, false diagnosis of placenta previa or falsely elongated cervix). The cervix can usually be seen transabdominally without a full bladder. If it cannot be seen transabdominally, transvaginal sonography almost always provides satisfactory images. Similarly, if transabdominal visualization of the pregnancy is inadequate in the first trimester, transvaginal sonography will almost always show more detail and is optimally performed with an empty bladder.",
"   </p>",
"   <p>",
"    In gynecologic patients, not allowing the patient to empty whatever urine is in her bladder just prior to a transabdominal ultrasound examination generally permits sufficient initial visualization of the pelvis. As discussed above, transvaginal sonography should be performed with an empty bladder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Patient position",
"    </span>",
"    &nbsp;&mdash;&nbsp;In obstetrics and gynecology, most exams are performed with the woman in a semi-recumbent position. A padded table and pillows provide reasonable comfort. It is desirable to be able to elevate the head of the bed because many pregnant women are unable to lie flat, especially later in pregnancy. Others will require pillows underneath their knees or behind their back to achieve a comfortable position.",
"   </p>",
"   <p>",
"    Transvaginal ultrasound examinations are done with the woman in a lithotomy position. Alternatively, a cushion can be placed under the buttocks to raise the pelvis, while the lower extremities are frog-legged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Gel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound waves do not pass through air well; therefore, coupling gel is necessary. The gel, which is placed on the patient's skin for transabdominal scans and on the covered probe for transvaginal scans, prevents air from coming between the transducer and the patient. The gel also permits the ultrasound probe to gently slide over the abdomen or along the vagina. Warming the gel in a commercial warming device improves patient comfort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Transducers and probes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transducer is located inside the ultrasound probe. The most common transducers used for transabdominal scanning are sector or curvilinear transducers that have frequencies up to 7.0 or 8.0 MHz [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/2\">",
"     2",
"    </a>",
"    ]. Transducers used for transvaginal scanning typically have frequencies up to 9.0 MHz. It is important to keep in mind that higher frequency transducers provide superior resolution, but have less tissue penetration. This trade-off is important for achieving images of diagnostic quality.",
"   </p>",
"   <p>",
"    Standard orientation when performing an ultrasound examination allows a consistent optimal interpretation of the ultrasound findings. The transabdominal ultrasound probe is held in the right hand with the mark (ie, a groove or ridge on one side of the ultrasound transducer) on the thumb side. With this orientation, the right side of the patient is displayed on the left side of the ultrasound imaging screen. The top of the image (the small angled portion) represents structures that are closer to the transabdominal ultrasound transducer, and the bottom of the image (the wide pie shaped perimeter) represents structures further away from the transducer. Because the ultrasound probe can be maneuvered from many different vantage points, the image orientation is only limited by the flexibility of the hand holding the ultrasound probe.",
"   </p>",
"   <p>",
"    Transvaginal ultrasound probes differ from transabdominal probes. With a transvaginal probe, the ultrasound beam can project at an angle from the axis of the probe. The mark on the probe represents the left side of the screen. Therefore, if the probe is inserted into the vagina and the mark is held at 12:00, the left side of the image display represents the anterior aspect of the pelvis, and the right side represents the posterior aspect of the pelvis. The top of the image (the small angled portion) represents structures that are closer to the transvaginal ultrasound transducer, and the bottom of the image (the wide pie shaped perimeter) represents pelvic structures further away from the transducer. When the probe is rotated with the mark at 9:00, the orientation is quite different. The inferior and superior portions are unchanged, but the left and right sides of the screen now represent the right and left aspects of the pelvis, respectively. The transvaginal probe can be both rotated and angled to both sides of the pelvis. This maneuvering can be disorienting to inexperienced examiners, yet is essential for a complete examination of the female pelvis.",
"   </p>",
"   <p>",
"    It may be more comfortable for the patient if she inserts the transvaginal probe into her vagina herself. A disposable probe cover (eg, male condom) is used to keep the transvaginal probe clean during examinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/3\">",
"     3",
"    </a>",
"    ]. After each use, transvaginal probes are cleaned and disinfected according to the manufacturer recommendations. The goal of preparing transvaginal ultrasound transducers for patient use is to achieve a high-level of disinfection. This is accomplished by removing the disposable probe cover and using running water to remove any debris. A cloth or similar pad can be used to clean and dry the transvaginal probe. The probe is then disinfected with a high-level disinfectant to provide maximum safety for reuse in the next patient. There are many such disinfectants, including 2.4 to 3.2 percent glutaraldehyde products, such as \"Cidex,\" \"Metricide,\" and \"Procide,\" non-glutaraldehyde products, such as \"Cidex OPA\" and \"Cidex PA,\" and 7.5 percent",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    solution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Manual settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several parameters require manual adjustment to obtain optimal images because patients differ in body shape and in the area targeted for examination (eg, cul-de-sac, upper abdomen, kidney).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The size of the image field should be adjusted to obtain the best visualization. The area of interest should be enlarged to allow for critical evaluation.",
"     </li>",
"     <li>",
"      The depth of penetration should be adjusted for thorough assessment of the structure of interest and its environment. If set high, a broad anatomic area can be seen, but individual structures will be small, indistinct, and 'far away,' while at low settings, the image will be seen 'close up' and detailed, but surrounding structures will not be visualized. Depending on the area of interest, the depth of penetration will typically be adjusted many times during an ultrasound examination to both obtain a broad view and to hone in on specific structures.",
"     </li>",
"     <li>",
"      The focal zone should be electronically adjusted to enhance visualization of structures at the depth being evaluated. The transmit zone focus should be manually placed at, or just below, the level of the structure of interest.",
"     </li>",
"     <li>",
"      The gain should be adjusted to achieve an appropriate level of brightness. Turning the gain up too high will make the image too bright, and turning it down too low will make the image too dark. There is progressive loss of amplitude and intensity of returning sound waves when imaging structures that are at greater distances from the probe. This loss varies with the particular tissue being insonated. Echoes from deeper structures can be amplified or enhanced to improve visualization. Similarly, excessive reverberant echoes can be decreased by turning down the gain, thus raising the threshold for echo detection at a particular level. This is accomplished by using the time-gain-compensation (TGC) knobs, which are adjusted to change the brightness at various levels of the image [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/2,4\">",
"       2,4",
"      </a>",
"      ]. Some newer ultrasound machines have an automatically adjusting gain feature. This may be especially helpful for those with less experience, and for those patients who are more difficult to insonate, such as obese women or those with prior abdominal surgery.",
"     </li>",
"     <li>",
"      Tissue harmonic imaging is an ultrasound technique that enhances visualization of structures that may not have been visualized clearly with standard gray-scale imaging [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/5\">",
"       5",
"      </a>",
"      ]. Standard two-dimensional gray-scale ultrasound uses a certain fundamental frequency, specific to the transducer. The returning echoes are detected at this frequency. Harmonic frequencies occur as the sound wave moves through tissues and are formed in multiples of the fundamental frequency. The first harmonic, which is twice the fundamental frequency, is used for tissue harmonic imaging. These harmonic frequencies increase with more penetration of the ultrasound beam, and they are at lower amplitude than the fundamental frequency. The inclusion of these harmonic frequencies results in an image with better contrast. Tissue harmonic imaging is especially helpful in obstetrics and gynecology in the obese patient when visualization is limited [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/4,6\">",
"       4,6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Scanning and documentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's name, medical record number, date of exam, referring clinician, and reason for referral should be documented. It is best to start the examination by getting an overall view of the uterus in an obstetrical ultrasound examination or the pelvis in a gynecologic examination. After this global view, the exam can focus on specific aspects of anatomy. To accomplish this overall view, the depth of penetration should be great enough to allow for a broad view of the uterus and pelvis. Without this global view, important aspects of the examination could be missed (eg, large pedunculated fibroids or large ovarian dermoids).",
"   </p>",
"   <p>",
"    Almost all obstetrical and gynecologic sonography is done in real-time, freely moving the probe to view each structure from multiple orientations and then freezing and storing the desired images. Most ultrasound systems can reevaluate the last few seconds of images by scrolling through them as slow as frame-by-frame in a cine loop. Short clips of mobile structures, such as the fetal heart, are also commonly kept as part of the patient's record. Images of both normal and abnormal anatomy, including size measurements where appropriate, should be stored. Biometric measurements are typically performed on the display monitor from a frozen image. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/47/34553?source=see_link\">",
"     \"Prenatal assessment of gestational age\"",
"    </a>",
"    .) The ultrasound images should be retained as long as clinically useful and consistent with local legal requirements.",
"   </p>",
"   <p>",
"    A written ultrasound report should be included in the patient's medical record, and sent to the referring clinician in a timely fashion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Clinically significant findings should be called to the referring clinician to ensure and facilitate appropriate follow-up. Emergent findings should be called to the referring clinician while the patient is still in the ultrasound facility or en route to the physician's office or hospital.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ADVANCED TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional clinical techniques are used selectively to provide further evaluation of uncertain findings on real time grey scale two dimensional sonography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Three-dimensional sonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three-dimensional sonography refers to a two-dimensional static display of three-dimensional data. Special probes and software are needed to acquire and render the images. Although not a new technique, the indications for its use have not been well-defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/4\">",
"     4",
"    </a>",
"    ]. The use of three-dimensional technology can reduce scanning time while maintaining adequate visualization of the fetus in obstetrical ultrasound and the pelvis in gynecologic ultrasound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Surface rendering of the fetus with three-dimensional sonography can better demonstrate abnormalities previously detected with two-dimensional sonography, especially facial abnormalities and neural tube defects. Fetal central nervous system three-dimensional data sets can be examined remotely to diagnose fetal brain malformations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In gynecology, the coronal plane of the uterus is easily obtained with three-dimensional but not two-dimensional sonography, thus enhancing visualization of the uterus, especially the uterine cavity. This has improved the capabilities for the sonographic diagnosis of uterine anomalies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three-dimensional sonography has been used to identify malposition of an intrauterine device (IUD), especially among symptomatic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Four-dimensional sonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four-dimensional sonography refers to three-dimensional images that can be viewed in real-time. It is also called dynamic three-dimensional sonography. It has been used to study the fetal heart, fetal movement, and fetal behavioral states.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Sonohysterography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Saline infusion sonohysterography refers to a procedure in which fluid is instilled into the uterine cavity transcervically to provide enhanced endometrial visualization during transvaginal ultrasound examination. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40823?source=see_link\">",
"     \"Saline infusion sonohysterography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Doppler ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Real-time ultrasound is primarily used to evaluate morphology, and is especially useful for studying the anatomy of moving objects, such as the fetus. By comparison, Doppler ultrasound is used to study blood flow and is particularly helpful in evaluating the functional state of the fetal cardiovascular system, fetoplacental and uteroplacental blood flow, and pelvic tumors. Specific uses of Doppler sonography are for evaluation of fetal anemia by assessing peak systolic flow in the middle cerebral artery, for evaluation of uteroplacental insufficiency in fetuses with growth restriction, and for assessing blood flow to suspected ovarian tumors among menopausal women. Doppler color flow mapping uses different colors to depict the direction of flow on a real-time ultrasound image. Power Doppler enables visualization of slower flow in small vessels without differentiating the direction of blood flow.",
"   </p>",
"   <p>",
"    Doppler ultrasound and specific uses of Doppler ultrasound are discussed in detail separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10728?source=see_link\">",
"       \"Doppler ultrasound of the umbilical artery for fetal surveillance\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/56/14217?source=see_link\">",
"       \"Venous Doppler for fetal assessment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/40/34440?source=see_link\">",
"       \"Sonographic differentiation of benign versus malignant adnexal masses\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/21/5464?source=see_link&amp;anchor=H11#H11\">",
"       \"Management of pregnancy complicated by Rhesus (Rh) alloimmunization\", section on 'Middle cerebral artery-peak systolic velocity'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OBSTETRICAL SONOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstetrical ultrasound provides information about the pregnancy that is useful for providing optimal prenatal care. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific obstetrical indications for ultrasound examination are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef58590 \" href=\"mobipreview.htm?12/16/12556\">",
"     table 1",
"    </a>",
"    ). More than one examination is indicated for patients with ongoing risk factors for adverse pregnancy outcome.",
"   </p>",
"   <p>",
"    The American College of Obstetricians and Gynecologists also states that the benefits and limitations of ultrasonography should be discussed with all patients, after which performance of a screening procedure is reasonable in patients who request it [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/16\">",
"     16",
"    </a>",
"    ]. Aneuploidy screening examinations can be performed in the first",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    second trimester. A fetal structure screening examination is typically performed in the second trimester. If a single screening examination is performed, the optimal time is at 18 to 20 weeks of gestation. This represents a balance between accurate dating of gestational age and detection of fetal anomalies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43576?source=see_link\">",
"     \"Routine prenatal ultrasonography as a screening tool\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Basic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A basic obstetrical ultrasound examination provides the following information [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fetal number (chorionicity if multiple gestation)",
"     </li>",
"     <li>",
"      Fetal biometry",
"     </li>",
"     <li>",
"      Fetal presentation",
"     </li>",
"     <li>",
"      Documentation of fetal cardiac activity",
"     </li>",
"     <li>",
"      Placental appearance and location",
"     </li>",
"     <li>",
"      Assessment of amniotic fluid volume",
"     </li>",
"     <li>",
"      Survey of fetal anatomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fetal biometry is used to estimate gestational age and fetal weight, as appropriate for the stage of pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/47/34553?source=see_link\">",
"     \"Prenatal assessment of gestational age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/1/25?source=see_link\">",
"     \"Prenatal sonographic assessment of fetal weight\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American College of Obstetricians and Gynecologists recommends that the cervix and adnexa be examined when clinically appropriate and technically feasible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/16\">",
"     16",
"    </a>",
"    ]. The American Institute of Ultrasound in Medicine and the American College of Radiology echo this position, and further state that \"a transperineal or transvaginal scan may be considered when evaluation of the cervix is needed\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/8,18,19\">",
"     8,18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21017?source=see_link\">",
"     \"Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fetal movement should be assessed, although temporary absence or reduction of fetal movement during an examination is not necessarily worrisome as it can be due to a normal fetal sleep cycle. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15959?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation of decreased fetal movements\", section on 'Normal fetal movement'",
"    </a>",
"    .) Abnormal positioning or unusually restricted or persistently absent fetal movements may suggest an abnormality, such as arthrogryposis.",
"   </p>",
"   <p>",
"    The specific components of first versus second and third trimester examinations are listed in the tables (",
"    <a class=\"graphic graphic_table graphicRef75784 \" href=\"mobipreview.htm?14/58/15275\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63045 \" href=\"mobipreview.htm?11/19/11579\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In-depth discussions of sonographic examination of congenital anomalies, the placenta, amniotic fluid, and fetal growth abnormalities can be found separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35032?source=see_link\">",
"       \"Clinical features, diagnosis, and course of placenta previa\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/7/8311?source=see_link\">",
"       \"Clinical features and diagnosis of placenta accreta, increta, and percreta\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31558?source=see_link\">",
"       \"Assessment of amniotic fluid volume\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/23/22906?source=see_link\">",
"       \"Diagnosis of fetal growth restriction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/38/31337?source=see_link\">",
"       \"Fetal macrosomia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22170?source=see_link\">",
"       \"Sonographic findings associated with fetal aneuploidy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21017?source=see_link\">",
"       \"Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      See individual topic reviews on specific congenital anomalies",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Limited examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited ultrasound examinations can be performed to address specific focused questions, ideally in patients who have been previously evaluated by a complete examination. Examples of appropriate use of limited studies include confirmation of the presence or absence of fetal cardiac activity, checking fetal presentation, and assessment of amniotic fluid volume in conjunction with nonstress testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Transabdominal examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's abdomen is exposed from the pubic bone to the umbilicus or xiphoid (depending upon stage of pregnancy) and draped to prevent gel from soiling clothing. It is prudent to document fetal cardiac activity as the initial step, as a diagnosis of fetal demise determines the context for the remainder of the examination. Using real-time scanning, the transabdominal ultrasound probe is maneuvered into different positions to allow visualization of multiple structures, to view a single structure from many different vantage points, and to avoid interference from impediments such as bone and intestinal air. Other maneuvers that may improve the quality of the image include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adjusting the frequency of the ultrasound wave: higher frequencies result in lower penetration and improved resolution. Multiple transducers of different frequencies may be necessary during an examination to balance resolution and need for tissue penetration. As an example, if one of the areas to be examined is close to the ultrasound probe, a higher frequency probe would give the best resolution, but may not give an adequate image of another structure deep in the pelvis.",
"     </li>",
"     <li>",
"      Using the probe to apply pressure. This can be particularly helpful when assessing the relationship between two or more contiguous structures.",
"     </li>",
"     <li>",
"      Having the patient roll from side to side. Scanning from the side of the maternal abdomen can sometimes greatly improve visualization of the fetus in pregnant women with truncal obesity.",
"     </li>",
"     <li>",
"      If the fetal presenting part is low in the pelvis, elevating the maternal hips may help move the presenting part cephalad, making it easier to visualize.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Transvaginal examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A transvaginal ultrasound examination is indicated for evaluating an early pregnancy, assessing the cervix to evaluate bleeding (eg, length, proximity to placenta), or improving visualization of fetal parts low in the pelvis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/47/34553?source=see_link\">",
"     \"Prenatal assessment of gestational age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21017?source=see_link\">",
"     \"Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transvaginal probes are manipulated both by rotation and angling from the midline. Proper orientation is essential as the field of view is much smaller with the transvaginal probe as compared to transabdominal probes (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Transducers and probes'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8826672\">",
"    <span class=\"h2\">",
"     Nonmedical use",
"    </span>",
"    &nbsp;&mdash;&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/60/27592?source=see_link&amp;anchor=H31630993#H31630993\">",
"     \"Basic principles and safety of diagnostic ultrasound in obstetrics and gynecology\", section on 'Nonmedical use'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     GYNECOLOGIC SONOGRAPHY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2938298\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gynecologic ultrasound examination has multiple uses, including but not limited to [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Evaluation of the menstrual cycle (endometrial thickness, follicular development)",
"     </li>",
"     <li>",
"      Monitoring natural or stimulated follicular development during infertility therapy",
"     </li>",
"     <li>",
"      Localization of an intrauterine device",
"     </li>",
"     <li>",
"      Evaluation of abnormal uterine bleeding",
"     </li>",
"     <li>",
"      Assessment of a pelvic mass (eg, adenomyosis, fibroid, cancer, cysts)",
"     </li>",
"     <li>",
"      Evaluation for sequelae of pelvic infection (eg, abscess, hydrosalpinx)",
"     </li>",
"     <li>",
"      Evaluation of congenital uterine anomalies",
"     </li>",
"     <li>",
"      Screening for malignancy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Components",
"    </span>",
"    &nbsp;&mdash;&nbsp;The components of a typical gynecologic sonographic examination include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Uterine size, shape, and orientation",
"     </li>",
"     <li>",
"      Evaluation of endometrium, myometrium, and cervix",
"     </li>",
"     <li>",
"      Identification and morphology of ovaries, if possible",
"     </li>",
"     <li>",
"      Assessment of the uterus and adnexa for masses, cysts, hydrosalpinges, fluid collections",
"     </li>",
"     <li>",
"      Evaluation of the cul-de-sac for free fluid or masses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Normal fallopian tubes usually cannot be seen during pelvic sonography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ultrasound examination is usually initiated transabdominally. The bladder does not have to be full; however, if the pelvis cannot be seen well, it may be necessary to have the patient fill her bladder to a comfortable capacity. This may be especially important for those women who are unable to tolerate placement of a transvaginal ultrasound probe. Often in these cases, the entire examination can be performed transabdominally. If a specific question remains unanswered, or if an abnormality is suspected, other approaches, such as a transrectal examination or even a transperineal examination, may be considered. Other techniques for improving visualization are described above (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Transabdominal examination'",
"    </a>",
"    above). Transabdominal scanning is important for evaluating the upper pelvis and abdomen, such as with large fibroids, ovarian neoplasms that extend into the upper abdomen, or ovaries lying high in the pelvis. Images only obtained by transvaginal scanning may not be adequate, or may miss pathology, as distance between the area under investigation and the vagina increases.",
"   </p>",
"   <p>",
"    After evaluation of the pelvis transabdominally, the patient is asked to void because transvaginal sonography is best performed with an empty bladder. Guiding the probe toward the area of interest, such as an ovary, and watching how this area moves in relation to the other pelvic organs is helpful for evaluation of complicated or unclear pelvic anatomy, especially in the setting of abnormalities. As an example, a pelvic mass (pedunculated fibroid or solid ovarian mass) may lie between the uterus and normal appearing ovarian tissue. On a still image, the uterus, mass, and normal ovary may appear contiguous. With movement of the probe, the specific origin of the mass can usually be determined.",
"   </p>",
"   <p>",
"    Visualization of pelvic structures with the transvaginal probe is limited by the relative positions of the pelvic organs and the presence of any pelvic masses. The resolution of high-frequency vaginal probes is good up to a depth of 6 to 8 cm. Transvaginal sonography can be performed concurrently with an abdominal examination to better define normal and abnormal anatomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/21\">",
"     21",
"    </a>",
"    ]. As an example, by applying pressure abdominally, the uterus with any associated fibroids, and even the intestines, can be moved away from the ovaries, allowing better visualization.",
"   </p>",
"   <p>",
"    Uterine weight correlates with uterine volume, which can be calculated using the prolate ellipsoid method where volume =",
"    <span class=\"nowrap\">",
"     4/3",
"    </span>",
"    (pi)(uterine",
"    <span class=\"nowrap\">",
"     length/2)(anteroposterior",
"    </span>",
"    <span class=\"nowrap\">",
"     diameter/2)(transverse",
"    </span>",
"    <span class=\"nowrap\">",
"     diameter/2)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Uterine measurements are most accurately obtained by transvaginal sonography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/24\">",
"     24",
"    </a>",
"    ]. The mean outer dimensions of the uterus among 263 premenopausal women (nulliparas, primiparas, multiparas) and menopausal women (less than or equal to five years of menopause, and greater than five years of menopause) with no uterine or ovarian pathological findings are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef76299 \" href=\"mobipreview.htm?38/39/39547\">",
"     table 4",
"    </a>",
"    ). The average transverse width of the endometrial cavity (ie, inside dimension of the uterus) is 2.7 cm among nulliparas, 3.0 cm among primiparas, and 3.2 cm among multiparas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The typical measurement of endometrial thickness includes both the anterior and posterior endometrial walls. If fluid is present within the endometrial cavity, the anterior and posterior endometrial echoes can be measured independently and summed. Immediately after menses, the endometrium is 1 to 4 mm thick; as the estrogen concentration rises, the thickness increases to 7 to 10 mm. After ovulation, echogenicity increases starting in the basal area; by the luteal phase, the entire endometrium is hyperechogenic with a thickness of 8 to 16 mm. In postmenopausal women, a thick endometrial lining (defined as &gt;4 mm) can be a marker of endometrial hyperplasia or malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple 2 to 5 mm follicles may be seen in the ovaries. A leading follicle of about 10 mm can be identified at the 9",
"    <sup>",
"     th",
"    </sup>",
"    or 10",
"    <sup>",
"     th",
"    </sup>",
"    cycle day; it grows rapidly and is 20 to 24 mm in diameter just before ovulation. After ovulation, the corpus luteum develops and may have a slightly heterogeneous consistency. The wall typically appears to be thick with low-level internal echoes and circumferential blood flow. The diameter of a normal follicle or corpus luteum does not usually exceed 30 mm. A corpus luteum cyst appears as a homogeneous hypoechogenic thin-walled structure.",
"   </p>",
"   <p>",
"    Any abnormality noted should be described, as appropriate: size, shape, location, echogenicity, echo pattern (cystic, solid, complex, septations), and a differential diagnosis of the most likely causes of the abnormality should be provided. Additional studies, such as Doppler velocimetry or saline infusion sonohysterography, may be useful in defining suspected lesions, or three-dimensional sonography, which may be helpful for evaluating the uterine shape in those patients with infertility.",
"   </p>",
"   <p>",
"    The use of ultrasound in gynecology and ultrasound images of gynecologic disorders can be found separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/40/34440?source=see_link\">",
"       \"Sonographic differentiation of benign versus malignant adnexal masses\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/24/34184?source=see_link\">",
"       \"Ultrasonography of pregnancy of unknown location\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/8/44166?source=see_link\">",
"       \"Ultrasound evaluation of the normal menstrual cycle\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38744?source=see_link\">",
"       \"Evaluation of the endometrium for malignant or premalignant disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pelvic floor sonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Translabial or transperineal ultrasound is being used increasingly to evaluate the pelvic floor in the work-up of women with pelvic organ prolapse and urinary or anal incontinence. Other uses of pelvic floor sonography include evaluation of urethral diverticula, rectal intussusception, mesh location, and residual urine volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/27\">",
"     27",
"    </a>",
"    ]. The role of pelvic floor sonography in the evaluation of women with pelvic floor symptoms is still under investigation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21735?source=see_link\">",
"     \"Endorectal endoscopic ultrasound in the evaluation of fecal incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     CREDENTIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sonography is an operator-dependent technology: a high level of competence can only be achieved by supervised experience with a large variety of normal and abnormal examinations.",
"   </p>",
"   <p>",
"    In the United States, ultrasound examinations in obstetrics and gynecology are typically performed by diagnostic medical sonographers. Almost all of these health professionals are credentialed by the American Registry of Diagnostic Medical Sonography (ARDMS) and receive the credentials RDMS upon completion of extensive education, training, and testing. Some sonographers are also credentialed by the American Registry of Radiologic Technologists.",
"   </p>",
"   <p>",
"    The examinations are supervised and interpreted by a sonologist, who is a physician with training and experience in this area. It is up to the physician to provide a report based upon the data provided by the sonographer, and, if indicated, by personally scanning the patient to confirm or modify the differential diagnosis. In the United States, the American Institute of Ultrasound in Medicine and the American College of Radiology have formulated guidelines for training, credentialing, continuing education, and ultrasound laboratory accreditation (available on the Internet at",
"    <a class=\"external\" href=\"file://www.aium.org/\">",
"     www.aium.org",
"    </a>",
"    and",
"    <a class=\"external\" href=\"file://www.acr.org/\">",
"     www.acr.org",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/7,28\">",
"     7,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no well-documented harmful effects to the fetus from diagnostic ultrasound examination. Nevertheless, examinations should be performed only for valid medical reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/60/27592?source=see_link\">",
"     \"Basic principles and safety of diagnostic ultrasound in obstetrics and gynecology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2186478\">",
"    <span class=\"h1\">",
"     GUIDELINES FROM NATIONAL ORGANIZATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      American College of Obstetricians and Gynecologists (ACOG) practice bulletin: Ultrasonography in pregnancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      American Institute of Ultrasound in Medicine (AIUM)",
"      <a class=\"external\" href=\"file://www.aium.org/resources/guidelines/obstetric.pdf\">",
"       practice guideline for the performance of obstetric ultrasound",
"      </a>",
"     </li>",
"     <li>",
"      International Society of Ultrasound in Obstetrics and Gynecology (ISUOG): performance of first trimester fetal ultrasound scan [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/29\">",
"       29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      ISUOG: practice guideline for performance of routine mid-trimester fetal ultrasound scan [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36824/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Royal College of Obstetricians and Gynaecologists (RCOG):",
"      <a class=\"external\" href=\"file://www.rcog.org.uk/womens-health/clinical-guidance/ultrasound-screening\">",
"       Ultrasound screening",
"      </a>",
"     </li>",
"     <li>",
"      Society of Obstetetricians and Gynaecologists of Canada (SOGC)",
"      <a class=\"external\" href=\"file://www.sogc.org/searchResults_guidelines_e.asp?cx=002944021877497107070:9qwhmqzxpyu&amp;cof=FORID:11&amp;ie=UTF-8&amp;q=ultrasound&amp;sa=Search+Guidelines\">",
"       ultrasound guidelines",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sonography is an operator-dependent technology: a high level of competence can only be achieved by supervised experience with a large variety of normal and abnormal examinations. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Credentials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard orientation when performed using a transabdominal ultrasound probe is to hold it in the right hand with the mark on the thumb side, which is the side displayed on the left side of the ultrasound image. With a transvaginal probe, the mark on the probe represents the left side of the screen; therefore, if the probe is inserted into the vagina and the mark is held at 12:00, the left side of the image display represents the anterior aspect of the pelvis, and the right side of the image represents the posterior aspect of the pelvis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Transducers and probes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Manual adjustment of settings (size, depth, focal zone, gain, tissue harmonic imaging) is important to obtain optimal images. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Manual settings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Information gained from real-time ultrasound examination can be enhanced, when indicated, by additional studies using Doppler, sonohysterography, and three-dimensional imaging. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Advanced techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The indications for obstetrical ultrasound examination are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef58590 \" href=\"mobipreview.htm?12/16/12556\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Suggested components of a basic obstetrical and gynecologic evaluation have been outlined by various groups. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Basic examination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Gynecologic sonography'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36824/abstract/1\">",
"      Benacerraf BR, Shipp TD, Bromley B. Is a full bladder still necessary for pelvic sonography? J Ultrasound Med 2000; 19:237.",
"     </a>",
"    </li>",
"    <li>",
"     Tempkin, BB. Ultrasound Scanning: Principles and protocols. 2nd edition. W.B. Saunders Company, Philadelphia 1999.",
"    </li>",
"    <li>",
"     American Institute of Ultrasound in Medicine website. Official Statements, Cleaning and Preparing Endocavity Ultrasound Transducers Between Patients, approved June 4, 2003.",
"    </li>",
"    <li>",
"     Brant, WE. Ultrasound: The core curriculum. Lippincott Williams &amp; Wilkins, New York 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36824/abstract/5\">",
"      Whittingham TA. New and future developments in ultrasonic imaging. Br J Radiol 1997; 70 Spec No:S119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36824/abstract/6\">",
"      Desser TS, Jeffrey RB. Tissue harmonic imaging techniques: physical principles and clinical applications. Semin Ultrasound CT MR 2001; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36824/abstract/7\">",
"      Roberts WE. Practical and financial considerations that affect selection and purchase of ultrasound equipment. Obstet Gynecol Clin North Am 1998; 25:663.",
"     </a>",
"    </li>",
"    <li>",
"     American Institute of Ultrasound in Medicine, Standards AIUM Practice Guideline for the performance of the antepartum obstetrical ultrasound examinations. American Institute of Ultrasound in Medicine, Laurel, MD 2007.",
"    </li>",
"    <li>",
"     American Institute of Ultrasound in Medicine, Guidelines for performance of the ultrasound examination of the female pelvis. American Institute of Ultrasound in Medicine, Laurel, MD 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36824/abstract/10\">",
"      Benacerraf BR, Shipp TD, Bromley B. How sonographic tomography will change the face of obstetric sonography: a pilot study. J Ultrasound Med 2005; 24:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36824/abstract/11\">",
"      Benacerraf BR, Shipp TD, Bromley B. Improving the efficiency of gynecologic sonography with 3-dimensional volumes: a pilot study. J Ultrasound Med 2006; 25:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36824/abstract/12\">",
"      Benacerraf BR, Shipp TD, Bromley B. Three-dimensional US of the fetus: volume imaging. Radiology 2006; 238:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36824/abstract/13\">",
"      Rizzo G, Abuhamad AZ, Benacerraf BR, et al. Collaborative study on 3-dimensional sonography for the prenatal diagnosis of central nervous system defects. J Ultrasound Med 2011; 30:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36824/abstract/14\">",
"      Bermejo C, Mart&iacute;nez Ten P, Cantarero R, et al. Three-dimensional ultrasound in the diagnosis of M&uuml;llerian duct anomalies and concordance with magnetic resonance imaging. Ultrasound Obstet Gynecol 2010; 35:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36824/abstract/15\">",
"      Benacerraf BR, Shipp TD, Bromley B. Three-dimensional ultrasound detection of abnormally located intrauterine contraceptive devices which are a source of pelvic pain and abnormal bleeding. Ultrasound Obstet Gynecol 2009; 34:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36824/abstract/16\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 101: Ultrasonography in pregnancy. Obstet Gynecol 2009; 113:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36824/abstract/17\">",
"      Salomon LJ, Alfirevic Z, Berghella V, et al. Practice guidelines for performance of the routine mid-trimester fetal ultrasound scan. Ultrasound Obstet Gynecol 2011; 37:116.",
"     </a>",
"    </li>",
"    <li>",
"     ACR-ACOG-AIUM Practice Guideline for the performance of obstetrical ultrasound. American College of Radiology, Reston, VA, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36824/abstract/19\">",
"      Glanc P, Andreotti RF, Lee SI, et al. ACR Appropriateness Criteria&reg; assessment of gravid cervix. Ultrasound Q 2011; 27:275.",
"     </a>",
"    </li>",
"    <li>",
"     AIUM Practice Guideline for the Performance of Pelvic Ultrasound Examinations. American Institute of Ultrasound in Medicine. Laurel, MD 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36824/abstract/21\">",
"      Timor-Tritsch IE, Monteagudo A. Scanning techniques in obstetrics and gynecology. Clin Obstet Gynecol 1996; 39:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36824/abstract/22\">",
"      Goldstein SR, Horii SC, Snyder JR, et al. Estimation of nongravid uterine volume based on a nomogram of gravid uterine volume: its value in gynecologic uterine abnormalities. Obstet Gynecol 1988; 72:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36824/abstract/23\">",
"      Kung FT, Chang SY. The relationship between ultrasonic volume and actual weight of pathologic uterus. Gynecol Obstet Invest 1996; 42:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36824/abstract/24\">",
"      Merz E, Miric-Tesanic D, Bahlmann F, et al. Sonographic size of uterus and ovaries in pre- and postmenopausal women. Ultrasound Obstet Gynecol 1996; 7:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36824/abstract/25\">",
"      Benacerraf BR, Shipp TD, Lyons JG, Bromley B. Width of the normal uterine cavity in premenopausal women and effect of parity. Obstet Gynecol 2010; 116:305.",
"     </a>",
"    </li>",
"    <li>",
"     ACOG Committee Opinion, The role of transvaginal ultrasonography in the evaluation of postmenopausal bleeding. Number 440. The American College of Obstetricians and Gynecologists, Washington, DC 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36824/abstract/27\">",
"      Dietz HP. Pelvic floor ultrasound: a review. Am J Obstet Gynecol 2010; 202:321.",
"     </a>",
"    </li>",
"    <li>",
"     American Institute of Ultrasound in Medicine, Training guidelines for physicians who evaluate and interpret diagnostic ultrasound examinations. American Institute of Ultrasound in Medicine, Laurel, MD 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36824/abstract/29\">",
"      Salomon LJ, Alfirevic Z, Bilardo CM, et al. ISUOG practice guidelines: performance of first-trimester fetal ultrasound scan. Ultrasound Obstet Gynecol 2013; 41:102.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5388 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-CE64EF4B76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_61_36824=[""].join("\n");
var outline_f35_61_36824=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BASIC PROCEDURE AND EQUIPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Preprocedure issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Patient position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Gel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Transducers and probes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Manual settings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Scanning and documentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ADVANCED TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Three-dimensional sonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Four-dimensional sonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Sonohysterography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Doppler ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OBSTETRICAL SONOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Basic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Limited examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Transabdominal examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Transvaginal examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8826672\">",
"      Nonmedical use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      GYNECOLOGIC SONOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2938298\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Components",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pelvic floor sonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      CREDENTIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2186478\">",
"      GUIDELINES FROM NATIONAL ORGANIZATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5388\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5388|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/16/12556\" title=\"table 1\">",
"      Indications for OB ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/58/15275\" title=\"table 2\">",
"      Components of a first trimester ultrasound examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/19/11579\" title=\"table 3\">",
"      Components of second and third trimester ultrasound examinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/39/39547\" title=\"table 4\">",
"      Normal uterine dimensions on ultrasound examination",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31558?source=related_link\">",
"      Assessment of amniotic fluid volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/60/27592?source=related_link\">",
"      Basic principles and safety of diagnostic ultrasound in obstetrics and gynecology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/7/8311?source=related_link\">",
"      Clinical features and diagnosis of placenta accreta, increta, and percreta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35032?source=related_link\">",
"      Clinical features, diagnosis, and course of placenta previa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/23/22906?source=related_link\">",
"      Diagnosis of fetal growth restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10728?source=related_link\">",
"      Doppler ultrasound of the umbilical artery for fetal surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21735?source=related_link\">",
"      Endorectal endoscopic ultrasound in the evaluation of fecal incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15959?source=related_link\">",
"      Evaluation of decreased fetal movements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38744?source=related_link\">",
"      Evaluation of the endometrium for malignant or premalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/38/31337?source=related_link\">",
"      Fetal macrosomia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/21/5464?source=related_link\">",
"      Management of pregnancy complicated by Rhesus (Rh) alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/47/34553?source=related_link\">",
"      Prenatal assessment of gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/1/25?source=related_link\">",
"      Prenatal sonographic assessment of fetal weight",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43576?source=related_link\">",
"      Routine prenatal ultrasonography as a screening tool",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40823?source=related_link\">",
"      Saline infusion sonohysterography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/40/34440?source=related_link\">",
"      Sonographic differentiation of benign versus malignant adnexal masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22170?source=related_link\">",
"      Sonographic findings associated with fetal aneuploidy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21017?source=related_link\">",
"      Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/24/34184?source=related_link\">",
"      Ultrasonography of pregnancy of unknown location",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/8/44166?source=related_link\">",
"      Ultrasound evaluation of the normal menstrual cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/56/14217?source=related_link\">",
"      Venous Doppler for fetal assessment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_61_36825="Actions of angiotensin II on the heart";
var content_f35_61_36825=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Actions of angiotensin II on the heart",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/61/36825/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/61/36825/contributors\">",
"     Timothy W Smith, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/61/36825/contributors\">",
"     James P Morgan, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/61/36825/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/61/36825/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/61/36825/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/61/36825/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/61/36825/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The renin-angiotensin system is a classic endocrine system, and angiotensin II is the primary effector hormone that is secreted in response to physiologic stimuli. However, there is now general agreement that there are complete local renin-angiotensin systems existing entirely within organs or tissues, which function in an autocrine or paracrine fashion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/1\">",
"     1",
"    </a>",
"    ]. Aldosterone and angiotensin converting enzyme are also produced by the failing heart, in proportion to the severity of heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32455?source=see_link\">",
"     \"Pathophysiology of heart failure: Neurohumoral adaptations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Synthesis of angiotensin II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin II is an oligopeptide of eight amino acids, formed from its original precursor, angiotensinogen, by a series of two enzymatic cleavages.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Angiotensinogen is released into the circulation by the liver. Renin, produced by the kidney, in response to glomerular hypoperfusion, catalyzes cleavage of angiotensinogen to angiotensin I, a decapeptide.",
"     </li>",
"     <li>",
"      Angiotensin I is in turn cleaved by angiotensin converting enzyme (ACE), to produce the octapeptide angiotensin II. The concentration of ACE is highest in the lung and it had been thought that most angiotensin II formation occurred in the pulmonary circulation. It is now clear, however, that ACE is produced in the vascular endothelium of many tissues, thus angiotensin II can be synthesized at a variety of sites, including the kidney, vascular endothelium, adrenal gland, and brain. In addition, alternative enzymatic pathways not involving ACE may contribute to angiotensin II production. Human heart chymase may be one such enzyme but its clinical significance remains uncertain (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Alternate pathways of angiotensin II production'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Angiotensin II binds to its specific receptors and exerts its effects in the brain, kidney, adrenal, vascular wall, and the heart.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Angiotensin converting enzyme 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;A related enzyme to ACE has been identified and called angiotensin converting enzyme 2 (ACE2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. ACE2 is predominantly expressed in the endothelium of the coronary and intrarenal vessels and the epithelium of the renal tubules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/4\">",
"     4",
"    </a>",
"    ]. The gene for ACE2 maps to the X chromosome in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Like ACE, ACE2 acts on angiotensin I. However, the reaction with ACE2 generates angiotensin 1-9 rather than the octapeptide angiotensin II (angiotensin 1-8) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/4\">",
"     4",
"    </a>",
"    ]. Angiotensin 1-9 has no known vascular activity but can be cleaved by ACE to angiotensin 1-7, a vasodilator, and smaller peptides. In contrast to ACE, ACE2 is not inhibited by ACE inhibitors and does not metabolize bradykinin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The physiologic importance of ACE2 is not completely understood. Disruption of the ACE2 gene in mice results in markedly reduced cardiac contractility and upregulation of hypoxia-induced genes in the heart, suggesting a role in the response to cardiac ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/5\">",
"     5",
"    </a>",
"    ]. Disruption of ACE2 did not interfere with blood pressure regulation.",
"   </p>",
"   <p>",
"    The cardiac changes in mice with disruption of the ACE2 gene were associated with increased plasma angiotensin II and were completely reversed by ablation of the ACE genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/5\">",
"     5",
"    </a>",
"    ]. These observations, plus the demonstration that angiotensin 1-7 is a vasodilator, suggest that ACE2 and ACE have counterbalancing effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ACE GENE POLYMORPHISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma and tissue concentrations of ACE, and therefore levels of angiotensin II, are determined in part by the ACE gene, which is located on chromosome 17. This gene may manifest insertion (I) or deletion (D) polymorphisms and therefore three genotypes (DD, II, and ID). Plasma and cardiac levels of ACE are 1.5 to 3-fold higher in patients with the DD compared to those with II genotype; they are intermediate in patients with ID genotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/7\">",
"     7",
"    </a>",
"    ]. This is concordant with the observation that, in normotensive subjects, the acute effect of an ACE inhibitor is significantly greater and lasts longer in patients with the II ACE genotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/8\">",
"     8",
"    </a>",
"    ]. These data suggest that relatively low doses of ACE inhibitor may be sufficient for patients with low ACE activity and lower levels of angiotensin II while larger doses are required for those with high ACE activity. In addition, the DD genotype is associated with elevated levels of aldosterone, despite therapy with an ACE inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/9\">",
"     9",
"    </a>",
"    ], and an increased degradation of bradykinin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The DD genotype has been associated with a variety of adverse cardiovascular effects. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progressive ventricular dilatation and remodeling after an acute MI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Left ventricular hypertrophy in hypertension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/13,14\">",
"       13,14",
"      </a>",
"      ], hypertrophic cardiomyopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/15\">",
"       15",
"      </a>",
"      ], and with physical training [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduced survival and increased left ventricular mass in patients with heart failure due to idiopathic dilated cardiomyopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. The reduction in survival may be ameliorated by beta blocker therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32455?source=see_link&amp;anchor=H7#H7\">",
"       \"Pathophysiology of heart failure: Neurohumoral adaptations\", section on 'ACE gene polymorphism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An increased risk of cardiomyopathy induced by excess alcohol intake [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35672?source=see_link\">",
"       \"Alcoholic cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There are conflicting data as to whether there is an increase in atherosclerosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/20,21\">",
"       20,21",
"      </a>",
"      ] or coronary disease. An initial report suggesting an increase in risk of coronary disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/22\">",
"       22",
"      </a>",
"      ] was not confirmed in much larger studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/23,24\">",
"       23,24",
"      </a>",
"      ], with the possible exception of specific patient populations such as those with type 2 diabetes mellitus or familial hypercholesterolemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The impact of ACE gene polymorphism on modification of cardiovascular risk in response to antihypertensive treatment was evaluated in the GenHAT substudy of participants in the ALLHAT trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/27\">",
"     27",
"    </a>",
"    ]. There was no difference in cardiovascular outcomes between the DD genotype and",
"    <span class=\"nowrap\">",
"     ID/II",
"    </span>",
"    genotypes as a combined group, and ACE",
"    <span class=\"nowrap\">",
"     I/D",
"    </span>",
"    genotype did not modify the effect of antihypertensive treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20218?source=see_link\">",
"     \"Choice of therapy in essential hypertension: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ANGIOTENSIN II RECEPTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two well-described subtypes of angiotensin II receptors, designated AT1 and AT2, both of which are present in the heart and have a high affinity for angiotensin II [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The AT1 subtype mediates the vasoconstrictor effect of angiotensin II and is generally thought to mediate angiotensin II-induced growth in the left ventricle and the arterial wall [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/30\">",
"       30",
"      </a>",
"      ]. The AT1 subtype is further subdivided into AT1A and AT1B.",
"     </li>",
"     <li>",
"      The actions of the AT2 receptor are less well understood. AT2 receptors are expressed in greater abundance in fetal tissues, followed by a decline in expression after birth [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. Their role in development has not been elucidated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. The AT2 receptor is not found in the skeletal muscle of patients with heart failure, suggesting that the AT2 receptor is unlikely to contribute to the beneficial effects of AT1 receptor antagonism on skeletal muscle vasculature in heart failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One animal study found that the AT2 receptor was a mediator of left ventricular hypertrophy in response to pressure overload [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/34\">",
"     34",
"    </a>",
"    ]. The AT2 receptor has also been implicated as an inhibitor of arterial endothelium wall growth when activated by angiotensin II. However, in vivo data in a model of angiotensin II-induced hypertension showed that exposure of a specific inhibitor of the AT2 receptor (PD123319) prevented angiotensin II-induced arterial hypertrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/35\">",
"     35",
"    </a>",
"    ]. These observations suggest that the AT2 receptor plays a greater role in stimulating growth in the arterial wall.",
"   </p>",
"   <p>",
"    The receptor subtypes may also exert different actions on left ventricular function. An animal study evaluated the effects of selective AT1 and AT2 receptor antagonists on the recovery of mechanical function after 30 minutes of global ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/36\">",
"     36",
"    </a>",
"    ]. The selective AT2 antagonist PD123319 was cardioprotective; when given before ischemia, it improved the recovery of left ventricular work and efficiency. In contrast, selective AT1 antagonism with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    blocked the recovery of left ventricular work and depressed efficiency. However, in another study with a very similar preparation and protocol, selective AT1 antagonism with losartan enhanced the recovery of myocardial function and attenuated the increase in expression of AT1 receptors induced by ischemia-reperfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/37\">",
"     37",
"    </a>",
"    ]. Differences in dose and preischemia exposure do not appear to explain the discrepant results.",
"   </p>",
"   <p>",
"    Further investigation is required to fully elucidate the action of the angiotensin II receptors in myocardium as well as vascular tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. The results of such investigation will have important implications for pharmacologic therapy in several cardiac conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ACE INHIBITORS AND ARBS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors have been successfully used in the management of a number of cardiovascular diseases including hypertension, congestive heart failure, and postmyocardial infarction. ACE inhibition reduces the amount of angiotensin II available to bind all angiotensin II receptors, while the angiotensin II receptor blockers (ARBs) such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/48/38663?source=see_link\">",
"     candesartan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    are specific AT1 receptor antagonists (",
"    <a class=\"graphic graphic_figure graphicRef55726 \" href=\"mobipreview.htm?9/23/9597\">",
"     figure 1",
"    </a>",
"    ). The greater specificity of ARB action may offer some benefits (eg, fewer side effects) but the less specific effects of ACE inhibition may provide other advantages.",
"   </p>",
"   <p>",
"    The angiotensin II receptor blockers are effective antihypertensive drugs that lack the side effects of ACE inhibitors resulting from their actions on the bradykinin system (particularly cough and angioedema) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25224?source=see_link\">",
"     \"Renin-angiotensin system inhibition in the treatment of hypertension\"",
"    </a>",
"    .) There is substantial evidence that angiotensin II receptor blockers have many of the same clinical benefits as ACE inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/30/26088?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2680?source=see_link\">",
"     \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, there may be differences since some of the benefits of ACE inhibitors may rely on preventing the actions of ACE that are not associated with the AT1 receptor or not associated with angiotensin at all. As an example, increased kinins may contribute to the action of ACE inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/42\">",
"     42",
"    </a>",
"    ]. On the other hand, if some angiotensin II is produced by a pathway that circumvents ACE, angiotensin II receptor antagonists might prove to be superior to ACE inhibitors in some settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ANGIOTENSIN II AND HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The actions of circulating angiotensin II contribute to hypertension. This may indirectly influence cardiac function, irrespective of any direct effect on the heart and myocardium.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Circulating angiotensin II promotes sodium and water reabsorption, increasing intravascular fluid volume which in turn increases cardiac preload and therefore stroke volume.",
"     </li>",
"     <li>",
"      Circulating angiotensin II causes systemic arteriolar vasoconstriction, increasing vascular resistance and cardiac afterload.",
"     </li>",
"     <li>",
"      Angiotensin II promotes endothelial dysfunction through AT1 receptor-mediated generation of superoxide anions from smooth muscle and endothelial cell membrane-bound reduced nicotinamide adenine dinucleotide-dependent oxidase (NADPH oxidase) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/44\">",
"       44",
"      </a>",
"      ]. These interactions may contribute to the development of vascular hypertrophy and hypertension, although the mechanisms are not well understood [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23162?source=see_link\">",
"       \"Endothelial dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Angiotensin II also affects the autonomic nervous system, stimulating the sympathetic nervous system and reducing vagal activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These actions are oriented toward maintaining the blood pressure when the renin-angiotensin system is activated by effective volume depletion. The net effect on cardiac function depends upon the interplay between the increase in preload (which would tend to increase cardiac output) and enhanced afterload (which would tend to diminish cardiac output).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIRECT CARDIAC EFFECTS OF ANGIOTENSIN II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the systemic, indirect effects of angiotensin II on the heart are complicated, it has frequently been difficult to interpret the cardiac effects of experimental manipulation of the renin-angiotensin system. The weight of evidence, however, supports three main direct effects on the heart: inotropy; chronotropy; and hypertrophy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Inotropy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inotropic effects of angiotensin II have been demonstrated in numerous species and preparations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. However, the magnitude of the effects ranges from very small to substantial. Furthermore, studies in some preparations have failed to show positive inotropy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/50-52\">",
"     50-52",
"    </a>",
"    ], emphasizing the need for careful control of confounding factors, such as the autonomic nervous system, temperature, heart rate, preload, and species differences. One study in human myocardium found a positive inotropic effect in the atrium but not the ventricle; the authors suggested that increased atrial contractility may enhance ventricular filling, leading to a rise in stroke volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of a possible inotropic effect of angiotensin II has not been fully resolved and may again be species dependent. Most investigators believe that inotropy is modulated by changes in the intracellular calcium transient which mediates excitation-contraction coupling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10632?source=see_link\">",
"     \"Excitation-contraction coupling in myocardium\"",
"    </a>",
"    .) However, others have suggested that an important effect of angiotensin II (in rabbit myocardium) is increasing the calcium-sensitivity of the myofilament, possibly by changing the intracellular pH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chronotropy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The direct effect of angiotensin II on chronotropy is less clear. The administration of angiotensin II may result in increased or decreased heart rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/48\">",
"     48",
"    </a>",
"    ]. These effects are largely indirect, resulting from stimulation of adrenergic nerves or reflex bradycardia induced by increases in vascular resistance and blood pressure. Any consistent direct chronotropic action of angiotensin II is obscured in the clinical setting by these indirect effects, which appear to be of greater magnitude.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is increasing evidence that angiotensin II stimulates hypertrophy of cardiac myocytes, independent of its systemic hemodynamic actions. This effect may be mediated in part by the generation of reactive oxygen intermediates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of angiotensin II in cardiac hypertrophy can be illustrated by the following experimental observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The administration of angiotensin II increased left ventricular mass even if the dose given produced no pressor effect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Administration of an ACE inhibitor completely prevented the development of hypertrophy in aortic banded rats, even though afterload was not reduced [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/56\">",
"       56",
"      </a>",
"      ]. The same effect was not observed with the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      or of a calcium channel blocker. Furthermore, if the drugs were administered after the development of left ventricular hypertrophy, only the ACE inhibitor caused regression of the hypertrophy.",
"     </li>",
"     <li>",
"      Angiotensin II-induced hypertrophy has been demonstrated at the cellular level. In isolated cardiac myocytes, for example, exposure to angiotensin II resulted in increased protein synthesis, an effect that was inhibited by an angiotensin II antagonist [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/57\">",
"       57",
"      </a>",
"      ]. The action of angiotensin II may be mediated by release of factors with paracrine activity, for example fibroblast growth factor (FGF)-2. As an example, one study found that animals lacking FGF-2 did not develop compensatory hypertrophy in response to angiotensin II-induced hypertension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some data suggest that protein kinase C (PKC) is an intracellular messenger in this response, since angiotensin II-induced hypertrophy is blocked by staurosporine (a specific inhibitor of PKC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential physiologic role of angiotensin II in the hypertrophic response is suggested by the findings of another in vitro study. In this model, mechanical stretch directly increased angiotensin II release from cardiac myocytes; the locally released angiotensin II then contributed to the development of stretch-induced hypertrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Role in humans",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are data suggesting that these observations apply to human disease. A clinical study evaluated correlates of left ventricular mass in 84 young healthy subjects aged 16 to 24 and provided findings compatible with a direct role for angiotensin II in the development of LVH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/60\">",
"     60",
"    </a>",
"    ]. Regression analysis showed that plasma angiotensin II, renin, and angiotensin converting enzyme levels correlated significantly with left ventricular mass, with the most important component being angiotensin II levels. This relationship was independent of systolic blood pressure and body size.",
"   </p>",
"   <p>",
"    The importance of angiotensin II in the development of LVH in hypertensive patients is also suggested indirectly by the observation that antihypertensive therapy with an ACE inhibitor or angiotensin II receptor blocker more predictably causes regression of LVH than beta blockers (",
"    <a class=\"graphic graphic_figure graphicRef82558 \" href=\"mobipreview.htm?42/42/43693\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17959?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical implications and treatment of left ventricular hypertrophy in hypertension\", section on 'Effect of antihypertensive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Ventricular remodeling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin II appears to contribute to the maladaptive (over the long-term) remodeling that occurs in patients with left ventricular dysfunction. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/25/19865?source=see_link\">",
"     \"Cardiac remodeling: Basic aspects\"",
"    </a>",
"    .) The effect on remodeling may explain part of the survival benefit associated with the use of ACE inhibitors after myocardial infarction or in asymptomatic or symptomatic left ventricular dysfunction of any cause. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/30/26088?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Electrical remodeling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation, even after only a few minutes, induces transient changes in atrial electrophysiology that promote its perpetuation; there is a progressive decrease in atrial refractoriness, known as \"electrical remodeling\" of the atria. It is possible, for example, that the shortening in atrial refractory period observed during and after an episode of atrial fibrillation predisposes to the spontaneous recurrence of atrial fibrillation in the days following cardioversion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/42/26278?source=see_link\">",
"     \"The electrocardiogram in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Angiotensin converting enzyme inhibitors can reduce the incidence of atrial fibrillation after a myocardial infarction and in chronic left ventricular dysfunction, which suggests that angiotensin II may have a role in the mechanism of atrial electrical remodeling. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/1/20503?source=see_link&amp;anchor=H2#H2\">",
"     \"ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation\", section on 'Possible mechanisms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pathogenesis of atherosclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased plasma concentrations of angiotensin II and increased activity of angiotensin II receptors promote the development and severity of atherosclerosis, particularly when combined with hyperlipidemia and in the absence of hemodynamic influences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]; lesions are predominantly lipid-laden macrophages and lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/63\">",
"     63",
"    </a>",
"    ]. Angiotensin II plays a role in increasing the plasma levels of intercellular adhesion molecule-1, which modulates leukocyte adhesion to the vascular endothelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/64\">",
"     64",
"    </a>",
"    ]; modulating the proliferation of vascular smooth muscle; and the production of extracellular matrix, which are major events in the pathogenesis of atherosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/65\">",
"     65",
"    </a>",
"    ]. In addition, angiotensin II and the AT1 receptor also induce the oxidized LDL receptor-1 (LOX-1), a human endothelial receptor that mediates the uptake of oxidized LDL and plays a role in oxidized LDL-mediated monocyte adhesion to coronary artery endothelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. In addition, the presence of oxidized LDL is associated with increased levels of inflammatory markers, such as vascular cell adhesion molecule-1, soluble tumor necrosis factor receptor II, and superoxide; treatment with an angiotensin II receptor blocker (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/37/21079?source=see_link\">",
"     irbesartan",
"    </a>",
"    ) significantly reduces the levels of these markers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Substantial amounts of ACE, AT1 receptor, and angiotensin II, all of which colocalized with macrophages, have been found in atherosclerotic lesions from monkeys and humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Angiotensin II induces the synthesis and release of interleukin 6, which is involved with inflammation and the stimulation of metalloproteinases, enzymes related to plaque instability and rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/70\">",
"     70",
"    </a>",
"    ]. Regression of atherosclerosis is associated with a reduction in angiotensin II and macrophages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/15/20729?source=see_link\">",
"     \"Pathology and pathogenesis of the vulnerable plaque\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further support for the role of angiotensin II in atherosclerosis comes from a number of animal models. As examples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The angiotensin II receptor blocker",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/35/26168?source=see_link\">",
"       losartan",
"      </a>",
"      reduced the formation of fatty streaks by about 50 percent in hypercholesteremic animals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/71\">",
"       71",
"      </a>",
"      ]. The mechanism for this beneficial effect included a reduction in the susceptibility of LDL to oxidation and the suppression of vascular monocyte activation and recruitment factors.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/35/26168?source=see_link\">",
"       Losartan",
"      </a>",
"      decreased the progression of established atherosclerotic lesions in hypercholesteremic apolipoprotein E-deficient mice [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/72\">",
"       72",
"      </a>",
"      ]. Losartan had no effect on macrophages. However, it increased the proportion of the atherosclerotic lesion that was occupied by collagen and decreased the breakdown of elastin, both of which may stabilize atherosclerotic lesions.",
"     </li>",
"     <li>",
"      The renin inhibitor,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9142?source=see_link\">",
"       aliskiren",
"      </a>",
"      , reduced the size of atherosclerotic lesions in the aortic arch and root of fat-fed LDL receptor-deficient mice [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Infarct-related artery patency and infarction size",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     I/D",
"    </span>",
"    ACE genotype, which determines plasma and tissue levels of angiotensin converting enzyme and hence angiotensin II levels, may be an independent predictor of both perfusion defect size and patency of the infarct related artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/74\">",
"     74",
"    </a>",
"    ]. Among 113 patients with an acute myocardial infarction, those with the DD genotype had a larger total and reversible defect on adenosine-thallium perfusion scan compared to patients with the II or ID genotype. Occlusion of the infarct-related artery was also more common in patients with the DD genotype compared to the other genotypes (odds ratio 3.9).",
"   </p>",
"   <p>",
"    Therapy with an ACE inhibitor can reduce the severity of injury associated with a coronary occlusion in cholesterol-fed, but not normally-fed, animals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/75\">",
"     75",
"    </a>",
"    ]. This benefit may be mediated by reversal of the enhanced interaction between leukocytes and the endothelium in the ischemic myocardium via a bradykinin-related pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Neointima formation after balloon injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin II, via the AT1 receptor, may play an important role in the development of proliferation of vascular smooth muscle cells and neointima formation after balloon injury. In animal models, ACE inhibitors and antagonists of the angiotensin AT1 receptor prevent neointima formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/76\">",
"     76",
"    </a>",
"    ]. Arterial extracellular signal-regulated kinases, members of the mitogen activated protein kinase family which have a role in apoptosis and cell proliferation, are significantly activated by balloon injury, mediated in part by the AT1 receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CARDIAC RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lack of a good correlation between levels of circulating renin and angiotensin II and the clinical benefits associated with ACE inhibitors prompted speculation of the existence of complete renin-angiotensin systems localized to the heart (and other tissues) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/78\">",
"     78",
"    </a>",
"    ]. As noted above, experimental manipulation of the renin-angiotensin system in vitro produced results suggestive of a local system operating in myocardium. Each component of the system (renin, angiotensinogen, angiotensin converting enzyme, and angiotensin II) can be found in myocardium, but ruling out myocardial sequestration of circulating components was not possible by these methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Molecular biology techniques have demonstrated local myocardial synthesis of each component of the system, including the angiotensin II receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/79\">",
"     79",
"    </a>",
"    ] and ACE binding sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/81\">",
"     81",
"    </a>",
"    ]. Modulation of local synthesis of the renin-angiotensin system (in the absence of change in circulating renin and angiotensin levels) in response to pressure overload has suggested an autocrine or paracrine action of the cardiac renin-angiotensin system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compelling evidence for such a role was demonstrated, as noted above, by the observation that stretch directly increased release of angiotensin II from cardiac myocytes; stretch also increased expression of the angiotensinogen gene in these cells in the long-term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/59\">",
"     59",
"    </a>",
"    ]. (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25224?source=see_link\">",
"     \"Renin-angiotensin system inhibition in the treatment of hypertension\"",
"    </a>",
"    ). Studies in the failing human myocardium have demonstrated reduced gene expression and selective downregulation of the AT1 receptor and an increased number of ACE binding sites; these findings are compatible with enhanced local activity of angiotensin II [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/81,83,84\">",
"     81,83,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been more difficult to document physiologically relevant renin release in the heart, but cardiac mast cells both produce and secrete renin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. The renin that is released from the mast cells can lead to the formation of angiotensin II and, in ischemia-reperfusion models, norepinephrine release and ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/86\">",
"     86",
"    </a>",
"    ]. These effects could be reduced by mast cell stabilizers such as cromolyn or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5555?source=see_link\">",
"     lodoxamide",
"    </a>",
"    and AT1 receptor blockers and were much less prominent in the hearts of mice that were mast cell deficient.",
"   </p>",
"   <p>",
"    The presence of both circulating and local renin-angiotensin systems implies that there may be settings in which activation and action of the local system may be different from the circulating system. It has been suggested, for example, that the circulating system is more important for short-term fluid and electrolyte homeostasis and that the local system functions more chronically to modulate cardiac function and structure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/80\">",
"     80",
"    </a>",
"    ]. ACE inhibitor therapy, therefore, may have a more important and prolonged effect on the local renin-angiotensin systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/80\">",
"     80",
"    </a>",
"    ]. It has been suggested that the more lipophilic ACE inhibitors may be more effective in inhibiting tissue ACE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/87\">",
"     87",
"    </a>",
"    ]. Whether this will translate into clinical benefit remains to be proven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Alternate pathways of angiotensin II production",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another difference between the circulating and cardiac renin-angiotensin systems is that alternative enzymatic pathways not involving ACE may contribute to angiotensin II production. Human heart chymase appears to be the most important of these pathways, particularly in the ventricles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/88-90\">",
"     88-90",
"    </a>",
"    ]. The physiologic importance of chymase is uncertain because of the presence of natural protease inhibitors in the interstitial fluid which inhibit chymase-induced angiotensin II production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/91\">",
"     91",
"    </a>",
"    ]. It is possible, however, that such pathways could in part explain the possibly additive effects of ACE inhibitors and angiotensin II receptor antagonists (which would abolish activation of the AT1 receptor by angiotensin II from any source) in certain cardiac conditions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/14/19685?source=see_link&amp;anchor=H5#H5\">",
"     \"Differences between angiotensin converting enzyme inhibitors and receptor blockers\", section on 'Rationale for combined therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to the possible association between ACE genotype and adverse cardiovascular effects, there is no association between allelic variants of chymase and blood pressure, heart size, or acute myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Mineralocorticoid receptors and aldosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the cardiac renin-angiotensin system, there are mineralocorticoid receptors in the heart, coronary arteries, and aorta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/93\">",
"     93",
"    </a>",
"    ]. These receptors can be activated by aldosterone, produced locally in the heart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/2,3\">",
"     2,3",
"    </a>",
"    ] or in the adrenal glands, and by angiotensin II [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/94\">",
"     94",
"    </a>",
"    ]. Local production of aldosterone in the diseased ventricle results from angiotensin II-mediated induction of aldosterone synthase (CYP11B2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36825/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stimulation of the cardiac and vascular mineralocorticoid receptors can contribute to the progression of heart failure, thereby providing the rationale for the administration of mineralocorticoid receptor antagonists, and to increased rates of stroke and coronary events in patients with primary aldosteronism compared to matched patients with essential hypertension. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28521?source=see_link\">",
"     \"Use of aldosterone antagonists in heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features of primary aldosteronism\", section on 'Cardiovascular risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19249671\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Angiotensinogen is produced in the liver and cleaved by renin to make angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to make angiotensin II. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Synthesis of angiotensin II'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two types of angiotensin II receptors, AT1 and AT2. AT1 has been better characterized and is thought to mediate ventricular and arterial hypertrophy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Angiotensin II receptors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ACE inhibitors and angiotensin II receptor blockers are the pharmacologic agents used clinically to affect the renin-angiotensin system. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'ACE inhibitors and ARBs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Angiotensin II affects cardiac function indirectly (eg, via systemic arteriolar vasoconstriction and sodium and water retention) and directly via direct cardiac effects (eg, promotion of cardiomyopathy hypertrophy and maladaptive remodeling with LV dysfunction such as after MI). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Direct cardiac effects of angiotensin II'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Angiotensin II and hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Experimental work suggests that there is an entire localized renin-angiotensin system acting in a paracrine fashion within the heart (and other organs). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Cardiac renin-angiotensin-aldosterone system'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/1\">",
"      van Kats JP, Danser AH, van Meegen JR, et al. Angiotensin production by the heart: a quantitative study in pigs with the use of radiolabeled angiotensin infusions. Circulation 1998; 98:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/2\">",
"      Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001; 103:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/3\">",
"      Silvestre JS, Heymes C, Oub&eacute;na&iuml;ssa A, et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999; 99:2694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/4\">",
"      Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/5\">",
"      Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/6\">",
"      Boehm M, Nabel EG. Angiotensin-converting enzyme 2--a new cardiac regulator. N Engl J Med 2002; 347:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/7\">",
"      Danser AH, Schalekamp MA, Bax WA, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 1995; 92:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/8\">",
"      Ueda S, Meredith PA, Morton JJ, et al. ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. Circulation 1998; 98:2148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/9\">",
"      Cicoira M, Zanolla L, Rossi A, et al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 2001; 37:1808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/10\">",
"      Murphey LJ, Gainer JV, Vaughan DE, Brown NJ. Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. Circulation 2000; 102:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/11\">",
"      Pinto YM, van Gilst WH, Kingma JH, Schunkert H. Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. Captopril and Thrombolysis Study Investigators. J Am Coll Cardiol 1995; 25:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/12\">",
"      Oosterga M, Voors AA, de Kam PJ, et al. Plasma angiotensin-converting enzyme activity and left ventricular dilation after myocardial infarction. Circulation 1997; 95:2607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/13\">",
"      Schunkert H, Hense HW, Holmer SR, et al. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med 1994; 330:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/14\">",
"      Celentano A, Mancini FP, Crivaro M, et al. Cardiovascular risk factors, angiotensin-converting enzyme gene I/D polymorphism, and left ventricular mass in systemic hypertension. Am J Cardiol 1999; 83:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/15\">",
"      Tesson F, Dufour C, Moolman JC, et al. The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation. J Mol Cell Cardiol 1997; 29:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/16\">",
"      Montgomery HE, Clarkson P, Dollery CM, et al. Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. Circulation 1997; 96:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/17\">",
"      Andersson B, Sylv&eacute;n C. The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure. J Am Coll Cardiol 1996; 28:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/18\">",
"      McNamara DM, Holubkov R, Janosko K, et al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 2001; 103:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/19\">",
"      Fern&aacute;ndez-Sol&agrave; J, Nicol&aacute;s JM, Oriola J, et al. Angiotensin-converting enzyme gene polymorphism is associated with vulnerability to alcoholic cardiomyopathy. Ann Intern Med 2002; 137:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/20\">",
"      Pfohl M, Athanasiadis A, Koch M, et al. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is associated with coronary artery plaque calcification as assessed by intravascular ultrasound. J Am Coll Cardiol 1998; 31:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/21\">",
"      Pfohl M, Koch M, Prescod S, et al. Angiotensin I-converting enzyme gene polymorphism, coronary artery disease and myocardial infarction. An angiographically controlled study. Eur Heart J 1999; 20:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/22\">",
"      Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/23\">",
"      Keavney B, McKenzie C, Parish S, et al. Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators. Lancet 2000; 355:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/24\">",
"      Lindpaintner K, Pfeffer MA, Kreutz R, et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995; 332:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/25\">",
"      Ruiz J, Blanch&eacute; H, Cohen N, et al. Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 1994; 91:3662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/26\">",
"      O'Malley JP, Maslen CL, Illingworth DR. Angiotensin-converting enzyme DD genotype and cardiovascular disease in heterozygous familial hypercholesterolemia. Circulation 1998; 97:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/27\">",
"      Arnett DK, Davis BR, Ford CE, et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation 2005; 111:3374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/28\">",
"      Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/29\">",
"      Griendling KK, Lass&egrave;gue B, Alexander RW. Angiotensin receptors and their therapeutic implications. Annu Rev Pharmacol Toxicol 1996; 36:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/30\">",
"      Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996; 334:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/31\">",
"      Tsutsumi K, Saavedra JM. Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain. Am J Physiol 1991; 261:R209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/32\">",
"      Grady EF, Sechi LA, Griffin CA, et al. Expression of AT2 receptors in the developing rat fetus. J Clin Invest 1991; 88:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/33\">",
"      Malendowicz SL, Ennezat PV, Testa M, et al. Angiotensin II receptor subtypes in the skeletal muscle vasculature of patients with severe congestive heart failure. Circulation 2000; 102:2210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/34\">",
"      Senbonmatsu T, Ichihara S, Price E Jr, et al. Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload. J Clin Invest 2000; 106:R25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/35\">",
"      Stoll M, Steckelings UM, Paul M, et al. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995; 95:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/36\">",
"      Ford WR, Clanachan AS, Jugdutt BI. Opposite effects of angiotensin AT1 and AT2 receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts. Circulation 1996; 94:3087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/37\">",
"      Yang BC, Phillips MI, Ambuehl PE, et al. Increase in angiotensin II type 1 receptor expression immediately after ischemia-reperfusion in isolated rat hearts. Circulation 1997; 96:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/38\">",
"      Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation 2002; 105:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/39\">",
"      Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part II: AT(1) receptor regulation. Circulation 2002; 105:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/40\">",
"      Bauer JH, Reams GP. The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs. Arch Intern Med 1995; 155:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/41\">",
"      Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001; 103:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/42\">",
"      Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997; 95:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/43\">",
"      Munger MA, Furniss SM. Angiotensin II receptor blockers: novel therapy for heart failure? Pharmacotherapy 1996; 16:59S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/44\">",
"      Pueyo ME, Michel JB. Angiotensin II receptors in endothelial cells. Gen Pharmacol 1997; 29:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/45\">",
"      Dikalova A, Clempus R, Lass&egrave;gue B, et al. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 2005; 112:2668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/46\">",
"      Matsuno K, Yamada H, Iwata K, et al. Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation 2005; 112:2677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/47\">",
"      Clemson B, Gaul L, Gubin SS, et al. Prejunctional angiotensin II receptors. Facilitation of norepinephrine release in the human forearm. J Clin Invest 1994; 93:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/48\">",
"      Baker KM, Booz GW, Dostal DE. Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system. Annu Rev Physiol 1992; 54:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/49\">",
"      Lindpaintner K, Ganten D. The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence. Circ Res 1991; 68:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/50\">",
"      Allen IS, Cohen NM, Dhallan RS, et al. Angiotensin II increases spontaneous contractile frequency and stimulates calcium current in cultured neonatal rat heart myocytes: insights into the underlying biochemical mechanisms. Circ Res 1988; 62:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/51\">",
"      Baker KM, Singer HA. Identification and characterization of guinea pig angiotensin II ventricular and atrial receptors: coupling to inositol phosphate production. Circ Res 1988; 62:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/52\">",
"      Doggrell SA. The effects of atriopeptin and angiotensin on the rat right ventricle. Gen Pharmacol 1989; 20:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/53\">",
"      Holubarsch C, Hasenfuss G, Schmidt-Schweda S, et al. Angiotensin I and II exert inotropic effects in atrial but not in ventricular human myocardium. An in vitro study under physiological experimental conditions. Circulation 1993; 88:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/54\">",
"      Ikenouchi H, Barry WH, Bridge JH, et al. Effects of angiotensin II on intracellular Ca2+ and pH in isolated beating rabbit hearts and myocytes loaded with the indicator indo-1. J Physiol 1994; 480 ( Pt 2):203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/55\">",
"      Nakamura K, Fushimi K, Kouchi H, et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 1998; 98:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/56\">",
"      Linz W, Sch&ouml;lkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens A 1989; 11:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/57\">",
"      Baker KM, Aceto JF. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol 1990; 259:H610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/58\">",
"      Pellieux C, Foletti A, Peduto G, et al. Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. J Clin Invest 2001; 108:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/59\">",
"      Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993; 75:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/60\">",
"      Harrap SB, Dominiczak AF, Fraser R, et al. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation 1996; 93:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/61\">",
"      Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/62\">",
"      Dahl&ouml;f B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/63\">",
"      Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000; 105:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/64\">",
"      Pastore L, Tessitore A, Martinotti S, et al. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 1999; 100:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/65\">",
"      Itoh H, Mukoyama M, Pratt RE, et al. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 1993; 91:2268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/66\">",
"      Morawietz H, Rueckschloss U, Niemann B, et al. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 1999; 100:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/67\">",
"      Li D, Mehta JL. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation 2000; 101:2889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/68\">",
"      Navalkar S, Parthasarathy S, Santanam N, Khan BV. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 2001; 37:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/69\">",
"      Potter DD, Sobey CG, Tompkins PK, et al. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation 1998; 98:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/70\">",
"      Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000; 101:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/71\">",
"      Strawn WB, Chappell MC, Dean RH, et al. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000; 101:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/72\">",
"      Suganuma E, Babaev VR, Motojima M, et al. Angiotensin inhibition decreases progression of advanced atherosclerosis and stabilizes established atherosclerotic plaques. J Am Soc Nephrol 2007; 18:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/73\">",
"      Lu H, Rateri DL, Feldman DL, et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 2008; 118:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/74\">",
"      Dakik HA, Mahmarian JJ, Verani MS, et al. Association of angiotensin I-converting enzyme gene polymorphism with myocardial ischemia and patency of infarct-related artery in patients with acute myocardial infarction. J Am Coll Cardiol 1997; 29:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/75\">",
"      Hoshida S, Yamashita N, Kawahara K, et al. Amelioration by quinapril of myocardial infarction induced by coronary occlusion/reperfusion in a rabbit model of atherosclerosis: possible mechanisms. Circulation 1999; 99:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/76\">",
"      Dzau VJ, Gibbons GH, Pratt RE. Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension 1991; 18:II100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/77\">",
"      Kim S, Izumi Y, Yano M, et al. Angiotensin blockade inhibits activation of mitogen-activated protein kinases in rat balloon-injured artery. Circulation 1998; 97:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/78\">",
"      Dostal DE, Baker KM. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 1999; 85:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/79\">",
"      Raman VK, Lee YA, Lindpaintner K. The cardiac renin-angiotensin-aldosterone system and hypertensive cardiac hypertrophy. Am J Cardiol 1995; 76:18D.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/80\">",
"      Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993; 153:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/81\">",
"      Zisman LS, Asano K, Dutcher DL, et al. Differential regulation of cardiac angiotensin converting enzyme binding sites and AT1 receptor density in the failing human heart. Circulation 1998; 98:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/82\">",
"      Baker KM, Chernin MI, Wixson SK, Aceto JF. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol 1990; 259:H324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/83\">",
"      Asano K, Dutcher DL, Port JD, et al. Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium. Circulation 1997; 95:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/84\">",
"      Haywood GA, Gullestad L, Katsuya T, et al. AT1 and AT2 angiotensin receptor gene expression in human heart failure. Circulation 1997; 95:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/85\">",
"      Silver RB, Reid AC, Mackins CJ, et al. Mast cells: a unique source of renin. Proc Natl Acad Sci U S A 2004; 101:13607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/86\">",
"      Mackins CJ, Kano S, Seyedi N, et al. Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. J Clin Invest 2006; 116:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/87\">",
"      Nash DT. Comparative properties of angiotensin-converting enzyme inhibitors: relations with inhibition of tissue angiotensin-converting enzyme and potential clinical implications. Am J Cardiol 1992; 69:26C.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/88\">",
"      Chandrasekharan UM, Sanker S, Glynias MJ, et al. Angiotensin II-forming activity in a reconstructed ancestral chymase. Science 1996; 271:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/89\">",
"      Urata H, Boehm KD, Philip A, et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993; 91:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/90\">",
"      Nishimura H, Hoffmann S, Baltatu O, et al. Angiotensin I converting enzyme and chymase in cardiovascular tissues. Kidney Int Suppl 1996; 55:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/91\">",
"      Kokkonen JO, Saarinen J, Kovanen PT. Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1-9) formed by heart carboxypeptidase A-like activity. Circulation 1997; 95:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/92\">",
"      Pfeufer A, Busjahn A, Vergopoulos A, et al. Chymase gene locus is not associated with myocardial infarction and is not linked to heart size or blood pressure. Am J Cardiol 1998; 82:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/93\">",
"      Khan NU, Movahed A. The role of aldosterone and aldosterone-receptor antagonists in heart failure. Rev Cardiovasc Med 2004; 5:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36825/abstract/94\">",
"      Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 2005; 96:643.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3505 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-8DAC4F1F78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_61_36825=[""].join("\n");
var outline_f35_61_36825=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19249671\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Synthesis of angiotensin II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Angiotensin converting enzyme 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ACE GENE POLYMORPHISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ANGIOTENSIN II RECEPTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ACE INHIBITORS AND ARBS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ANGIOTENSIN II AND HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIRECT CARDIAC EFFECTS OF ANGIOTENSIN II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Inotropy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chronotropy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Role in humans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Ventricular remodeling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Electrical remodeling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pathogenesis of atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Infarct-related artery patency and infarction size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Neointima formation after balloon injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CARDIAC RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Alternate pathways of angiotensin II production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Mineralocorticoid receptors and aldosterone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19249671\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3505\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3505|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/23/9597\" title=\"figure 1\">",
"      Comparison of the actions of ACE inhibitors and ARBs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/42/43693\" title=\"figure 2\">",
"      Regression of LV hypertrophy with antihypertensive therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/1/20503?source=related_link\">",
"      ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35672?source=related_link\">",
"      Alcoholic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2680?source=related_link\">",
"      Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/30/26088?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/25/19865?source=related_link\">",
"      Cardiac remodeling: Basic aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20218?source=related_link\">",
"      Choice of therapy in essential hypertension: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17959?source=related_link\">",
"      Clinical implications and treatment of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/14/19685?source=related_link\">",
"      Differences between angiotensin converting enzyme inhibitors and receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23162?source=related_link\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10632?source=related_link\">",
"      Excitation-contraction coupling in myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/15/20729?source=related_link\">",
"      Pathology and pathogenesis of the vulnerable plaque",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32455?source=related_link\">",
"      Pathophysiology of heart failure: Neurohumoral adaptations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25224?source=related_link\">",
"      Renin-angiotensin system inhibition in the treatment of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/42/26278?source=related_link\">",
"      The electrocardiogram in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_61_36826="Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults";
var content_f35_61_36826=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/61/36826/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/61/36826/contributors\">",
"     James N George, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/61/36826/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/61/36826/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/61/36826/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/61/36826/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/61/36826/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) describes acute syndromes with abnormalities in multiple organ systems (",
"    <a class=\"graphic graphic_table graphicRef69868 \" href=\"mobipreview.htm?4/25/4508\">",
"     table 1",
"    </a>",
"    ). Although these syndromes have multiple different etiologies, different demographics, different responses to treatment, and different prognoses, their presenting features are similar in many patients: thrombocytopenia and microangiopathic hemolytic anemia",
"    <strong>",
"     without",
"    </strong>",
"    another apparent cause and, in many patients, neurologic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    renal abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In some patients, neurologic abnormalities are dominant and acute renal failure is minimal or not present; these patients are considered by some to represent classical or \"idiopathic\" TTP, typically associated with severe ADAMTS13 deficiency.",
"     </li>",
"     <li>",
"      In other patients, acute renal failure is dominant and neurologic abnormalities are minimal or absent; these patients are considered by some to represent HUS. However, some patients present with both severe neurologic abnormalities, such as seizures and coma, and acute renal failure, making this distinction difficult.",
"     </li>",
"     <li>",
"      Some patients may have thrombocytopenia and microangiopathic hemolytic anemia with no neurologic or renal abnormalities. For example, over half of patients with severe ADAMTS13 deficiency have no or minimal neurologic or renal abnormalities (",
"      <a class=\"graphic graphic_table graphicRef57941 \" href=\"mobipreview.htm?24/37/25180\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therefore, when these patients are initially evaluated, they can best be described by the comprehensive term TTP-HUS. An additional justification for the use of the term TTP-HUS is that the pathologic changes in patients described as having TTP or HUS are identical and the initial treatment of all adult patients is the same: plasma exchange [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Evolution of disease definitions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As a result, these syndromes in adults will be considered together and referred to as TTP-HUS; the one exception is &ldquo;typical&rdquo; childhood HUS following an episode of abdominal pain and diarrhea that is often bloody, due most often to Shiga toxin-producing enterohemorrhagic Escherichia coli (",
"    <a class=\"graphic graphic_table graphicRef69868 \" href=\"mobipreview.htm?4/25/4508\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This syndrome of children has the important difference that plasma exchange treatment is not a standard initial treatment.",
"   </p>",
"   <p>",
"    The causes of TTP-HUS will be discussed here. The clinical manifestations, diagnosis, and treatment of TTP-HUS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=see_link\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42490?source=see_link\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVOLUTION OF DISEASE DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The names used for the TTP-HUS syndromes have potentially major implications for treatment. As new treatments are proposed, the nomenclature continues to evolve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Thrombotic thrombocytopenic purpura",
"    </span>",
"    &nbsp;&mdash;&nbsp;TTP was first described by Moschowitz in 1925 as a new disease characterized by unique pathological findings of hyaline thrombi in many organs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/3\">",
"     3",
"    </a>",
"    ]. Amorosi and Ultmann reviewed all 271 published cases up to 1964 and defined the &ldquo;classic pentad&rdquo; of clinical features. These features were present in 88 to 98 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thrombocytopenia",
"     </li>",
"     <li>",
"      Microangiopathic hemolytic anemia",
"     </li>",
"     <li>",
"      Neurologic symptoms and signs",
"     </li>",
"     <li>",
"      Renal function abnormalities",
"     </li>",
"     <li>",
"      Fever",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of TTP was supported by the pathologic demonstration of hyaline thrombi in 93 percent of patients; 90 percent of the patients died. However, with the routine use of therapeutic plasma exchange, TTP has changed from a fatal to a mostly curable illness and the classical pentad is only rarely seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42490?source=see_link\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The availability of curative treatment has created an urgency for diagnosis, and therefore the stringency of diagnostic criteria has decreased. At the present time, only the dyad of",
"    <strong>",
"     otherwise unexplained",
"    </strong>",
"    thrombocytopenia and microangiopathic hemolytic anemia (",
"    <a class=\"graphic graphic_picture graphicRef70851 \" href=\"mobipreview.htm?37/50/38694\">",
"     picture 1",
"    </a>",
"    ) is required to establish a diagnosis of thrombotic microangiopathy and initiate treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. This clinical evolution has led to a dramatically increased frequency of diagnosis of TTP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/6\">",
"     6",
"    </a>",
"    ], and a broader spectrum of conditions diagnosed as TTP-HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thrombocytopenia and microangiopathic hemolytic anemia, a form of nonimmune hemolysis (defined by the presence of fragmented red cells [schistocytes] on the blood smear and a negative direct Coombs&rsquo; test [direct antiglobulin test]), are the clinical features of thrombotic microangiopathy (TMA), a specific histologic lesion of arterioles and capillaries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/7\">",
"     7",
"    </a>",
"    ]. However, thrombotic microangiopathy is a histologic description that is characteristic of several diverse disorders, such as malignant hypertension and scleroderma, as well as TTP and HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/2,7\">",
"     2,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hemolytic-uremic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term hemolytic uremic syndrome (HUS) is used to describe cases presenting with microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS was first described in 1955 in a report of five children with acute renal failure who died with renal cortical necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/8\">",
"     8",
"    </a>",
"    ]. Since its original description, it has become clear that HUS is not a single disorder and that the constellation of symptoms that define this syndrome may be due to congenital defects or acquired conditions. Following the recognition of HUS associated with Shiga toxin-producing Escherichia coli in the 1980s, cases of HUS in children have been generally classified into one of two main subtypes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Typical HUS",
"      </strong>",
"      &mdash; The name typical HUS is generally reserved for children. Typical HUS was first recognized in the 1980s, with the appearance of Shiga toxin-producing Escherichia coli (usually E. coli O157:H7) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. This disorder, also called diarrhea-associated HUS, accounts for approximately 90 to 95 percent of HUS in children. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/55/35704?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The term typical HUS is not generally used for adults. However, adults can develop a diarrhea-associated syndrome of microangiopathic hemolytic anemia, thrombocytopenia, and renal failure caused by Shiga toxin-producing Escherichia coli (usually E. coli O157:H7) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/11\">",
"       11",
"      </a>",
"      ]. Such cases are included in the comprehensive term TTP-HUS.",
"     </li>",
"     <li>",
"      <strong>",
"       Atypical HUS",
"      </strong>",
"      &mdash; Atypical HUS is a heterogeneous disorder distinguished by the absence of diarrhea or Shiga toxin-producing E. coli infection. It is estimated that atypical HUS accounts for 5 to 10 percent of cases of childhood HUS. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/52/43849?source=see_link\">",
"       \"Atypical hemolytic uremic syndrome in children\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A subset of patients with atypical HUS are found to have mutations in the genes for complement proteins including C3, factors H, B, and I, and CD46 (previously known as membrane cofactor protein, MCP). Children comparable to those in the original 1955 report would probably currently be considered to have atypical HUS. Atypical HUS is also known as non-Shiga toxin associated HUS. Identifying these rare pediatric patients is important because their treatment may differ from typical HUS. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/52/43849?source=see_link&amp;anchor=H15#H15\">",
"       \"Atypical hemolytic uremic syndrome in children\", section on 'Treatment'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The term atypical HUS has been applied to adult patients, especially those with a syndrome of thrombocytopenia, thrombotic microangiopathy (TMA), renal failure, and normal ADAMTS13 activity (or activity &gt;10 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/12-16\">",
"       12-16",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Mutations of complement regulation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       TTP-HUS",
"      </strong>",
"      &mdash; The comprehensive term TTP-HUS is more appropriate nomenclature for most sporadic cases in adults, since the distinction between these entities is less clear and the treatment choice is not dependent upon the presumed underlying etiology, with the exception of rare cases of familial complement mutations. Children without renal failure may also be diagnosed as having TTP-HUS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on information collected between 1996 and 2004 from the Oklahoma TTP-HUS Registry, we have estimated the incidence of TTP-HUS as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Suspected TTP-HUS &mdash; 11",
"      <span class=\"nowrap\">",
"       cases/million",
"      </span>",
"      population per year",
"     </li>",
"     <li>",
"      Idiopathic TTP-HUS &mdash; 4.5",
"      <span class=\"nowrap\">",
"       cases/million",
"      </span>",
"      per year",
"     </li>",
"     <li>",
"      Severe ADAMTS13 deficiency &mdash; 1.7",
"      <span class=\"nowrap\">",
"       cases/million",
"      </span>",
"      per year",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For all three categories, incidence rates were greater for women and for blacks. As an example, for those with severe ADAMTS13 deficiency (ie, &lt;10 percent of normal activity), the age-sex standardized incidence rate ratio of blacks to non-blacks was 9.3 (95% CI 4.3-20).",
"   </p>",
"   <p>",
"    For the 427 patients with suspected TTP-HUS in the Oklahoma TTP-HUS Registry from 1989 to 2011 (ie, all patients with an initial episode of clinically suspected TTP-HUS in whom the decision to initiate plasma exchange treatment was made), the clinical setting in which these patients presented included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Idiopathic &mdash; 40 percent (idiopathic only implies the absence of the other conditions in this list; patients described as idiopathic are very heterogeneous)",
"     </li>",
"     <li>",
"      Additional (eg, autoimmune disease) or alternative (eg, infection, cancer) disorders &mdash; 27 percent",
"     </li>",
"     <li>",
"      Drug-associated &mdash; 12 percent (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      , 6 percent; other drugs, 6 percent)",
"     </li>",
"     <li>",
"      Bloody diarrhea prodrome &mdash; 8 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Pregnancy/postpartum",
"      </span>",
"      &mdash; 7 percent",
"     </li>",
"     <li>",
"      Hematopoietic cell transplantation &mdash; 6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The table (",
"    <a class=\"graphic graphic_table graphicRef85772 \" href=\"mobipreview.htm?9/0/9229\">",
"     table 3",
"    </a>",
"    ) presents the relative frequency of the different clinical categories of patients treated with plasma exchange for a clinical diagnosis of TTP or HUS in the Oklahoma TTP-HUS Registry, 1995-2009, and also the frequency of severe ADAMTS13 deficiency (activity &lt;10 percent) within each clinical category.",
"   </p>",
"   <p>",
"    Since 1995, the Oklahoma TTP-HUS Registry has measured ADAMTS13 activity on 299 (93 percent) of 321 consecutive patients. Of the 68 patients (1995 to 2010) with severe ADAMTS13 deficiency (activity &lt;10 percent), 54 (79 percent) were deemed to be idiopathic. Of the 14 remaining patients, three were postpartum; three had additional autoimmune disorders (two with systemic lupus erythematosus, one with Sjogren&rsquo;s syndrome); two presented with bloody diarrhea and were initially suspected to have TTP-HUS associated with E. coli O157:H7 infection; one had severe GVHD following allogeneic hematopoietic stem cell transplantation; four had systemic infections; and one had a systemic malignancy. Therefore, although severe ADAMTS13 deficiency defined as ADAMTS13 activity &lt;10 percent is clinically important to identify patients who are at risk for relapse, it is not completely specific for patients with TTP-HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    &ldquo;Idiopathic TTP&rdquo; is often used as a term synonymous with severe ADAMTS13 deficiency, but in fact &ldquo;idiopathic&rdquo; only represents a very heterogeneous group of patients who do not qualify for any of the other five clinical categories. In our experience, only approximately half of patients described as idiopathic have severe ADAMTS13 deficiency.",
"   </p>",
"   <p>",
"    In two series, including our own, patients with severe ADAMTS13 deficiency were more likely to have a number of the following features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/2,18,19\">",
"     2,18,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      African-Caribbean ancestry",
"     </li>",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Female sex",
"     </li>",
"     <li>",
"      Presence of other autoimmune manifestations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with severe ADAMTS13 deficiency also have a higher frequency of blood group O [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/20\">",
"     20",
"    </a>",
"    ]. This observation was unexpected because people with blood group O have lower levels of von Willebrand factor (vWF) and less risk for other thrombotic disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;TTP-HUS is associated with thrombi composed primarily of platelets in affected organs. In the kidney, for example, the primary histologic changes are thrombi in the glomeruli and arterioles, subendothelial widening of the glomerular capillary wall on electron microscopy due to the deposition of fibrin-like material, and, during healing, mucoid intimal thickening and then onion-skin hypertrophy of the interlobular arteries (",
"    <a class=\"graphic graphic_picture graphicRef63511 graphicRef54840 graphicRef69687 graphicRef78330 graphicRef75317 \" href=\"mobipreview.htm?43/7/44154\">",
"     picture 2A-E",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/30/18921?source=see_link\">",
"     \"Mechanisms of immune injury of the glomerulus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These histologic changes are consequences or manifestations of endothelial cell injury. The term glomerular capillary endotheliosis that describes this injury was first used to describe the injury in preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/21\">",
"     21",
"    </a>",
"    ]. The pathologic and some of the clinical findings of TTP-HUS are similar to those seen in several other renal disorders, including malignant nephrosclerosis, preeclampsia, scleroderma, chronic transplant rejection, the antiphospholipid syndrome, and rarely",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    nephrotoxicity and radiation nephritis (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     ADAMTS13 deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;An underlying cause of, and the mechanism for, platelet consumption in some patients with TTP-HUS has been elucidated, which may help to identify patients with TTP who are at risk for relapse (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/2,18,22,23\">",
"     2,18,22,23",
"    </a>",
"    ]. Von Willebrand factor (VWf) is synthesized in endothelial cells and assembled in larger multimers than are present in normal plasma. The larger multimers, called unusually large von Willebrand factor (ULVWf), are rapidly degraded in the circulation into the normal size range of VWf multimers by a specific von Willebrand factor-cleaving protease (or cleaving metalloproteinase), now called ADAMTS13 (",
"    <strong>",
"     A",
"    </strong>",
"    &nbsp;",
"    <strong>",
"     D",
"    </strong>",
"    isintegrin",
"    <strong>",
"     A",
"    </strong>",
"    nd",
"    <strong>",
"     M",
"    </strong>",
"    etalloprotease with a",
"    <strong>",
"     T",
"    </strong>",
"    hrombo",
"    <strong>",
"     S",
"    </strong>",
"    pondin type 1 motif, member",
"    <strong>",
"     13",
"    </strong>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Employing a genome-wide linkage analysis, the responsible locus among four pedigrees with",
"    <strong>",
"     congenital",
"    </strong>",
"    TTP (Upshaw-Schulman syndrome) was identified on chromosome 9q34, an area subsequently found to contain a gene that encodes for ADAMTS13 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/24\">",
"     24",
"    </a>",
"    ]. This study identified 12 mutations in the ADAMTS13 gene, accounting for 14 of the 15 disease alleles studied in individuals with a congenital deficiency of ADAMTS13 activity (2 to 7 percent of normal activity). Numerous additional mutations in the ADAMTS13 gene have since been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ADAMTS13 deficiency leads sequentially to the accumulation of ULVWf multimers, platelet aggregation, and the platelet thrombi that are characteristic of the disease. ULVWf multimers (including unique forms arising from proteolytic digestion) accumulate in patients with TTP, being found in the platelet thrombi and serum. These ULVWf multimers can attach to activated platelets, promoting platelet aggregation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/41/17049?source=see_link\">",
"     \"Biology and normal function of von Willebrand factor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ULVWf multimer accumulation in TTP has been associated with absent or markedly diminished ADAMTS13 activity due to an inherited or acquired deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/27\">",
"     27",
"    </a>",
"    ]. However, absent ADAMTS13 activity without manifestations of a thrombotic microangiopathy has been reported in several families with congenital TTP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/28\">",
"     28",
"    </a>",
"    ], as well as in mouse models of homozygous ADAMTS13 deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In these mouse models additional (\"second hit\") inflammatory or prothrombotic stimuli, Shiga toxin, or a",
"    <span class=\"nowrap\">",
"     collagen/thrombin",
"    </span>",
"    infusion, were required in order to initiate a clinical syndrome resembling TTP.",
"   </p>",
"   <p>",
"    This observation in mouse models of TTP is consistent with the clinical observations that approximately 20 percent of patients with TTP-HUS may have persistent severe ADAMTS13 deficiency following recovery, at a time when they are hematologically normal. Persistent severe ADAMTS13 deficiency does not appear to indicate a risk for relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An additional finding in support of the role of reduced ADAMTS13 activity as a major inciting cause of TTP is the observation that repeated injections of an inhibitory monoclonal antibody prepared against purified human recombinant ADAMTS13 was sufficient to induce mild TTP in the baboon in the absence of inciting triggers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Antibody to ADAMTS13",
"    </span>",
"    &nbsp;&mdash;&nbsp;An inhibitory autoantibody to the ADAMTS13 metalloproteinase has been found at varying titers among a high percentage of patients with idiopathic TTP who have severe ADAMTS13 deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/18\">",
"     18",
"    </a>",
"    ]. The inhibitory antibodies, most of which are IgG, are postulated to be directed against varying elements of the protease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. It is unclear why the antibodies recognize this complex and why they are produced, although it has been suggested that levels of ADAMTS13 less than 5 percent with or without an inhibitor antibody may be part of a larger autoimmune response",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    related to presence of the HLA-DRB1*11 allele [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/34\">",
"     34",
"    </a>",
"    ]. Non-inhibitory antibodies to ADAMTS13 have also been demonstrated in patients with TTP using immunologic detection techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Autoimmunity in TTP'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Presence of an antibody to ADAMTS13 suggests the potential for benefit of adding glucocorticoids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    at some point during the treatment program. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=see_link&amp;anchor=H10#H10\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'ADAMTS13 deficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42490?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\", section on 'Immunosuppression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42490?source=see_link&amp;anchor=H33#H33\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12895661\">",
"    <span class=\"h3\">",
"     Recombinant human ADAMTS13",
"    </span>",
"    &nbsp;&mdash;&nbsp;A recombinant human ADAMTS13 has been produced, which has the in vitro ability to normalize VWF-cleaving activity in the plasma of patients with acquired TTP by overriding inhibitory antibodies to ADAMTS13 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/36\">",
"     36",
"    </a>",
"    ]. Although recombinant ADAMTS13 may primarily have value for patients with TTP caused by congenital ADAMTS13 deficiency, additional studies will be required in order to determine whether a recombinant ADAMTS13 will have utility in the treatment of patients with TTP and acquired autoimmune ADAMTS13 deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     ADAMTS13 activity in other conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;ADAMTS13 activity is typically absent or severely deficient (ie, &lt;10 percent of normal) in patients with &ldquo;classical&rdquo; TTP-HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/18\">",
"     18",
"    </a>",
"    ]. While severe ADAMTS13 deficiency is characteristic of TTP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/18,38\">",
"     18,38",
"    </a>",
"    ], ADAMTS13 activity &lt;10 percent has also been documented in other conditions, such as severe sepsis and associated disseminated intravascular coagulation or ischemic organ failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/2,39,40\">",
"     2,39,40",
"    </a>",
"    ] and patients with severe liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. The clinical importance of ADAMTS13 activity levels that are below normal but not severely deficient (eg, 10 to 50 percent) is not known. Many conditions, including normal pregnancy, can have minimally or moderately decreased levels of ADAMTS13 activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies have noted an inverse relationship between plasma levels of the protease and von Willebrand factor (vWF) antigen and collagen-binding activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/43-45\">",
"     43-45",
"    </a>",
"    ], suggesting that ADAMTS13 activity levels may fall as a response to the liberation of ultralarge vWF multimers into the circulation in these settings. This may be the explanation for low ADAMTS13 activity levels following cardiac surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/46\">",
"     46",
"    </a>",
"    ] and other inflammation-inducing events. These minor decreases of ADAMTS13 activity may be related to clinical observations that cardiac surgery and disorders of acute inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/47\">",
"     47",
"    </a>",
"    ], have been postulated to be &ldquo;trigger&rdquo; events for acute episodes of TTP.",
"   </p>",
"   <p>",
"    ADAMTS13 activity appears to decrease during the last two trimesters of pregnancy, being lowest at 36 to 40 weeks of gestation and the early puerperium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/43,48\">",
"     43,48",
"    </a>",
"    ]. This observation may be relevant to the increased frequency of TTP-HUS during pregnancy, especially at the time of delivery and postpartum. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33479?source=see_link\">",
"     \"Acute kidney injury (acute renal failure) in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ADAMTS13 levels can also be influenced by previous transfusions, which have been given to most patients by emergency department physicians before consideration of the diagnosis of TTP. These may mask the presence of severe ADAMTS13 deficiency, since the half-life of ADAMTS13 in plasma is two to three days and may also neutralize low titer ADAMTS13 inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other hypotheses have been proposed for the pathogenesis of TTP-HUS in patients who do not have ADAMTS13 deficiency. These include endothelial injury, increased platelet aggregation, and genetic factors. The loss or inhibition of vascular endothelial growth factor (VEGF) results in renal thrombotic angiopathy in animal models and in humans, suggesting a protective role for VEGF in glomerular endothelial injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Chemotherapy agents'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H112796012\">",
"     'Ticlopidine'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H21\">",
"     'Quinine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A related issue is the propensity of only certain vascular endothelial beds to be damaged in TTP-HUS. Renal and cerebral vessels are commonly involved, while pulmonary and hepatic microvasculature is often spared [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/51\">",
"     51",
"    </a>",
"    ]. These differences in vascular endothelial damage might be explained by the anatomic restriction of CD36, the thrombospondin receptor (also known as glycoprotein [GP] IV when found on the platelet surface). CD36 is found on human microvascular endothelial cells (HMVEC), but not endothelial cells of large (umbilical) vessels (HUVEC), and may function to bind ADAMTS13 to the endothelial cell surface or the platelet surface, where it regulates the cleavage of vWF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a series of patients with &ldquo;classical&rdquo; TTP-HUS, antibodies were found to bind to HMVEC and HUVEC in 73 to 100 percent and 36 to 55 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/53\">",
"     53",
"    </a>",
"    ]. Antibody reactivity in these patients was significantly greater against HMVEC than HUVEC, was inhibited by pretreatment with a heterologous anti-CD36 antibody, and was reduced following successful plasma exchange therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36009?source=see_link&amp;anchor=H1854511#H1854511\">",
"     \"The endothelium: A primer\", section on 'Structural specializations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of anti-CD36 antibodies in some patients with TTP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/54,55\">",
"     54,55",
"    </a>",
"    ] suggests that they could impair the ability of CD36 to bind ADAMTS13, thereby impairing proteolysis of ultralarge VWF multimers and potentially contributing to the pathogenesis of TTP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/52,56\">",
"     52,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Plasminogen activator inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another factor that may underlie vascular damage in TTP-HUS is the presence of increased levels of plasminogen-activator inhibitor type 1 (PAI-1). Increased levels of PAI-1, the primary inhibitor of the fibrinolytic compounds tissue-type plasminogen activator and urokinase, have been described in children with postdiarrheal HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. More severely affected patients had a higher plasma PAI-1 concentration, and normalization of plasma levels spontaneously or following peritoneal dialysis was correlated with an improvement in renal function.",
"   </p>",
"   <p>",
"    It is not clear, however, if the enhanced release of PAI-1 was a primary response or was secondary to endothelial injury. A primary elevation in this factor might be expected to lead to fibrin thrombi rather than the platelet thrombi characteristic of TTP-HUS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/60/21450?source=see_link&amp;anchor=H19#H19\">",
"     \"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis\", section on 'Plasminogen activator inhibitor'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Mutations of complement regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autosomal recessive and autosomal dominant forms of familial HUS have been rarely described and are predominantly observed in children. A number of studies have identified mutations in complement regulatory proteins, with abnormalities in other proteins not related to the complement system also appearing to be causative. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/52/43849?source=see_link&amp;anchor=H7#H7\">",
"     \"Atypical hemolytic uremic syndrome in children\", section on 'Genetic forms of HUS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complement abnormalities may account for a subset of adult patients with atypical HUS, especially those with a syndrome of thrombocytopenia, thrombotic microangiopathy (TMA), renal failure, and normal ADAMTS13 activity (or activity &gt;10 percent). A second group for whom complement abnormalities may occur includes postpartum women with TMA, thrombocytopenia, and renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/56/38793?source=see_link&amp;anchor=H18#H18\">",
"     \"Thrombocytopenia in pregnancy\", section on 'TTP-HUS associated with pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Autoimmunity in TTP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of autoantibodies to ADAMTS13, the occurrence of other autoimmune disorders before or after the occurrence of TTP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/2\">",
"     2",
"    </a>",
"    ], and the frequent occurrence of a TTP-like picture in patients with systemic lupus erythematosus or other autoimmune disorders has suggested that idiopathic TTP with severe ADAMTS13 deficiency may represent a feature of a broader autoimmune disorder, perhaps modified by the HLA type of the individual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/34,60\">",
"     34,60",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Antiphospholipid antibodies'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Vasculitis and other connective tissue disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study evaluated clinical and laboratory manifestations in 46 patients with idiopathic TTP-HUS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/19\">",
"       19",
"      </a>",
"      ]. When compared with the 15 patients with detectable ADAMTS13 activity (ie, &gt;25 percent of normal), the 31 patients with undetectable levels (ie, &lt;5 percent of normal) had a higher incidence of autoimmune manifestations, including presence of an ADAMTS13 inhibitor in 55 percent and antinuclear antibodies in 71 percent. In contrast, those with detectable ADAMTS13 activity had mainly severe renal failure without findings suggestive of an autoimmune disorder, more consistent with a diagnosis of HUS.",
"     </li>",
"     <li>",
"      Another study evaluated the co-occurrence of other forms of autoimmunity in 76 patients with TTP-HUS and found a higher prevalence of a variety of autoimmune disorders compared with the general population, particularly Hashimoto&rsquo;s thyroiditis (24 versus 1 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/61\">",
"       61",
"      </a>",
"      ]. Other autoimmune disorders with increased prevalence included systemic lupus erythematosus, immune thrombocytopenic purpura, psoriasis, and celiac disease. These observations suggest that a predisposition to autoimmune diseases may underlie the development of antibodies to ADAMTS13 or other mediators of vascular homeostasis in some individuals with TTP-HUS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many cases of TTP-HUS are idiopathic, a variety of underlying causes have been identified (",
"    <a class=\"graphic graphic_table graphicRef69868 \" href=\"mobipreview.htm?4/25/4508\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/2\">",
"     2",
"    </a>",
"    ]. Importantly, TTP-HUS is often a multi-factorial disease. TTP-HUS can occur (or recur) after pregnancy, infection, pancreatitis, and surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/47,62-66\">",
"     47,62-66",
"    </a>",
"    ]. These and other acute stresses can trigger an initial or recurrent episode, perhaps due to the release of inflammatory cytokines or other prothrombotic mediators, which could alter the balance between levels of von Willebrand factor and ADAMTS13 activity in a susceptible patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/46,67,68\">",
"     46,67,68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112794356\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Shiga toxin-producing E. coli",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of childhood HUS and occasional cases of TTP-HUS in adults follow an episode of bloody diarrhea. A Shiga toxin released from E. coli (particularly types O157:H7, O111, and O104:H4) or other bacteria is felt to be etiologic in most of these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/19/18745?source=see_link&amp;anchor=H5#H5\">",
"     \"Microbiology, pathogenesis, epidemiology, and prevention of enterohemorrhagic Escherichia coli (EHEC)\", section on 'Shiga toxins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The appropriate terminology for sporadic cases in adults is TTP-HUS, since some adults present with acute thrombocytopenia and microangiopathic hemolytic anemia with no renal function abnormalities following hemorrhagic colitis caused by E. coli O157 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/69\">",
"     69",
"    </a>",
"    ], while some adults who present with acute bloody diarrhea have severe ADAMTS13 deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In the patients with underlying ADAMTS13 deficiency, the acute bloody diarrhea may be the result of ischemic colitis, rather than Shiga toxin-induced enterocolitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112794614\">",
"    <span class=\"h3\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombotic microangiopathy (TMA) has been reported in patients with HIV infection, although its incidence in the post-highly active antiretroviral therapy (HAART) era appears to be declining [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. The mechanism by which thrombotic microangiopathy occurs in this population is not understood, but direct endothelial injury may be involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TMA in HIV-infected patients is most commonly observed among patients with advanced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/71,73\">",
"     71,73",
"    </a>",
"    ]. As an example, in the CHORUS study of 6022 patients with HIV infection, the 17 patients (0.3 percent) with thrombotic microangiopathy had the following significant characteristics compared with those who did not have TMA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/71\">",
"     71",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lower mean CD4+ cell counts",
"     </li>",
"     <li>",
"      Higher HIV-1 RNA levels",
"     </li>",
"     <li>",
"      A higher incidence of AIDS",
"     </li>",
"     <li>",
"      Higher incidences of infection with Mycobacterium avium complex and hepatitis C",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite treatment, one-year survival is very low due to the severity of the underlying disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/70,71,73,74\">",
"     70,71,73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our own experience and that of others, TMA in HIV-infected patients has most often been associated with the presence of opportunistic infection or other illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/75\">",
"     75",
"    </a>",
"    ]. This suggests that in patients with HIV infection, opportunistic infections, with associated endothelial cell injury and TMA, are merely mimicking TTP-HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In occasional cases, however, HIV infection serves as an inflammatory trigger for the development of an acute episode of quite typical TTP-HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/75,76\">",
"     75,76",
"    </a>",
"    ], comparable to the experimental observations in transgenic mice lacking ADAMTS13, who only develop signs of TTP following an inflammatory or prothrombotic stimulus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In such cases, prompt initiation of HAART in parallel with plasma exchange is of paramount importance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112794635\">",
"    <span class=\"h3\">",
"     Pneumococcal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most cases of postinfectious HUS occur after an episode of bloody diarrhea caused by Shiga toxin-producing E. coli, rarely, adult patients have developed this disorder after a pneumococcal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/77\">",
"     77",
"    </a>",
"    ]. This association is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/52/43849?source=see_link&amp;anchor=H5#H5\">",
"     \"Atypical hemolytic uremic syndrome in children\", section on 'Streptococcus pneumoniae'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plasma exchange or infusion should be avoided in the HUS associated with pneumococcal infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42490?source=see_link&amp;anchor=H36#H36\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\", section on 'Treatment of concomitant infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112794370\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many drugs are associated with TTP-HUS. Some of the more common etiologic drugs are discussed here. In addition, drugs used inappropriately or accidentally may cause TTP-HUS. As an example, TTP-HUS has been described following injection of the extended-release opioid Opana, which is intended for oral administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/78\">",
"     78",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Quinine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15080?source=see_link\">",
"     Quinine",
"    </a>",
"    , commonly used in over-the-counter preparations to treat muscle cramps, has been associated with recurrent episodes of TTP-HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/79-82\">",
"     79-82",
"    </a>",
"    ]. Quinine is present in beverages such as tonic water and bitter lemon. The observation that this etiology of TTP-HUS can be triggered by a single quinine tablet or by quinine-containing beverages taken many months or years after a previous exposure suggests that the mechanism may be antibody-dependent. The clinical abnormalities may be caused by a broad spectrum of quinine-dependent antibodies, including antibodies to platelets, neutrophils, lymphocytes, red cells, and endothelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our experience,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    is the most common cause of",
"    <strong>",
"     drug-induced",
"    </strong>",
"    TTP-HUS, accounting for 25 of 52 cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/2\">",
"     2",
"    </a>",
"    ]. Quinine is the only drug-induced cause of TTP-HUS that has been confirmed by the occurrence of recurrent TTP-HUS with recurrent drug exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/79\">",
"     79",
"    </a>",
"    ]. Quinine may also be the only drug-induced cause of TTP-HUS that has been confirmed by the documentation of drug-dependent antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A careful history is often required to establish the presence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    -induced disease. In some cases, for example, initial or recurrent episodes can be triggered by quinine contained in beverages or nutrition health products (eg, tonic water, quinine water, or listed in herbal products as cinchona or cramp bark) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/79,81\">",
"     79,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our series of 17 patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    -induced TTP-HUS, all were females who had been taking quinine intermittently for nocturnal leg cramps for many years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/79\">",
"     79",
"    </a>",
"    ]. Most presented with the acute onset of anuria, nausea and vomiting, chills and fever, abdominal pain, and diarrhea. Neurologic symptoms, most commonly confusion and lethargy, were present in 12. The frequency and severity of neurologic abnormalities suggest that the disorder should be termed TTP-HUS, rather than HUS, as in previous reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic kidney disease appears to be very common following",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    -induced TTP-HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/79\">",
"     79",
"    </a>",
"    ]. Hemodialysis was required in 14 of 17 patients, chronic renal failure developed in eight, and there were four deaths, three of which occurred during the initial episode [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/79\">",
"     79",
"    </a>",
"    ]. This experience contrasts with a previous report suggesting that the prognosis for complete recovery was good [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/81\">",
"     81",
"    </a>",
"    ]. Two of the 13 survivors have had a total of three relapses after repeat use of quinine. If recurrences are to be prevented, patients and clinicians must be alert for unrecognized quinine ingestion as a possible cause of TTP-HUS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Chemotherapy agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;TTP-HUS has also been described as a complication of cancer chemotherapy. Clinical and pathologic evidence of thrombotic microangiopathy following exposure to chemotherapy agents are postulated to result from dose-dependent toxicity. The clinical course is often characterized by the gradual development of renal failure, sometimes after the chemotherapy has been stopped. Because this clinical course and etiology are distinct from TTP-HUS associated with severe ADAMTS13 deficiency, we do not use plasma exchange for these patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42490?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\", section on 'Exceptions to the use of plasma exchange'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The agents most commonly implicated include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/84-95\">",
"     84-95",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       Mitomycin",
"      </a>",
"      C",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"     </li>",
"     <li>",
"      BCNU",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       Oxaliplatin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/9/40086?source=see_link\">",
"       Pentostatin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       Bevacizumab",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"     </li>",
"     <li>",
"      Use of radiation and high dose chemotherapy prior to hematopoietic cell transplantation (HCT)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to the acute onset of immune-mediated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    -induced TTP-HUS, these syndromes often appear to be dose-dependent toxicities that have an insidious onset. It is presumed that direct endothelial injury is the initiating event in these settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/85\">",
"     85",
"    </a>",
"    ]. However, the onset of clinically evident disease is often delayed, frequently occurring months after chemotherapy has been discontinued or hematopoietic cell transplant has been performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/86,96,97\">",
"     86,96,97",
"    </a>",
"    ]. Affected patients typically present with slowly progressive renal failure, new or exacerbated hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/91\">",
"     91",
"    </a>",
"    ], and a relatively bland urine sediment, often occurring in the absence of a clinically apparent tumor.",
"   </p>",
"   <p>",
"    There is no evidence that plasma exchange is beneficial in disease that is induced by chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/36/1609?source=see_link&amp;anchor=H10#H10\">",
"     \"Kidney disease following hematopoietic cell transplantation\", section on 'Treatment and prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112795998\">",
"    <span class=\"h3\">",
"     Immunosuppressive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal thrombotic microangiopathy, with clinical manifestations of TTP-HUS, may be induced by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. Although direct endothelial injury probably plays an important role in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/98\">",
"     98",
"    </a>",
"    ], cyclosporine may also increase platelet aggregation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/100\">",
"     100",
"    </a>",
"    ]. This form of TTP-HUS is often, but not always, reversible with discontinuation of cyclosporine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/98,100\">",
"     98,100",
"    </a>",
"    ]. The pathologic abnormality of thrombotic microangiopathy is almost always restricted to the kidneys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/7,101\">",
"     7,101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reports suggest that the immunosuppressive agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (FK506) can also produce TTP-HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. Other studies, however, have found that among renal allograft recipients with TTP-HUS who are taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , switching to tacrolimus is associated with a significantly high rate of graft salvage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HUS has also been reported with the combination",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    immunosuppressive regimen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/9/17562?source=see_link\">",
"     \"Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another factor that can cause an HUS-like picture following renal transplantation is the administration of the anti-T cell monoclonal antibody muromonab-CD3 (OKT3) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. Microvascular thrombus formation appears to be limited to the kidney, rather than being a systemic phenomenon. There is a first-dose effect with OKT3 to stimulate coagulation, a response that may be mediated by the release of tumor necrosis factor-alpha (and perhaps other cytokines) from circulating mononuclear cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/107\">",
"     107",
"    </a>",
"    ]. The risk appears to be greatest in patients receiving high doses of OKT3 (eg, 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for two weeks versus the more standard dose of 5",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    occurring in 10 percent of patients in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/108\">",
"     108",
"    </a>",
"    ]. The development of HUS has been limited to patients receiving OKT3 as prophylaxis against rejection; in this early post-transplant period, endothelial injury from ischemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgery may contribute to the thrombotic process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112796005\">",
"    <span class=\"h3\">",
"     Antiplatelet agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     Ticlopidine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    have been reported to be associated with the development of TTP-HUS. However in none of these patients has the suspected ticlopidine or clopidogrel etiology been supported by either demonstration of ticlopidine- or clopidogrel-dependent antibodies reactive with platelets or any other cell or protein, or by recurrent TTP-HUS with recurrent drug exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112796012\">",
"    <span class=\"h4\">",
"     Ticlopidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of TTP-HUS following",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    use for cardiac stenting has ranged from 1 case in 1600 to 1 in 4800 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/109,110\">",
"     109,110",
"    </a>",
"    ]. In two series of more than 90 cases of TTP-HUS associated with ticlopidine, 90 percent occurred after two weeks of treatment, and all cases occurred within 12 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/109,111\">",
"     109,111",
"    </a>",
"    ]. Among these patients, ADAMTS13 levels were frequently &lt;15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/111\">",
"     111",
"    </a>",
"    ]. It is possible that the ticlopidine use was unrelated to the occurrence of TTP-HUS associated with ADAMTS13 deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112796065\">",
"    <span class=\"h4\">",
"     Clopidogrel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although phase III clinical trials reported no incidence of TTP-HUS with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , its subsequent widespread use has been associated with infrequent reports of TTP-HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/111-115\">",
"     111-115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112796673\">",
"    <span class=\"h3\">",
"     Valacyclovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;A TTP-HUS-like syndrome has been reported with high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    prophylaxis (8",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    against cytomegalovirus infection in patients with advanced HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/116,117\">",
"     116,117",
"    </a>",
"    ]. In a large trial, thrombotic microangiopathy occurred in 14 of 523 patients receiving valacyclovir compared with 4 of 704 patients randomly assigned to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    (2.7 versus 0.6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/116\">",
"     116",
"    </a>",
"    ]. The precise role of valacyclovir, if any, remains unclear, since the patients were receiving many other drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112794386\">",
"    <span class=\"h2\">",
"     Other medical/surgical conditions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Disseminated malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with previously untreated disseminated, often occult, mucin-producing adenocarcinomas may present with a clinical picture of microangiopathic hemolytic anemia resembling TTP. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/43/35514?source=see_link&amp;anchor=H26#H26\">",
"     \"Hypercoagulable disorders associated with malignancy\", section on 'Thrombotic microangiopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A search for systemic malignancy, including a bone marrow biopsy, is appropriate when patients with possible TTP have atypical clinical features. Such atypical features can include some or all of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/118\">",
"     118",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Older age, male gender",
"     </li>",
"     <li>",
"      Previous diagnosis of cancer, even if in &ldquo;apparent&rdquo; clinical remission",
"     </li>",
"     <li>",
"      Gradual onset of symptoms (eg, weakness, weight loss, pain)",
"     </li>",
"     <li>",
"      Respiratory symptoms",
"     </li>",
"     <li>",
"      Leukoerythroblastic blood picture (ie, circulating nucleated red cells and immature granulocytes)",
"     </li>",
"     <li>",
"      Extremely elevated serum lactate dehydrogenase levels",
"     </li>",
"     <li>",
"      Coagulation abnormalities",
"     </li>",
"     <li>",
"      Normal or only slightly reduced levels of ADAMTS13",
"     </li>",
"     <li>",
"      Failure to respond to plasma exchange",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112795182\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;TTP-HUS may be related to pregnancy or the postpartum period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/119\">",
"     119",
"    </a>",
"    ]. Although there have been reports of the association of TTP-HUS with the use of estrogen-containing oral contraceptives, these reports have been neither convincing nor confirmed. In addition to de novo disease in pregnant women, TTP-HUS that initially occurred in nonpregnant women has relapsed during a subsequent pregnancy, and recurrent TTP-HUS has developed during successive pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/119,120\">",
"     119,120",
"    </a>",
"    ]. A review of published case reports suggests a high risk for recurrence of TTP-HUS with a subsequent pregnancy, but these data are almost certainly biased by only reporting positive associations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A report from the Oklahoma TTP-HUS Registry of 19 consecutive women with 30 pregnancies following recovery from TTP-HUS suggests that the risk of recurrence is lower than previously suggested. Five of 19 women each had one recurrence diagnosed during a subsequent pregnancy, but in two of these women severe preeclampsia may have been the more accurate diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/119\">",
"     119",
"    </a>",
"    ]. The current experience of the Oklahoma TTP-HUS Registry, through December 2011, with eight women who have recovered from TTP-HUS associated with severe ADAMTS13 deficiency and who have had 15 pregnancies, is that TTP-HUS recurred one to five weeks postpartum in two women (ie, 13 percent). Therefore the risk of recurrent TTP-HUS in a subsequent pregnancy may be real but small.",
"   </p>",
"   <p>",
"    When developing during or after pregnancy, TTP-HUS must be distinguished from severe preeclampsia and the HELLP syndrome. Differential diagnosis of TTP-HUS from these pregnancy-related conditions is discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=see_link&amp;anchor=H11#H11\">",
"       \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33479?source=see_link&amp;anchor=H2#H2\">",
"       \"Acute kidney injury (acute renal failure) in pregnancy\", section on 'Thrombotic microangiopathy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/30/17897?source=see_link&amp;anchor=H7#H7\">",
"       \"HELLP syndrome\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/56/38793?source=see_link&amp;anchor=H18#H18\">",
"       \"Thrombocytopenia in pregnancy\", section on 'TTP-HUS associated with pregnancy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Antiphospholipid antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiphospholipid antibodies (aPL) are autoantibodies directed against phospholipid antigens. These include anti-cardiolipin antibodies and lupus anticoagulants. Most patients present with venous and arterial thromboses or frequent spontaneous abortions, but a thrombotic microangiopathy similar to TTP-HUS can occur, with renal disease, thrombocytopenia, and microangiopathic hemolytic anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/121-124\">",
"     121-124",
"    </a>",
"    ]. In most cases, we consider this microangiopathic hemolytic anemia due to the antiphospholipid antibodies and not true TTP-HUS, although it is possible for a patient to have both true TTP-HUS and a lupus anticoagulant. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35287?source=see_link\">",
"     \"Antiphospholipid syndrome and the kidney\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, in some cases, a TTP-HUS-like syndrome occurs in systemic lupus erythematosus in the absence of aPL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/122\">",
"     122",
"    </a>",
"    ]. These cases may be clinically similar to idiopathic TTP-HUS. In patients with the antiphospholipid syndrome or systemic lupus erythematosus, the distinction from TTP-HUS may not be possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/124\">",
"     124",
"    </a>",
"    ] and plasma exchange treatment is appropriate. Autopsy evidence for TTP-HUS is common in patients who have died with systemic lupus erythematosus and neurologic abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/125\">",
"     125",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=see_link&amp;anchor=H16#H16\">",
"     \"Diagnosis and classification of renal disease in systemic lupus erythematosus\", section on 'Vascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Cardiovascular surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classical TTP-HUS, with response to plasma exchange, has been described in a small number of patients following cardiovascular surgery, most often coronary artery bypass grafting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/126-129\">",
"     126-129",
"    </a>",
"    ]. In at least one case, TTP-HUS followed placement of a femoral-popliteal bypass graft and recurred after a repeated vascular repair more than one year later; both episodes responded to plasma exchange [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/126\">",
"     126",
"    </a>",
"    ]. In another case, decreased ADAMTS13 activity, along with an inhibitor of ADAMTS13, were demonstrated preoperatively in a patient with a prior history of TTP-HUS and a subsequent episode of post-cardiac surgery TTP-HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These episodes of TTP-HUS occurred within the first few days or weeks postoperatively; diagnosis and appropriate treatment with plasmapheresis were often delayed because of confounding potential postoperative complications (eg, heparin-induced or other drug-induced thrombocytopenia, sepsis, DIC, complications of cardiac bypass, acute renal failure following cross-clamping of the aorta, large areas of denuded or damaged vascular endothelium, operative or postoperative neurologic complications) that could have explained the presence of thrombocytopenia, microangiopathic hemolytic anemia, fever, renal failure,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neurologic changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9440142\">",
"    <span class=\"h3\">",
"     Kidney transplant",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to TTP-HUS thought to be precipitated in renal transplant patients by anti-rejection drugs, a form of hyperacute humoral rejection with thrombosis limited to the transplanted kidney has been seen. This has become a rare phenomenon following institution of more sensitive tissue typing procedures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/49/12053?source=see_link\">",
"     \"TTP-HUS: Recurrence after transplantation\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112795498\">",
"    <span class=\"h3\">",
"     Allogeneic hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syndromes resembling TTP-HUS may be also diagnosed following allogeneic hematopoietic cell transplant (HCT). These syndromes are described as post-transplant thrombotic microangiopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/130\">",
"     130",
"    </a>",
"    ] or transplant-associated microangiopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An International Working Group proposed the following criteria, all of which must be present, for the diagnosis of transplant-associated microangiopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/131\">",
"     131",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Evolution of disease definitions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Schistocytes account for more than 4 percent of red blood cells",
"     </li>",
"     <li>",
"      De novo prolonged or progressive thrombocytopenia (ie, platelet count",
"      <span class=\"nowrap\">",
"       &lt;50,000/microL",
"      </span>",
"      or &ge;50 percent lower than previous values)",
"     </li>",
"     <li>",
"      Sudden and persistent increase in serum lactate dehydrogenase concentration",
"     </li>",
"     <li>",
"      Decrease in hemoglobin concentration or increase in transfusion requirement",
"     </li>",
"     <li>",
"      Decrease in serum haptoglobin",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Objection has been raised against the requirement of a schistocyte percentage &gt;4 percent, as well as for the requirement for concurrent renal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neurologic dysfunction (without other explanations) as proposed by the Bone Marrow Transplant Clinical Trials Network [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/130,132\">",
"     130,132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unclear whether transplant-associated microangiopathy is a complication of allogeneic HCT per se, since the thrombotic microangiopathy seen in these patients can often be attributed to many different causes (eg, prior chemotherapy, drug toxicity, total body irradiation, acute graft-versus-host disease, hepatic venoocclusive disease, use of calcineurin inhibitors,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    disseminated infections) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/89,90,133\">",
"     89,90,133",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The kidney is the primary site of microangiopathy documented by an autopsy study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/133,134\">",
"     133,134",
"    </a>",
"    ]. Plasma exchange is thought by some clinicians to have value in the HCT setting. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/49/12053?source=see_link\">",
"     \"TTP-HUS: Recurrence after transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/36/1609?source=see_link&amp;anchor=H9#H9\">",
"     \"Kidney disease following hematopoietic cell transplantation\", section on 'Thrombotic microangiopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/36/1609?source=see_link&amp;anchor=H10#H10\">",
"     \"Kidney disease following hematopoietic cell transplantation\", section on 'Treatment and prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The value of plasma exchange and other therapies for post HCT-associated microangiopathy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/36/1609?source=see_link&amp;anchor=H10#H10\">",
"     \"Kidney disease following hematopoietic cell transplantation\", section on 'Treatment and prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     ADDITIONAL INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional information concerning thrombocytopenic conditions (ie, drug-induced, ITP, TTP-HUS, and thrombocytopenia in pregnancy) can be found on a website maintained and updated by Dr. James N. George at the University of Oklahoma Health Sciences Center:",
"    <a class=\"external\" href=\"file://www.ouhsc.edu/platelets\">",
"     www.ouhsc.edu/platelets",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/61/36826/abstract/135\">",
"     135",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15875938\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) covers a broad range of disorders that culminate in thrombotic microangiopathy (TMA), microangiopathic hemolytic anemia (MAHA), and thrombocytopenia. Fever, renal failure, and neurologic symptoms are present in some cases depending on the site(s) of microangiopathic damage. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=see_link&amp;anchor=H2#H2\">",
"       \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Clinical and laboratory manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It is sometimes useful to distinguish between typical HUS, atypical HUS, and TTP-HUS, for purposes of therapy and disease reporting. Although definitions vary, we suggest the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Typical HUS refers to TMA associated with renal failure in children with a diarrheal prodrome. The pathogenesis is thought to be initiated by a Shiga toxin released from E. coli (particularly types O157:H7, O111, and O104:H4) or other bacteria. Typical HUS accounts for 90 to 95 percent of childhood HUS. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/55/35704?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Atypical HUS was originally used to describe the 5 to 10 percent of children with TMA associated with renal failure who lacked a diarrheal prodrome. Some of these children were found to have abnormalities of the complement cascade (eg, mutations in C3, factors H, B, and I, and CD46). The term atypical HUS is now also used for adult patients who have TMA associated with renal failure and who have genetic abnormalities of complement regulation without ADAMTS13 deficiency (eg, who have activity &gt;10 percent). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/52/43849?source=see_link\">",
"       \"Atypical hemolytic uremic syndrome in children\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H16\">",
"       'Mutations of complement regulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TTP-HUS is reasonable nomenclature for most adults with TMA, microangiopathic hemolytic anemia, and thrombocytopenia. A subset of these patients will have ADAMTS13 deficiency (&lt;10 percent activity) and are described simply as TTP. ADAMTS13 is a protease responsible for cleaving unusually large von Willebrand factor (ULVWf) multimers. Persistence of these multimers in patients with ADAMTS13 deficiency is thought to promote platelet aggregation and thrombus formation in the microvasculature. Patients with preserved ADAMTS13 activity may have other pathophysiologies, including damage to vascular beds by increased levels of plasminogen activator inhibitor (PAI-1) or autoantibodies to the ADAMTS13 receptor CD36. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Etiologic agents responsible for the TTP-HUS syndromes include Shiga toxin-producing bacteria; numerous drugs such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      (available over the counter in beverages such as tonic water and bitter lemon), antiplatelet agents, and chemotherapeutics; and factors related to malignancy, allogeneic hematopoietic cell transplant, cardiovascular surgery, and pregnancy. The common defect caused by these agents probably involves damage to vascular beds, although a shared molecular mechanism has not been established. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/1\">",
"      George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/2\">",
"      George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 2010; 116:4060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/3\">",
"      Moschowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries. Arch Intern Med 1925; 36:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/4\">",
"      Amorosi E, Ultmann J. Thrombotic thrombocytopenic purpura: Report of 16 cases and review of the literature. Medicine 1966; 45:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/5\">",
"      Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/6\">",
"      Clark WF, Garg AX, Blake PG, et al. Effect of awareness of a randomized controlled trial on use of experimental therapy. JAMA 2003; 290:1351.",
"     </a>",
"    </li>",
"    <li>",
"     Laszik ZG, Silva FG. Hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura, and systemic sclerosis (systemic scleroderma). In: Heptinstall's Pathology of the Kidney, 5th ed, Jennett JC, Olson JL, Schwartz MM, Silva FG (Eds), Lippincott-Raven, Philadelphia 1998. p.1003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/8\">",
"      GASSER C, GAUTIER E, STECK A, et al. [Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia]. Schweiz Med Wochenschr 1955; 85:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/9\">",
"      Karmali MA, Steele BT, Petric M, Lim C. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet 1983; 1:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/10\">",
"      Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/11\">",
"      Frank C, Werber D, Cramer JP, et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med 2011; 365:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/12\">",
"      Sall&eacute;e M, Daniel L, Piercecchi MD, et al. Myocardial infarction is a complication of factor H-associated atypical HUS. Nephrol Dial Transplant 2010; 25:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/13\">",
"      Hertig A, Ridel C, Rondeau E. [Hemolytic uremic syndrome in adults]. Nephrol Ther 2010; 6:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/14\">",
"      Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/15\">",
"      Loirat C, Fr&eacute;meaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011; 6:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/16\">",
"      Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/17\">",
"      Terrell DR, Williams LA, Vesely SK, et al. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 2005; 3:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/18\">",
"      Kremer Hovinga JA, Vesely SK, Terrell DR, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/19\">",
"      Coppo P, Bengoufa D, Veyradier A, et al. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) 2004; 83:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/20\">",
"      Terrell DR, Motto DG, Kremer Hovinga JA, et al. Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency. Transfusion 2011; 51:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/21\">",
"      Subramanya A, Houghton D, Watnick S. Steroid-responsive idiopathic glomerular capillary endotheliosis: case report and literature review. Am J Kidney Dis 2005; 45:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/22\">",
"      Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/23\">",
"      Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/24\">",
"      Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/25\">",
"      Kremer Hovinga JA, Studt JD, L&auml;mmle B. The von Willebrand factor-cleaving protease (ADAMTS-13) and the diagnosis of thrombotic thrombocytopenic purpura (TTP). Pathophysiol Haemost Thromb 2003; 33:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/26\">",
"      Camilleri RS, Scully M, Thomas M, et al. A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom. J Thromb Haemost 2012; 10:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/27\">",
"      Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008; 112:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/28\">",
"      Furlan M, L&auml;mmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol 2001; 14:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/29\">",
"      Banno F, Kokame K, Okuda T, et al. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood 2006; 107:3161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/30\">",
"      Motto DG, Chauhan AK, Zhu G, et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 2005; 115:2752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/31\">",
"      Feys HB, Roodt J, Vandeputte N, et al. Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus). Blood 2010; 116:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/32\">",
"      Klaus C, Plaimauer B, Studt JD, et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood 2004; 103:4514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/33\">",
"      Pos W, Luken BM, Sorvillo N, et al. Humoral immune response to ADAMTS13 in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2011; 9:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/34\">",
"      Coppo P, Busson M, Veyradier A, et al. HLA-DRB1*11: a strong risk factor for acquired severe ADAMTS13 deficiency-related idiopathic thrombotic thrombocytopenic purpura in Caucasians. J Thromb Haemost 2010; 8:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/35\">",
"      Varadi K, Schreiner J, Plaimauer B, et al. ADAMTS13 autoantibody detection by quantitative immunoblotting. Blood 2003; 102:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/36\">",
"      Plaimauer B, Kremer Hovinga JA, Juno C, et al. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost 2011; 9:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/37\">",
"      Schiviz A, Wuersch K, Piskernik C, et al. A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13. Blood 2012; 119:6128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/38\">",
"      Bianchi V, Robles R, Alberio L, et al. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/39\">",
"      Ono T, Mimuro J, Madoiwa S, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006; 107:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/40\">",
"      Nguyen TC, Liu A, Liu L, et al. Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Haematologica 2007; 92:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/41\">",
"      Uemura M, Fujimura Y, Matsumoto M, et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 2008; 99:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/42\">",
"      George JN. Clinical insights from observations on ADAMTS13 deficiency in liver cirrhosis. Thromb Haemost 2008; 99:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/43\">",
"      Mannucci PM, Canciani MT, Forza I, et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98:2730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/44\">",
"      Reiter RA, Kn&ouml;bl P, Varadi K, Turecek PL. Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin. Blood 2003; 101:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/45\">",
"      Mannucci PM, Capoferri C, Canciani MT. Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. Br J Haematol 2004; 126:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/46\">",
"      Mannucci PM, Parolari A, Canciani MT, et al. Opposite changes of ADAMTS-13 and von Willebrand factor after cardiac surgery. J Thromb Haemost 2005; 3:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/47\">",
"      Swisher KK, Doan JT, Vesely SK, et al. Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica 2007; 92:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/48\">",
"      S&aacute;nchez-Luceros A, Far&iacute;as CE, Amaral MM, et al. von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women. Thromb Haemost 2004; 92:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/49\">",
"      Furlan M, Robles R, Morselli B, et al. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1999; 81:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/50\">",
"      Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/51\">",
"      Ridolfi RL, Bell WR. Thrombotic thrombocytopenic purpura. Report of 25 cases and review of the literature. Medicine (Baltimore) 1981; 60:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/52\">",
"      Davis AK, Makar RS, Stowell CP, et al. ADAMTS13 binds to CD36: a potential mechanism for platelet and endothelial localization of ADAMTS13. Transfusion 2009; 49:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/53\">",
"      Wright JF, Wang H, Hornstein A, et al. Characterization of platelet glycoproteins and platelet/endothelial cell antibodies in patients with thrombotic thrombocytopenic purpura. Br J Haematol 1999; 107:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/54\">",
"      Tandon NN, Rock G, Jamieson GA. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura. Br J Haematol 1994; 88:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/55\">",
"      Schultz DR, Arnold PI, Jy W, et al. Anti-CD36 autoantibodies in thrombotic thrombocytopenic purpura and other thrombotic disorders: identification of an 85 kD form of CD36 as a target antigen. Br J Haematol 1998; 103:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/56\">",
"      George JN. ADAMTS13: what it does, how it works, and why it's important. Transfusion 2009; 49:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/57\">",
"      Bergstein JM, Riley M, Bang NU. Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome. N Engl J Med 1992; 327:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/58\">",
"      Chandler WL, Jelacic S, Boster DR, et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 2002; 346:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/59\">",
"      Fakhouri F, Roumenina L, Provot F, et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 2010; 21:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/60\">",
"      Scully M, Brown J, Patel R, et al. Human leukocyte antigen association in idiopathic thrombotic thrombocytopenic purpura: evidence for an immunogenetic link. J Thromb Haemost 2010; 8:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/61\">",
"      John ML, Scharrer I. Autoimmune disorders in patients with idiopathic thrombotic thrombocytopenic purpura. Hamostaseologie 2012; 32 Suppl 1:S86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/62\">",
"      Boyer A, Chadda K, Salah A, Bonmarchand G. Thrombotic microangiopathy: an atypical cause of acute renal failure in patients with acute pancreatitis. Intensive Care Med 2004; 30:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/63\">",
"      Talwalkar JA, Ruymann FW, Marcoux P, Farraye FA. Recurrent thrombotic thrombocytopenic purpura (TTP) as a complication of acute relapsing pancreatitis. Dig Dis Sci 2002; 47:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/64\">",
"      Upshaw JD Jr. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med 1978; 298:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/65\">",
"      McDonald V, Laffan M, Benjamin S, et al. Thrombotic thrombocytopenic purpura precipitated by acute pancreatitis: a report of seven cases from a regional UK TTP registry. Br J Haematol 2009; 144:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/66\">",
"      Park YA, Schultz EF, Hay SN, Brecher ME. Thrombotic thrombocytopenic purpura and urinary tract infections: is there a connection? Am J Clin Pathol 2011; 135:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/67\">",
"      Bernardo A, Ball C, Nolasco L, et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004; 104:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/68\">",
"      George JN. The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2003; 10:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/69\">",
"      Kovacs MJ, Roddy J, Gr&eacute;goire S, et al. Thrombotic thrombocytopenic purpura following hemorrhagic colitis due to Escherichia coli O157:H7. Am J Med 1990; 88:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/70\">",
"      Gervasoni C, Ridolfo AL, Vaccarezza M, et al. Thrombotic microangiopathy in patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy. Clin Infect Dis 2002; 35:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/71\">",
"      Becker S, Fusco G, Fusco J, et al. HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clin Infect Dis 2004; 39 Suppl 5:S267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/72\">",
"      Alpers CE. Light at the end of the TUNEL: HIV-associated thrombotic microangiopathy. Kidney Int 2003; 63:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/73\">",
"      Weiner NJ, Goodman JW, Kimmel PL. The HIV-associated renal diseases: current insight into pathogenesis and treatment. Kidney Int 2003; 63:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/74\">",
"      Moore RD. Schistocytosis and a thrombotic microangiopathy-like syndrome in hospitalized HIV-infected patients. Am J Hematol 1999; 60:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/75\">",
"      Benjamin M, Terrell DR, Vesely SK, et al. Frequency and significance of HIV infection among patients diagnosed with thrombotic thrombocytopenic purpura. Clin Infect Dis 2009; 48:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/76\">",
"      Hart D, Sayer R, Miller R, et al. Human immunodeficiency virus associated thrombotic thrombocytopenic purpura--favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy. Br J Haematol 2011; 153:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/77\">",
"      Begue R, Dennehy PH, Peter G. Hemolytic uremic syndrome associated with Streptococcus pneumoniae. N Engl J Med 1991; 325:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/78\">",
"      Centers for Disease Control and Prevention (CDC). Thrombotic thrombocytopenic purpura (TTP)-like illness associated with intravenous Opana ER abuse--Tennessee, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/79\">",
"      Kojouri K, Vesely SK, George JN. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes. Ann Intern Med 2001; 135:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/80\">",
"      Maguire RB, Stroncek DF, Campbell AC. Recurrent pancytopenia, coagulopathy, and renal failure associated with multiple quinine-dependent antibodies. Ann Intern Med 1993; 119:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/81\">",
"      Gottschall JL, Neahring B, McFarland JG, et al. Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome: clinical and serological findings in nine patients and review of literature. Am J Hematol 1994; 47:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/82\">",
"      Stroncek DF, Vercellotti GM, Hammerschmidt DE, et al. Characterization of multiple quinine-dependent antibodies in a patient with episodic hemolytic uremic syndrome and immune agranulocytosis. Blood 1992; 80:241.",
"     </a>",
"    </li>",
"    <li>",
"     Aster RA, et al. Experience of the BloodCenter of Wisconsin, Milwaukee.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/84\">",
"      Lesesne JB, Rothschild N, Erickson B, et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989; 7:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/85\">",
"      Groff JA, Kozak M, Boehmer JP, et al. Endotheliopathy: a continuum of hemolytic uremic syndrome due to mitomycin therapy. Am J Kidney Dis 1997; 29:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/86\">",
"      Jackson AM, Rose BD, Graff LG, et al. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 1984; 101:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/87\">",
"      Canpolat C, Pearson P, Jaffe N. Cisplatin-associated hemolytic uremic syndrome. Cancer 1994; 74:3059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/88\">",
"      Zupancic M, Shah PC, Shah-Khan F. Gemcitabine-associated thrombotic thrombocytopenic purpura. Lancet Oncol 2007; 8:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/89\">",
"      Roy V, Rizvi MA, Vesely SK, George JN. Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Bone Marrow Transplant 2001; 27:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/90\">",
"      George JN, Li X, McMinn JR, et al. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion 2004; 44:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/91\">",
"      Humphreys BD, Sharman JP, Henderson JM, et al. Gemcitabine-associated thrombotic microangiopathy. Cancer 2004; 100:2664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/92\">",
"      Izzedine H, Isnard-Bagnis C, Launay-Vacher V, et al. Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant 2006; 21:3038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/93\">",
"      Glezerman I, Kris MG, Miller V, et al. Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution. Clin Nephrol 2009; 71:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/94\">",
"      Gore EM, Jones BS, Marques MB. Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome? J Clin Apher 2009; 24:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/95\">",
"      Blake-Haskins JA, Lechleider RJ, Kreitman RJ. Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res 2011; 17:5858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/96\">",
"      Raife TJ, Lager DJ. Chronic thrombotic microangiopathy associated with antineoplastic therapy with minimal hematologic effects. Mayo Clin Proc 2002; 77:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/97\">",
"      Ruutu T, Hermans J, Niederwieser D, et al. Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002; 118:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/98\">",
"      Myers BD. Cyclosporine nephrotoxicity. Kidney Int 1986; 30:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/99\">",
"      Beaufils H, de Groc F, Gubler MC, et al. Hemolytic uremic syndrome in patients with Beh&ccedil;et's disease treated with cyclosporin A: report of 2 cases. Clin Nephrol 1990; 34:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/100\">",
"      Grace AA, Barradas MA, Mikhailidis DP, et al. Cyclosporine A enhances platelet aggregation. Kidney Int 1987; 32:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/101\">",
"      Shulman H, Striker G, Deeg HJ, et al. Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury. N Engl J Med 1981; 305:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/102\">",
"      Holman MJ, Gonwa TA, Cooper B, et al. FK506-associated thrombotic thrombocytopenic purpura. Transplantation 1993; 55:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/103\">",
"      Trimarchi HM, Truong LD, Brennan S, et al. FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. Transplantation 1999; 67:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/104\">",
"      Zarifian A, Meleg-Smith S, O'donovan R, et al. Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int 1999; 55:2457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/105\">",
"      Abramowicz D, Pradier O, Marchant A, et al. Induction of thromboses within renal grafts by high-dose prophylactic OKT3. Lancet 1992; 339:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/106\">",
"      Dlott JS, Danielson CF, Blue-Hnidy DE, McCarthy LJ. Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a concise review. Ther Apher Dial 2004; 8:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/107\">",
"      Pradier O, Marchant A, Abramowicz D, et al. Procoagulant effect of the OKT3 monoclonal antibody: involvement of tumor necrosis factor. Kidney Int 1992; 42:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/108\">",
"      Leaf AN, Laubenstein LJ, Raphael B, et al. Thrombotic thrombocytopenic purpura associated with human immunodeficiency virus type 1 (HIV-1) infection. Ann Intern Med 1988; 109:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/109\">",
"      Bennett CL, Davidson CJ, Raisch DW, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med 1999; 159:2524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/110\">",
"      Steinhubl SR, Tan WA, Foody JM, Topol EJ. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA 1999; 281:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/111\">",
"      Bennett CL, Kim B, Zakarija A, et al. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol 2007; 50:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/112\">",
"      Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/113\">",
"      Zakarija A, Bandarenko N, Pandey DK, et al. Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke 2004; 35:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/114\">",
"      Hankey GJ. Clopidogrel and thrombotic thrombocytopenic purpura. Lancet 2000; 356:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/115\">",
"      Paradiso-Hardy FL, Papastergiou J, Lanct&ocirc;t KL, Cohen EA. Thrombotic thrombocytopenic purpura associated with clopidogrel: further evaluation. Can J Cardiol 2002; 18:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/116\">",
"      Feinberg JE, Hurwitz S, Cooper D, et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis 1998; 177:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/117\">",
"      Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (Baltimore) 1997; 76:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/118\">",
"      George JN. Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia. Oncology (Williston Park) 2011; 25:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/119\">",
"      Vesely SK, Li X, McMinn JR, et al. Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 2004; 44:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/120\">",
"      Mokrzycki MH, Rickles FR, Kaplan AA, Kohn OF. Thrombotic thrombocytopenic purpura in pregnancy: successful treatment with plasma exchange. Case report and review of the literature. Blood Purif 1995; 13:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/121\">",
"      Kincaid-Smith P, Fairley KF, Kloss M. Lupus anticoagulant associated with renal thrombotic microangiopathy and pregnancy-related renal failure. Q J Med 1988; 68:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/122\">",
"      Nesher G, Hanna VE, Moore TL, et al. Thrombotic microangiographic hemolytic anemia in systemic lupus erythematosus. Semin Arthritis Rheum 1994; 24:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/123\">",
"      Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 2001; 80:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/124\">",
"      Amoura Z, Costedoat-Chalumeau N, Veyradier A, et al. Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome. Arthritis Rheum 2004; 50:3260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/125\">",
"      Devinsky O, Petito CK, Alonso DR. Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura. Ann Neurol 1988; 23:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/126\">",
"      Chang JC, Shipstone A, Llenado-Lee MA. Postoperative thrombotic thrombocytopenic purpura following cardiovascular surgeries. Am J Hematol 1996; 53:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/127\">",
"      Pavlovsky M, Weinstein R. Thrombotic thrombocytopenic purpura following coronary artery bypass graft surgery: prospective observations of an emerging syndrome. J Clin Apher 1997; 12:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/128\">",
"      Almehmi A, Malas A, Jubelirer SJ. Thrombotic thrombocytopenic purpura following cardiovascular surgery: a case report. W V Med J 2004; 100:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/129\">",
"      Anstadt MP, Carwile JM, Guill CK, et al. Relapse of thrombotic thrombocytopenic purpura associated with decreased VWF cleaving activity. Am J Med Sci 2002; 323:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/130\">",
"      Ho VT, Cutler C, Carter S, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/131\">",
"      Ruutu T, Barosi G, Benjamin RJ, et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 2007; 92:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/132\">",
"      Kennedy GA, Bleakley S, Butler J, et al. Posttransplant thrombotic microangiopathy: sensitivity of proposed new diagnostic criteria. Transfusion 2009; 49:1884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/133\">",
"      Laskin BL, Goebel J, Davies SM, Jodele S. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood 2011; 118:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/61/36826/abstract/134\">",
"      Siami K, Kojouri K, Swisher KK, et al. Thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation: an autopsy study. Transplantation 2008; 85:22.",
"     </a>",
"    </li>",
"    <li>",
"     Search on \"TTP-HUS.\" www.ouhsc.edu/platelets (Accessed on January 30, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1331 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-791DB7C3D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_61_36826=[""].join("\n");
var outline_f35_61_36826=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15875938\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVOLUTION OF DISEASE DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Thrombotic thrombocytopenic purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hemolytic-uremic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ADAMTS13 deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Antibody to ADAMTS13",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12895661\">",
"      - Recombinant human ADAMTS13",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - ADAMTS13 activity in other conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other mechanisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Plasminogen activator inhibitor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Mutations of complement regulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Autoimmunity in TTP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112794356\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Shiga toxin-producing E. coli",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112794614\">",
"      - HIV infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112794635\">",
"      - Pneumococcal infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112794370\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Quinine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112795998\">",
"      - Immunosuppressive agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112796005\">",
"      - Antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H112796012\">",
"      Ticlopidine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H112796065\">",
"      Clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112796673\">",
"      - Valacyclovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112794386\">",
"      Other medical/surgical conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Disseminated malignancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112795182\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Antiphospholipid antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Cardiovascular surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9440142\">",
"      - Kidney transplant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112795498\">",
"      - Allogeneic hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      ADDITIONAL INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15875938\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1331\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1331|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/50/38694\" title=\"picture 1\">",
"      Schistocytes on peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/51/22329\" title=\"picture 2A\">",
"      HUS Glomerular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/61/12246\" title=\"picture 2B\">",
"      HUS Vascular I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/49/26389\" title=\"picture 2C\">",
"      HUS Vascular II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/19/34099\" title=\"picture 2D\">",
"      HUS vascular III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/3/8255\" title=\"picture 2E\">",
"      HUS IF IV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1331|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/25/4508\" title=\"table 1\">",
"      Major causes of TTP-HUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/37/25180\" title=\"table 2\">",
"      Clinical features of decreased ADAMTS13 activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/0/9229\" title=\"table 3\">",
"      Clinical categories TTP frequency severe ADAMTS13 deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33479?source=related_link\">",
"      Acute kidney injury (acute renal failure) in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35287?source=related_link\">",
"      Antiphospholipid syndrome and the kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/52/43849?source=related_link\">",
"      Atypical hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/41/17049?source=related_link\">",
"      Biology and normal function of von Willebrand factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/55/35704?source=related_link\">",
"      Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=related_link\">",
"      Diagnosis and classification of renal disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/30/17897?source=related_link\">",
"      HELLP syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/36/1609?source=related_link\">",
"      Kidney disease following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/9/17562?source=related_link\">",
"      Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/30/18921?source=related_link\">",
"      Mechanisms of immune injury of the glomerulus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/19/18745?source=related_link\">",
"      Microbiology, pathogenesis, epidemiology, and prevention of enterohemorrhagic Escherichia coli (EHEC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/49/12053?source=related_link\">",
"      TTP-HUS: Recurrence after transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36009?source=related_link\">",
"      The endothelium: A primer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/56/38793?source=related_link\">",
"      Thrombocytopenia in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/60/21450?source=related_link\">",
"      Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42490?source=related_link\">",
"      Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_61_36827="HNPP and hereditary brachial plexopathy";
var content_f35_61_36827=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hereditary neuropathy with pressure palsy and hereditary brachial plexopathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Inheritance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chromosome (gene)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Hereditary neuropathy with pressure palsy",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        17p11.2-12 (PMP22)",
"       </td>",
"       <td>",
"        <p>",
"         Usual onset in second decade",
"        </p>",
"        <p>",
"         Isolated nerve palsies after trivial trauma",
"        </p>",
"        <p>",
"         Palsies resolve in days to months",
"        </p>",
"        <p>",
"         Cranial nerve involvement",
"        </p>",
"        <p>",
"         Nerve deafness",
"        </p>",
"        <p>",
"         Scoliosis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hereditary brachial plexopathy",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        17q25 (SEPT9)",
"       </td>",
"       <td>",
"        <p>",
"         Onset in childhood",
"        </p>",
"        <p>",
"         Pain followed by paresis of brachial plexus muscles",
"        </p>",
"        <p>",
"         Resolves spontaneously and recurs at irregular intervals",
"        </p>",
"        <p>",
"         Winging of the scapula",
"        </p>",
"        <p>",
"         Facial weakness",
"        </p>",
"        <p>",
"         Autonomic nervous system dysfunction",
"        </p>",
"        <p>",
"         Short stature",
"        </p>",
"        <p>",
"         Hypertelorism",
"        </p>",
"        <p>",
"         Small palpebral fissures",
"        </p>",
"        <p>",
"         Small face",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AD: autosomal dominant.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_61_36827=[""].join("\n");
var outline_f35_61_36827=null;
var title_f35_61_36828="Chances bc related outcomes";
var content_f35_61_36828=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F69681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F69681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chances of breast cancer&ndash;related outcomes among 1000 women screened annually or biennially, starting at age 40 or 50 and continuing through age 69 or 74",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"7\" width=\"14%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Screening program",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Cumulative consequences of screening program",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Mammogram frequency",
"       </td>",
"       <td class=\"subtitle2\">",
"        Starting age",
"       </td>",
"       <td class=\"subtitle2\">",
"        Ending age",
"       </td>",
"       <td class=\"subtitle2\">",
"        Lives saved, number",
"       </td>",
"       <td class=\"subtitle2\">",
"        Life-yrs gained, number",
"       </td>",
"       <td class=\"subtitle2\">",
"        False-positive mammograms, number",
"       </td>",
"       <td class=\"subtitle2\">",
"        Unnecessary biopsies, number",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"7\">",
"        Annual",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        8.3",
"       </td>",
"       <td>",
"        164",
"       </td>",
"       <td>",
"        2250",
"       </td>",
"       <td>",
"        158",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        7.3",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        1350",
"       </td>",
"       <td>",
"        95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        10.5",
"       </td>",
"       <td>",
"        188",
"       </td>",
"       <td>",
"        2470",
"       </td>",
"       <td>",
"        173",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        9.5",
"       </td>",
"       <td>",
"        156",
"       </td>",
"       <td>",
"        1570",
"       </td>",
"       <td>",
"        110",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"7\">",
"        Biennial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        6.1",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        1250",
"       </td>",
"       <td>",
"        88",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        5.4",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        780",
"       </td>",
"       <td>",
"        55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        8.2",
"       </td>",
"       <td>",
"        142",
"       </td>",
"       <td>",
"        1410",
"       </td>",
"       <td>",
"        99",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        7.5",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        940",
"       </td>",
"       <td>",
"        66",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted and calculated from: Mandelblatt JS, Cronin KA, Bailey S, et al. Effects of Mammography Screening Under Different Screening Schedules: Model Estimates of Potential Benefits and Harms. Ann Intern Med 2009; 151:738.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_61_36828=[""].join("\n");
var outline_f35_61_36828=null;
var title_f35_61_36829="Mortality in Hodgkin lymphoma";
var content_f35_61_36829=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F71648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F71648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Disease-related and non-Hodgkin mortality in Hodgkin lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 304px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Actuarial risk of death from Hodgkin lymphoma or other causes in 2498 patients treated for Hodgkin lymphoma at Stanford University from 1960 to 1995. Most of the early mortality is due to Hodgkin lymphoma, while almost all deaths after 10 to 15 years were due to other causes, mostly second malignancy and cardiovascular and pulmonary disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Hoppe RT. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol 1997; 8(Suppl 1):S115.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_61_36829=[""].join("\n");
var outline_f35_61_36829=null;
var title_f35_61_36830="Humeral ulnar angle";
var content_f35_61_36830=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anteroposterior radiograph angles of the elbow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 202px; height: 516px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The humeral-ulnar angle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Beaty JH, Kasser JR. The elbow region: General concepts in the pediatric patient. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_61_36830=[""].join("\n");
var outline_f35_61_36830=null;
var title_f35_61_36831="Stool diary blank PI";
var content_f35_61_36831=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F61504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F61504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 573px\">",
"   <div class=\"ttl\">",
"    Stool diary",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 553px; height: 611px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_61_36831=[""].join("\n");
var outline_f35_61_36831=null;
